Skip Navigation LinksHome > May 2010 - Volume 22 - Issue 3 > Current World Literature
Text sizing:
A
A
A
Current Opinion in Oncology:
doi: 10.1097/CCO.0b013e328339b479
Current World Literature: Bibliography

Current World Literature

Free Access

This bibliography is compiled by clinicians from the journals listed at the end of this publication. It is based on literature entered into our database between 1 January 2009 and 31 December 2009 (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

• Papers considered by the reviewers to be of special interest

•• Papers considered by the reviewers to be of outstanding interest

The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review.

Back to Top | Article Outline

Melanoma and other skin neoplasms

The biology behind prognostic factors of cutaneous melanoma

Review: (pp. 163–168)

•• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199–6206. PubMed | CrossRef [01]

•• Conway C, Mitra A, Jewell R, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 2009; 15:6939–6946.[19]

• de Vries E, Nijsten TE, Visser O, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 2008; 19:583–589. View Full Text | PubMed | CrossRef [37]

•• Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117–126. PubMed | CrossRef [28]

•• Fukunaga-Kalabis M, Martinez G, Telson SM, et al. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 2008; 27:2552–2560. View Full Text | PubMed | CrossRef [13]

•• Marconi C, Bianchini F, Mannini A, et al. Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells. Clin Exp Metastasis 2008; 25:225–231. View Full Text | PubMed | CrossRef [10]

•• Rodriguez M, Aladowicz E, Lanfrancone L, Goding CR. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res 2008; 68:7872–7881. PubMed | CrossRef [05]

Sun BK, Tsao H. X-Chromosome Inactivation and Skin Disease [Review]. J Invest Dermatol 2008; 128:2753–2759. PubMed | CrossRef

• Villares GJ, Dobroff AS, Wang H, et al. Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res 2009; 69:6730–6737. PubMed | CrossRef [23]

• Wu Y, Lin Y, Liu H, Li J. Inhibition of invasion and up-regulation of E-cadherin expression in human malignant melanoma cell line A375 by (−)-epigallocatechin-3-gallate. J Huazhong Univ Sci Technolog Med Sci 2008; 28:356–359. PubMed | CrossRef [07]

Back to Top | Article Outline
New developments in sentinel node staging in melanoma: controversies and alternatives

Review: (pp. 169–177)

Morton RL, Howard K, Thompson JF. The Cost-Effectiveness of Sentinel Node Biopsy in Patients with Intermediate Thickness Primary Cutaneous Melanoma. Ann Surg Oncol 2009; 16:929–940. View Full Text | PubMed | CrossRef

•• Murali R, Cochran AJ, Cook MG, et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. Cancer 2009; 115:5026–5037. PubMed | CrossRef [106]

• Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 2008; 5:18–23. View Full Text | PubMed | CrossRef [85]

• van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008; 248:949–955. View Full Text | PubMed [88]

•• van Akkooi AC, Spatz A, Eggermont AM, et al. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. Eur J Cancer 2009; 45:2736–2742. PubMed | CrossRef [107]

van Akkooi ACJ, Nowecki ZI, Voit C, Schafer-Hesterberg G, et al. Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients A Multicenter Study in 388 Patients With Positive Sentinel Nodes. Ann Surg 2008; 248:949–955. View Full Text | PubMed

•• Voit CA, van Akkooi ACJ, Schäfer-Hesterberg G, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol 2010. [Epub ahead of print][116]

•• Voit CA, van Akkooi AC, Schafer-Hesterberg G, et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol 2009; 27:4994–5000.[117]

Back to Top | Article Outline
Mutation-driven drug development in melanoma

Review: (pp. 178–183)

• Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14:6821–6828. PubMed[05]

Bozzo J, Dulsat C. Therapeutic targets for melanoma [Review]. Drugs of the Future 2008; 33:615–631.

di Pietro A, Tosti G, Ferrucci PF, Testori A. Oncophage: step to the future for vaccine therapy in melanoma. Expert Opin Biol Ther 2008; 8:1973–1984. PubMed | CrossRef

•• Flaherty KT, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27:15S.[26]

Gallagher SJ, Thompson JF, Indsto J, Scurr LL, et al. p16(INK4a) Expression and Absence of Activated B-RAF Are Independent Predictors of Chemosensitivity in Melanoma Tumors. Neoplasia 2008; 10:1231–1239. PubMed

Hamai A, Meslin F, Benlalam H, Jalil A, et al. ICAM-1 Has a Critical Role in the Regulation of Metastatic Melanoma Tumor Susceptibility to CTL Lysis by Interfering with PI3K/AKT Pathway. Cancer Res 2008; 68:9854–9864.

• Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14:7726–7732.[07]

Kishi Y, Kuba K, Nakamura T, Wen JH, et al. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Science 2009; 100:1351–1358. View Full Text | PubMed | CrossRef

Lesinski GB, Raig ET, Guenterberg K, Brown L, et al. IFN-alpha and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis. Cancer Res 2008; 68:8351–8360. PubMed | CrossRef

Matsuoka H, Tsubaki M, Yamazoe Y, Ogaki M, et al. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res 2009; 315:2022–2032. View Full Text | PubMed | CrossRef

•• Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009; 41:1127–1132. PubMed | CrossRef [33]

Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, et al. Melanoma: Molecular pathogenesis and emerging target therapies (Review) [Review]. Int J Oncol 2009; 34:1481–1489. PubMed

Schwartz AL, Malgor R, Dickerson E, Weeraratna AT, et al. Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration. Clin Cancer Res 2009; 15:4114–4122. PubMed

Sharma A, Sharma AK, Madhunapantula SV, Desai D, et al. Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clin Cancer Res 2009; 15:1674–1685. PubMed

Singh S, Sadanandam A, Nannuru KC, Varney ML, et al. Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis. Clin Cancer Res 2009; 15:2380–2386. PubMed

Smalley KSM, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy [Review]. Int J Cancer 2009; 124:1245–1250. PubMed | CrossRef

Umansky V, Abschuetz O, Osen W, Ramacher M, et al. Melanoma-Specific Memory T Cells Are Functionally Active in Ret Transgenic Mice without Macroscopic Tumors. Cancer Res 2008; 68:9451–9458. PubMed | CrossRef

•• Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599–602. View Full Text | PubMed | CrossRef [29]

Walther W, Siegel R, Kobelt D, Knosel T, et al. Novel Jet-Injection Technology for Nonviral Intratumoral Gene Transfer in Patients with Melanoma and Breast Cancer. Clin Cancer Res 2008; 14:7545–7553. PubMed

Zheng MZ, Bocangel D, Ramesh R, Ekmekcioglu S, et al. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O-6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther 2008; 7:3842–3851. PubMed | CrossRef

Back to Top | Article Outline
Pathology of melanoma and other skin neoplasms

Bardarov S, Michael CW, Lucas D, Pang Y, et al. Fine-needle aspiration biopsy of metastatic malignant melanoma resembling a malignant peripheral nerve sheath tumor. Diagn Cytopathol 2008; 36:754–757. PubMed | CrossRef

Baruthio F, Quadroni M, Ruegg C, Mariotti A. Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage. Proteomics 2008; 8:4733–4747. PubMed | CrossRef

Betti R M, Radaelli G, Mussino F, Menni S, et al. Anatomic Location and Histopathologic Subtype of Basal Cell Carcinomas in Adults Younger than 40 or 90 and Older: Any Difference? Dermatol Surg 2009; 35:201–206.

Cabrijan L, Lipozencic J, Batinac T, Lenkovic M, et al. Correlation Between Clinical-Dermatoscopic and Histopathologic Diagnosis of Skin Tumors in Our Patients. Collegium Antropol 2008; 32:195–197.

Carlson JA, Ross JS, Slominski AJ. New techniques in dermatopathology that help to diagnose and prognosticate melanoma [Review]. Clin Dermatol 2009; 27:75–102. PubMed | CrossRef

Chernyavskiy O, Vannucci L, Bianchini P, Difato F, et al. Imaging of Mouse Experimental Melanoma In Vivo and Ex Vivo by Combination of Confocal and Nonlinear Microscopy. Microsc Res Tech 2009; 72:411–423. PubMed | CrossRef

Dengel L, Turza K, Noland MMB, Patterson JW, et al. Skin Mapping With Punch Biopsies for Defining Margins in Melanoma: When You Don't Know How Far to Go. Ann Surg Oncol 2008; 15:3028–3035. View Full Text | PubMed | CrossRef

Gambichler T, Shtern M, Rotterdam S, Bechara FG, et al. Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions. J Am Acad Dermatol 2009; 60:808–813. View Full Text | PubMed | CrossRef

Geller AC, Elwood M, Swetter SM, Brooks DR, et al. Factors Related to the Presentation of Thin and Thick Nodular Melanoma From a Population-based Cancer Registry in Queensland Australia. Cancer 2009; 115:1318–1327. PubMed | CrossRef

Guitera P, Pellacani G, Longo C, Seidenari S, et al. In Vivo Reflectance Confocal Microscopy Enhances Secondary Evaluation of Melanocytic Lesions. J Invest Dermatol 2009; 129:131–138. PubMed | CrossRef

Herman K, Wysocki WM, Skotnicki P, Tabor J, et al. Stage III Thick (> 4.0 mm) Lower Extremity Melanoma: Is Timing of Lymph Node Involvement a Prognostic Factor? World J Surg 2009; 33:469–474.

Hinshaw M. Use of Genetic Tools to Control Tumor Margins in Melanoma. Arch Dermatol 2009; 145:475–477. View Full Text | PubMed | CrossRef

Houben R, Schrama D, Becker JC. Molecular pathogenesis of Merkel cell carcinoma [Review]. Exp Dermatol 2009; 18:193–198. View Full Text | PubMed | CrossRef

Hu S, Kim CC, Jessup C, Phung TL, et al. Primary Cutaneous Melanomas Seen as Inflamed Pigmented Lesions in Patients Undergoing Adjuvant Interferon Treatment A Possible Diagnostic Clue for Physicians. Arch Dermatol 2009; 145:565–568. View Full Text | PubMed | CrossRef

Kacerovska D, Sokol L, Michal M, Kazakov DV. Primary Cutaneous Signet-Ring Cell Melanoma With Pseudoglandular Features, Spindle Cells and Oncocytoid Changes. Am J Dermatopathol 2009; 31:81–83. View Full Text | PubMed | CrossRef

Kapucuoglu N, Basak PY, Bircan S, Sert S, et al. Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol Res Pract 2009; 205.

Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, et al. A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA 2009; 106:6268–6272. PubMed | CrossRef

Magro CM, Yaniv S, Mihm MC. The superficial atypical Spitz tumor and malignant melanoma of superficial spreading type arising in association with the superficial atypical Spitz tumor: A distinct form of dysplastic Spitzoid nevomelanocytic proliferation. J Am Acad Dermatol 2009; 60:814–823. View Full Text | PubMed | CrossRef

Mogensen M, Joergensen TM, Nurnberg BM, Morsy HA, et al. Assessment of Optical Coherence Tomography Imaging in the Diagnosis of Non-Melanoma Skin Cancer and Benign Lesions Versus Normal Skin: Observer-Blinded Evaluation by Dermatologists and Pathologists. Dermatol Surg 2009; 35:965–972. View Full Text | PubMed | CrossRef

Moore P, Hundley J, Levine EA, Williford P, et al. Does Shave Biopsy Accurately Predict the Final Breslow Depth of Primary Cutaneous Melanoma? Am Surg 2009; 75:369–373.

Murali R, Hughes MT, Fitzgerald P, Thompson JF, et al. Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma. Ann Surg 2009; 249:641–647. View Full Text | PubMed | CrossRef

Murali R, Loughman NT, McKenzie PR, Watson GF, et al. Cytologic Features of Metastatic and Recurrent Melanoma in Patients With Primary Cutaneous Desmoplastic Melanoma. Am J Clin Pathol 2008; 130:715–723. PubMed | CrossRef

Nakai N, Katoh N, Germeraad WTV, Kishida T, et al. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. J Dermatol Sci 2009; 53:40–47. PubMed

Prayaga AK, Loya A, Gottimukkala SR, Digumarti RR, et al. Cytologic Features of Primary Malignant Tumors of Skin and Adnexae. Acta Cytol 2008; 52:702–709. PubMed | CrossRef

Richmond-Sinclair NM, Lee E, Cummings MC, Williamson R, et al. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas. Melanoma Res 2008; 18:336–345. View Full Text | PubMed | CrossRef

Rinaggio J, Hameed M, Baredes S. Melanoma with cartilaginous differentiation originating within the mucosa of the nasal cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106:861–865. View Full Text | PubMed | CrossRef

Swetter SM, Johnson TM, Miller DR, Layton CJ, et al. Melanoma in Middle-aged and Older Men A Multi-institutional Survey Study of Factors Related to Tumor Thickness. Arch Dermatol 2009; 145:397–404. View Full Text | PubMed | CrossRef

Tran KT, Wright NA, Cockerell CJ. Biopsy of the pigmented lesion-When and how [Review]. J Am Acad Dermatol 2008; 59:852–871. View Full Text | PubMed | CrossRef

Trolet J, Hupe P, Huon I, Lebigot I, et al. Genomic Profiling and Identification of High-Risk Uveal Melanoma by Array CGH Analysis of Primary Tumors and Liver Metastases. Invest Ophthalmol Vis Sci 2009; 50:2572–2580. PubMed | CrossRef

Vazquez V, Otero LL, Laurent VE, Gabri MR, et al. Molecular detection of minimal residual disease in melanoma and solid tumors [Spanish]. Med-Buenos Aires 2009; 69:181–190.

Wang Y, Di Giovanna JJ, Stern JB, Hornyak TJ, et al. Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc Natl Acad Sci USA 2009; 106:6279–6284. PubMed | CrossRef

Back to Top | Article Outline
Expression of proteins and the mumor microenviroment in melanoma and other skin neoplasms

Ashida A, Takata M, Murata H, Kido K, et al. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009; 124:862–868. PubMed

Bachmann IM, Ladstein RG, Straume O, Naumov GN, et al. Tumor necrosis is associated with increased alpha(v)beta(3) integrin expression and poor prognosis in nodular cutaneous melanomas - art. no. 362. BMC Cancer 2008:362.

Bailet O, Fenouille N, Abbe P, Robert G, et al. Spleen Tyrosine Kinase Functions as a Tumor Suppressor in Melanoma Cells by Inducing Senescence-like Growth Arrest. Cancer Res 2009; 69:2748–2756. PubMed | CrossRef

Bartolome RA, Ferreiro S, Miquilena-Colina ME, Martinez-Prats L, et al. The Chemokine Receptor CXCR4 and the Metalloproteinase MT1-MMP Are Mutually Required during Melanoma Metastasis to Lungs. Am J Pathol 2009; 174:602–612. PubMed | CrossRef

Baruthio F, Quadroni M, Ruegg C, Mariotti A. Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage. Proteomics 2008; 8:4733–4747. PubMed | CrossRef

Becker MR, Siegelin MD, Rompel R, Enk AH, et al. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res 2009; 19:8–16.

Bedogni B, Powell MB. Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin [Review]. Pigment Cell Melanoma Res 2009; 22:166–174.

Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, et al. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 2008; 118:3660–3670. View Full Text | PubMed | CrossRef

Brody JR, Costantino CL, Berger AC, Sato T, et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009; 8:1930–1934. PubMed | CrossRef

Cassard L, Cohen-Solal JFG, Fournier EM, Camilleri-Broet S, et al. Selective expression of inhibitory Fc gamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int J Cancer 2008; 123:2832–2839. PubMed | CrossRef

Ch'ng S, Swee TT. Genetics, cellular biology and tumor microenvironment of melanoma [Review]. Front Biosci 2009:918–928.

Chen LX, Sun BC, Zhang SW, Zhao XL, et al. Influence of microenvironments on microcirculation patterns and tumor invasion-related protein expression in melanoma. Oncol Rep 2009; 21:917–923. PubMed

Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci USA 2009; 106:1193–1198. PubMed | CrossRef

Chua I, Setzer S, Govindarajan B, Sexton D, et al. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol 2009; 60:758–766. View Full Text | PubMed | CrossRef

Clarke LE, Fountaine TJ, Hennessy J, Bruggeman RD, et al. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi. J Cutan Pathol 2008; 36:433–438.

Csete B, Lengyel Z, Kadar Z, Battyani Z. Poly(Adenosine Diphosphate-Ribose) Polymerase-1 Expression in Cutaneous Malignant Melanomas as a New Molecular Marker of Aggressive Tumor. Pathol Oncol Res 2009; 15:47–53. PubMed | CrossRef

de Giorgi V, Mavilia C, Massi D, Gozzini A, et al. Estrogen Receptor Expression in Cutaneous Melanoma A Real-Time Reverse Transcriptase-Polymerase Chain Reaction and Immunohistochemical Study. Arch Dermatol 2009; 145:30–36. View Full Text | PubMed | CrossRef

Dhomen N, Reis-Filho JS, Dias SD, Hayward R, et al. Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice. Cancer Cell 2009; 15:294–303. PubMed | CrossRef

Dissanayake SK, Olkhanud PB, O'Connell MP, Carter A, et al. Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation. Cancer Res 2008; 68:10205–10214.

Elliott AM, Ai-Hajj MA. ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome. Mol Cancer Res 2009; 7:79–87, 2009 Jan.

Fang L, Lee VC, Cha E, Zhang H, et al. CCR7 regulates B16 murine melanoma cell tumorigenesis in skin. J Leukoc Biol 2008; 84:965–972. PubMed | CrossRef

Gambichler T, Kreuter A, Grothe S, Altmeyer P, et al. Versican overexpression in cutaneous malignant melanoma. Eur J Med Res 2008; 13:500–504. PubMed

Gambichler T, Rotterdam S, Radkowski K, Altmeyer P, et al. Differential Expression of Microtubule-Associated Protein 2 in Melanocytic Skin Lesions. Am J Clin Pathol 2009; 131:710–714.

Gruber F, Kastelan M, Brajac I, Saftic M, et al. Molecular and Genetic Mechanisms in Melanoma. Collegium Antropol 2008; 32:147–152.

Helmke BM, Renner M, Poustka A, Schirmacher P, et al. DMBT1 expression distinguishes anorectal from cutaneous melanoma. Histopathology 2009; 54:233–240. View Full Text | PubMed | CrossRef

Humpolikova-Adamkova L, Kovarik J, Dusek L, Lauerova L, et al. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein. Eur J Cancer 2009; 45:1315–1323. PubMed | CrossRef

Huu SN, Oster M, Avril MF, Boitier F, et al. Fetal Microchimeric Cells Participate in Tumour Angiogenesis in Melanomas Occurring during Pregnancy. Am J Pathol 2009; 174:630–637.

Ilkovitch D, Lopez DM. Immune modulation by melanoma-derived factors [Review]. Exp Dermatol 2008; 17:977–985.

Jinushi M, Nakazaki Y, Carrasco DR, Draganov D, et al. Milk Fat Globule EGF-8 Promotes Melanoma Progression through Coordinated Akt and Twist Signaling in the Tumor Microenvironment. Cancer Res 2008; 68:8889–8898. PubMed | CrossRef

Johansson CC, Egyhazi S, Masucci G, Harlin H, et al. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother 2009; 58:1085–1094. PubMed | CrossRef

Kim A, Yang Y, Lee MS, Yoo YD, et al. NDRG2 gene expression in B16F10 melanoma cells restrains melanogenesis via inhibition of Mitf expression. Pigment Cell Melanoma Res 2008; 21:653–664.

Kuphal S, Martyn AC, Pedley J, Crowther LM, et al. H-Cadherin expression reduces invasion of malignant melanoma. Pigment Cell Melanoma Res 2009; 22:296–306. PubMed

Larson AR, Konat E, Alani RM. Melanoma biomarkers: current status and vision for the future [Review]. Nat Clin Pract Oncol 2009; 6:105–117. View Full Text | PubMed

Leinweber B, Hofmann-Wellenhof R, Kaddu S, McCalmont TH. Procollagen 1 and Melan-A Expression in Desmoplastic Melanomas. Am J Dermatopathol 2009; 31:173–176. View Full Text | PubMed | CrossRef

Lesinski GB, Raig ET, Guenterberg K, Brown L, et al. IFN-alpha and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis. Cancer Res 2008; 68:8351–8360. PubMed | CrossRef

Lopez MN, Pereda C, Segal G, Munoz L, et al. Prolonged Survival of Dendritic Cell-Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor beta-Expressing T Cells. J Clin Oncol 2009; 27:945–952. PubMed | CrossRef

Ma YM, Sun T, Liu YX, Zhao N, et al. A pilot study on acute inflammation and cancer: a new balance between IFN-gamma and TGF-beta in melanoma - art. no. 23. J Exp Clin Cancer Res 2009:23.

Maciag PC, Seavey MM, Pan ZK, Ferrone S, et al. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 2008; 68:8066–8075. PubMed | CrossRef

Markel G, Seidman R, Cohen Y, Besser MJ, et al. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 2009; 126:186–200. View Full Text | PubMed

Massoumi R, Kuphal S, Hellerbrand C, Haas B, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009; 206:221–232.

Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol 2008; 35:1014–1019. View Full Text | PubMed | CrossRef

Orlandi A, Costantini S, Campione E, Ferlosio A, et al. Relation Between Animal-Type Melanoma and Reduced Nuclear Expression of Glutathione S-Transferase pi. Arch Dermatol 2009; 145:55–62.

Park HS, Park CH, Choi BR, Lim MS, et al. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi. J Cutan Pathol 2009; 36:511–516. View Full Text | PubMed | CrossRef

Passeron T, Valencia JC, Namiki T, Vieira WD, et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest 2009; 119:954–963. View Full Text | PubMed | CrossRef

Paulitschke V, Kunstfeld R, Mohr T, Slany A, et al. Entering a New Era of Rational Biomarker Discovery for Early Detection of Melanoma Metastases: Secretome Analysis of Associated Stroma Cells. J Proteome Res 2009; 8:2501–2510. PubMed | CrossRef

Poeck H, Besch R, Maihoefer C, Renn M, et al. 5 '-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008; 14:1256–1263. PubMed | CrossRef

Richards HW, Medrano EE. Epigenetic marks in melanoma [Review]. Pigment Cell Melanoma Res 2009; 22:14–29.

Salemi M, Calogero AE, Vicari E, Migliore E, et al. A High Percentage of Skin Melanoma Cells Expresses SPANX Proteins. Am J Dermatopathol 2009; 31:182–186. View Full Text | PubMed | CrossRef

Sanchez-del-Campo L, Tarraga A, Montenegro MF, Cabezas-Herrera J, et al. Melanoma Activation of 3-O-(3,4,5-Trimethoxybenzoyl)-(-)-Epicatechin to a Potent Irreversible Inhibitor of Dihydrofolate Reductase. Mol Pharm 2009; 6:883–894.

Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EHJG, et al. In situ Expression of Tumor Antigens by Messenger RNA-Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients. Cancer Res 2009; 69:2927–2934. PubMed | CrossRef

Schwartz AL, Malgor R, Dickerson E, Weeraratna AT, et al. Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration. Clin Cancer Res 2009; 15:4114–4122. PubMed

Schwinn N, Vokhminova D, Sucker A, Textor S, et al. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 2009; 124:1594–1604.

Shah KV, Chien AJ, Yee C, Moon RT. CTLA-4 Is a Direct Target of Wnt/beta-Catenin Signaling and Is Expressed in Human Melanoma Tumors. J Invest Dermatol 2008; 128:2870–2879.

Shurin MR, Potapovich AI, Tyurina YY, Tourkova IL, et al. Recognition of Live Phosphatidylserine-Labeled Tumor Cells by Dendritic Cells: A Novel Approach to Immunotherapy of Skin Cancer. Cancer Res 2009; 69:2487–2496. PubMed | CrossRef

Singh B, Schneider M, Knyazev P, Ullrich A. UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. Int J Cancer 2009; 124:531–539. PubMed | CrossRef

Smalley KSM, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas [Review]. Histol Histopathol 2009; 24:643–650. PubMed

Staudt MR, De Pass AL, Sarkar D, Fisher PB. Model Cell Culture System for Defining the Molecular and Biochemical Events Mediating Terminal Differentiation of Human Melanoma Cells. J Cell Physiol 2009; 218:304–314.

Stevens AP, Spangler B, Wallner S, Kreutz M, et al. Direct and Tumor Microenvironment Mediated Influences of 5 '-Deoxy-5 '-(Methylthio)Adenosine on Tumor Progression of Malignant Melanoma. J Cell Biochem 2009; 106:210–219. PubMed | CrossRef

Stoebner PE, Le Gallic L, Berthe ML, Boulle N, et al. Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas. Exp Dermatol 2008; 17:908–915. View Full Text | PubMed | CrossRef

Stromberg S, Agnarsdottir M, Magnusson K, Rexhepaj E, et al. Selective Expression of Syntaxin-7 Protein in Benign Melanocytes and Malignant Melanoma. J Proteome Res 2009; 8:1639–1646. PubMed | CrossRef

Tarhini AA, Stuckert J, Lee S, Sander C, et al. Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009; 27:38–44. PubMed | CrossRef

Wang W, Edington HD, Rao UNM, Jukic DM, et al. Effects of High-Dose IFN alpha 2b on Regional Lymph Node Metastases of Human Melanoma: Modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 2008; 14:8314–8320.

Weber JS. Tumor Evasion May Occur via Expression of Regulatory Molecules: A Case for CTLA-4 in Melanoma. J Invest Dermatol 2008; 128:2750–2752. PubMed | CrossRef

Wessel C, Westhoff CC, Nowak K, Moll I, et al. CD34(+) fibrocytes in melanocytic nevi and malignant melanomas of the skin. Virchows Arch 2008; 453:485–489. PubMed | CrossRef

Wolchok JD, Saenger Y. The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation. Oncologist 2008; 13:2–9. PubMed | CrossRef

Yang EV, Kim SJ, Donovan EL, Chen M, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: Implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009; 23.

Zaravinos A, Kanellou P, Baritaki S, Bonavida B, et al. BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle 2009; 8:1402–1408. PubMed | CrossRef

Zheng H, Gao L, Feng YF, Yuan LY, et al. Down-regulation of Rap1GAP via Promoter Hypermethylation Promotes Melanoma Cell Proliferation, Survival, and Migration. Cancer Res 2009; 69:449–457. PubMed | CrossRef

Back to Top | Article Outline
Surgical and non-surgical management of malanoma

Atkins MB, Hsu J, Lee S, Cohen GI, et al. Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748–5754. PubMed | CrossRef

Bar J, Yerushalmi R, Shapira-Frummer R, Kutchuk I, et al. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha 2b in patients with metastatic melanoma. Oncol Rep 2008; 20:1533–1538. PubMed

Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head and Neck 2008; 30:1592–1598.

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, et al. Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients. J Immunother 2009; 32:415–423.

Cebulla CM, Alegret AM, Feuer WJ, Shi W, et al. Tumor volume reduction using combined phacoemulsification and intravitreal triamcinolone injection for the management of cataract with treated uveal melanoma and atypical nevi. J Cataract Refract Surg 2008; 34:1669–1673. PubMed | CrossRef

Eigentler TK, Radny P, Hauschild A, Gutzmer R, et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 2008; 18:353–358. View Full Text | PubMed | CrossRef

Gow KW, Rapkin LB, Olson TA, Durham MM, et al. Sentinel lymph node biopsy in the pediatric population. J Pediatr Surg 2008; 43:2193–2198. PubMed | CrossRef

Hu S, Kim CC, Jessup C, Phung TL, et al. Primary Cutaneous Melanomas Seen as Inflamed Pigmented Lesions in Patients Undergoing Adjuvant Interferon Treatment A Possible Diagnostic Clue for Physicians. Arch Dermatol 2009; 145:565–568. View Full Text | PubMed | CrossRef

Humer J, Ferko B, Waltenberger A, Rapberger R, et al. Azidothymidine inhibits melanoma cell growth in vitro and in vivo. Melanoma Res 2008; 18:314–321. View Full Text | PubMed | CrossRef

Humpolikova-Adamkova L, Kovarik J, Dusek L, Lauerova L, et al. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein. Eur J Cancer 2009; 45:1315–1323. PubMed | CrossRef

Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, et al. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol 2009; 64:161–167. PubMed | CrossRef

Kim KB, Legha SS, Gonzalez R, Anderson CM, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 2009; 19:42–49. View Full Text | PubMed | CrossRef

Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ. Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nat Clin Pract Oncol 2009; 6:70–71.

Kroon BBR, Noorda EM, Vrouenraets BC, van Slooten GW, et al. Isolated limb perfusion for melanoma. Surg Oncol Clini N Am 2008; 17:785.

Liu X, Chan SY, Ho PCL. Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. Cancer Chemother Pharmacol 2008; 63:167–174. PubMed | CrossRef

Lutzky J, Weber R, Nunez Y, Gillett M, et al. A Phase 1 Study of Granulocyte Macrophage Colony-stimulating Factor (Sargramostim) and Escalating Doses of Thalidomide in Patients With High-risk Malignant Melanoma. J Immunother 2009; 32:79–85. View Full Text | PubMed | CrossRef

Minutilli E, Trefzer U, Stockfleth E, Sterry W. Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma. Nat Clin Pract Oncol 2009; 6:E1–NIL_18. PubMed | CrossRef

Nakamura Y, Hori E, Furuta J, Ishii Y, et al. Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma. Int J Dermatol 2009; 48:763–767. View Full Text | PubMed | CrossRef

Ott PA, Chang JL, Oratz R, Jones A, et al. Phase II Trial of Dacarbazine and Thalidomide for the Treatment of Metastatic Melanoma. Chemotherapy 2009; 55:221–227. PubMed | CrossRef

Patel D, Bassi R, Hooper AT, Sun H, et al. Enhanced Suppression of Melanoma Tumor Growth and Metastasis by Combined Therapy with Anti-VEGF Receptor and Anti-TYRP-1/gp75 Monoclonal Antibodies. Anticancer Res 2008; 28:2679–2686. PubMed

Perales MA, Yuan JDF, Powel S, Gallardo HF, et al. Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma. Mol Ther 2008; 16:2022–2029, 2008 Dec.

Ridolfi L, Fiorentini G, Guida M, Michiara M, et al. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Melanoma Res 2009; 19:100–105. View Full Text | PubMed | CrossRef

Rocca A, Minucci S, Tosti G, Croci D, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009; 100:28–36.

Rubin K. Management of Metastatic Melanoma: Nursing Challenges Today and Tomorrow. Clin J Oncol Nurs 2009; 13:81–89. View Full Text | PubMed | CrossRef

Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, et al. Melanoma: Molecular pathogenesis and emerging target therapies (Review) [Review]. Int J Oncol 2009; 34:1481–1489. PubMed

Sato T, Eschelman DJ, Gonsalves CF, Terai M, et al. Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol 2008; 26:5436–5442. PubMed | CrossRef

Tarhini AA, Millward M, Mainwaring P, Kefford R, et al. A Phase 2, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma. Cancer 2009; 115:859–868. PubMed | CrossRef

Trinh VA. Current management of metastatic melanoma. Am J Health-Syst Pharm 2008; 65:S3–S9. View Full Text | PubMed | CrossRef

Tripp CH, Sparber F, Hermans IF, Romani N, et al. Glycolipids Injected into the Skin Are Presented to NKT Cells in the Draining Lymph Node Independently of Migratory Skin Dendritic Cells. J Immunol 2009; 182:7644–7654. PubMed | CrossRef

Wang W, Edington HD, Rao UNM, Jukic DM, et al. Effects of High-Dose IFN alpha 2b on Regional Lymph Node Metastases of Human Melanoma: Modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 2008; 14:8314–8320.

Welsh MM, Karagas MR, Applebaum KM, Spencer SK, et al. A role for ultraviolet radiation immunosuppression in non-melanoma skin cancer as evidenced by gene-environment interactions. Carcinogenesis 2008; 29:1950–1954. View Full Text | PubMed | CrossRef

Yao K, Balch G, Winchester DJ. Multidisciplinary Treatment of Primary Melanoma. Surg Clin North Am 2009; 89:267. PubMed | CrossRef

Yosry M, Othman IS. Controlled hypotension in adults undergoing choroidal melanoma resection: comparison between the efficacy of nitroprusside and magnesium sulphate. Eur J Anaesthesiol 2008; 25:891–896. PubMed | CrossRef

Zamarin D, Vigil A, Kelly K, Garcia-Sastre A, et al. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther 2009; 16:796–804. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
Melanoma metastasis: innovation and angiogenesis

Bartolome RA, Ferreiro S, Miquilena-Colina ME, Martinez-Prats L, et al. The Chemokine Receptor CXCR4 and the Metalloproteinase MT1-MMP Are Mutually Required during Melanoma Metastasis to Lungs. Am J Pathol 2009; 174:602–612. PubMed | CrossRef

Cabello CM, Bair WB, Lamore SD, Ley S, et al. The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radic Biol Med 2009; 46:220–231. View Full Text | PubMed | CrossRef

Chua I, Setzer S, Govindarajan B, Sexton D, et al. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol 2009; 60:758–766. View Full Text | PubMed | CrossRef

Conesa CM, Sanchez NA, Ortega VV, Reverte JG, et al. In vitro and in vivo effect of IFN alpha on B16F10 melanoma in two models: Subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice). Biomed Pharmacother 2009; 63:305–312.

Erol B, Ufuk U, Husamettin T, Yasin U, et al. True hematogenous metastases of melanoma on contralateral skin graft donor site: a case report. Melanoma Res 2008; 18:443–446. View Full Text | PubMed | CrossRef

Hamai A, Meslin F, Benlalam H, Jalil A, et al. ICAM-1 Has a Critical Role in the Regulation of Metastatic Melanoma Tumor Susceptibility to CTL Lysis by Interfering with PI3K/AKT Pathway. Cancer Res 2008; 68:9854–9864.

Huu SN, Oster M, Avril MF, Boitier F, et al. Fetal Microchimeric Cells Participate in Tumour Angiogenesis in Melanomas Occurring during Pregnancy. Am J Pathol 2009; 174:630–637.

Kuphal S, Martyn AC, Pedley J, Crowther LM, et al. H-Cadherin expression reduces invasion of malignant melanoma. Pigment Cell Melanoma Res 2009; 22:296–306. PubMed

Liu X, Chan SY, Ho PCL. Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. Cancer Chemother Pharmacol 2008; 63:167–174. PubMed | CrossRef

Marneros AG. Tumor Angiogenesis in Melanoma. Hematol Oncol Clin North Am 2009; 23:431. PubMed | CrossRef

Patel D, Bassi R, Hooper AT, Sun H, et al. Enhanced Suppression of Melanoma Tumor Growth and Metastasis by Combined Therapy with Anti-VEGF Receptor and Anti-TYRP-1/gp75 Monoclonal Antibodies. Anticancer Res 2008; 28:2679–2686. PubMed

Roy S, Dhingra K, Mandal S, Khurana N. Unusual presentation of metastatic amelanotic melanoma of unknown primary origin as a solitary breast lump. Melanoma Res 2008; 18:447–450. View Full Text | PubMed | CrossRef

Singh S, Sadanandam A, Nannuru KC, Varney ML, et al. Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis. Clin Cancer Res 2009; 15:2380–2386. PubMed

Wang W, Edington HD, Rao UNM, Jukic DM, et al. Effects of High-Dose IFN alpha 2b on Regional Lymph Node Metastases of Human Melanoma: Modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 2008; 14:8314–8320.

Yang EV, Kim SJ, Donovan EL, Chen M, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: Implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009; 23.

Zhang SW, Li M, Zhang DF, Xu SY, et al. Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Lab Invest 2009; 89:575–586. PubMed | CrossRef

Zheng H, Gao L, Feng YF, Yuan LY, et al. Down-regulation of Rap1GAP via Promoter Hypermethylation Promotes Melanoma Cell Proliferation, Survival, and Migration. Cancer Res 2009; 69:449–457. PubMed | CrossRef

Back to Top | Article Outline
Immunotherapy of melanoma

Albertini MR, Macklin MD, Zuleger CL, Newton MA, et al. Clonal Expansions of 6-Thioguanine Resistant T Lymphocytes in the Blood and Tumor of Melanoma Patients. Environ Mol Mutagen 2008; 49:676–687. PubMed | CrossRef

Arbiser JL, Bonner MY. Melanomas Reveal Their Nakedness Uncovered by Interferon Alfa. Arch Dermatol 2009; 145:587–588. View Full Text | PubMed | CrossRef

Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade - art. no. 62 [Review]. J Transl Med 2008:62.

Atkins MB, Hsu J, Lee S, Cohen GI, et al. Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748–5754. PubMed | CrossRef

Balkow S, Loser K, Krummen M, Higuchi T, et al. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Exp Dermatol 2009; 18:78–87. View Full Text | PubMed | CrossRef

Bar J, Yerushalmi R, Shapira-Frummer R, Kutchuk I, et al. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha 2b in patients with metastatic melanoma. Oncol Rep 2008; 20:1533–1538. PubMed

Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head and Neck 2008; 30:1592–1598.

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, et al. Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients. J Immunother 2009; 32:415–423.

Bottomley A, Coens C, Suciu S, Santinami M, et al. Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27:2916–2923. PubMed | CrossRef

Cocco C, Pistoia V, Airoldi I. New Perspectives for Melanoma Immunotherapy: Role of IL-12 [Review]. Current Molecular Medicine 2009; 9:459–469. PubMed | CrossRef

Conesa CM, Sanchez NA, Ortega VV, Reverte JG, et al. In vitro and in vivo effect of IFN alpha on B16F10 melanoma in two models: Subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice). Biomed Pharmacother 2009; 63:305–312.

di Pietro A, Tosti G, Ferrucci PF, Testori A. Oncophage: step to the future for vaccine therapy in melanoma. Expert Opin Biol Ther 2008; 8:1973–1984. PubMed | CrossRef

Dumitru CD, Antonysamy MA, Gorski KS, Johnson DD, et al. NK1.1(+) cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother 2009; 58:575–587. PubMed | CrossRef

El Marsafy S, Bagot M, Bensussan A, Mauviel A. Dendritic cells in the skin - potential use for melanoma treatment [Review]. Pigment Cell Melanoma Res 2009; 22:30–41.

Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008 [Review]. Expert Rev Vaccines 2009; 8:51–66. View Full Text | PubMed | CrossRef

Fujisawa Y, Nabekura T, Nakao T, Nakamura Y, et al. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Exp Dermatol 2009; 18:396–403.

Glaspy J, Ribas A, Chmielowski B. Interferon Alfa in the Postsurgical Management of High-Risk Melanoma: Is It Worth It? J Clin Oncol 2009; 27:2896–2897.

Goforth R, Salem AK, Zhu XY, Miles S, et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother 2009; 58:517–530. PubMed | CrossRef

Gogas H, Kirkwood JM. Predictors of response to interferon therapy [Review]. Curr Opin Oncol 2009; 21:138–143. View Full Text | PubMed | CrossRef

Hamdy S, Molavi O, Ma ZS, Haddadi A, et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8(+) T cell-mediated anti-tumor immunity. Vaccine 2008; 26:5046–5057. PubMed | CrossRef

Hu S, Kim CC, Jessup C, Phung TL, et al. Primary Cutaneous Melanomas Seen as Inflamed Pigmented Lesions in Patients Undergoing Adjuvant Interferon Treatment A Possible Diagnostic Clue for Physicians. Arch Dermatol 2009; 145:565–568. View Full Text | PubMed | CrossRef

Kim KB, Legha SS, Gonzalez R, Anderson CM, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 2009; 19:42–49. View Full Text | PubMed | CrossRef

Kirkwood JM, Lee S, Moschos S, Albertini MR, et al. Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/- Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-alpha 2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009; 15:1443–1451.

Kirkwood JM, Tarhini AA. Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy. J Clin Oncol 2009; 27:2583–2585. PubMed | CrossRef

Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ. Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nat Clin Pract Oncol 2009; 6:70–71.

Klein O, Ebert LM, Nicholaou T, Browning J, et al. Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4. Clin Cancer Res 2009; 15:2507–2513.

Kreis S, Philippidou D, Margue C, Behrmann I. IL-24: a classic cytokine and/or a potential cure for cancer ? [Review]. J Cell Mol Med 2008; 12:2505–2510. View Full Text | PubMed | CrossRef

Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, et al. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes. J Pathol 2008; 216:451–459.

Lesinski GB, Raig ET, Guenterberg K, Brown L, et al. IFN-alpha and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis. Cancer Res 2008; 68:8351–8360. PubMed | CrossRef

Lopez MN, Pereda C, Segal G, Munoz L, et al. Prolonged Survival of Dendritic Cell-Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor beta-Expressing T Cells. J Clin Oncol 2009; 27:945–952. PubMed | CrossRef

Lu XL, Jiang XB, Liu RE, Zhang SM. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine 2008; 26:5352–5357.

Lutzky J, Weber R, Nunez Y, Gillett M, et al. A Phase 1 Study of Granulocyte Macrophage Colony-stimulating Factor (Sargramostim) and Escalating Doses of Thalidomide in Patients With High-risk Malignant Melanoma. J Immunother 2009; 32:79–85. View Full Text | PubMed | CrossRef

Maciag PC, Seavey MM, Pan ZK, Ferrone S, et al. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 2008; 68:8066–8075. PubMed | CrossRef

Margolin K. Cytokine therapy in cancer [Review]. Expert Opin Biol Ther 2008; 8:1495–1505. PubMed | CrossRef

Matsumoto K, Kubo H, Murata H, Uhara H, et al. A Pilot Study of Human Interferon beta Gene Therapy for Patients with Advanced Melanoma by in vivo Transduction Using Cationic Liposomes. Jpn J Clin Oncol 2008; 38:849–856. View Full Text | PubMed | CrossRef

Myint AM, Schwarz MJ, Steinbusch HWM, Leonard BE. Neuropsychiatric disorders related to interferon and interleukins treatment [Review]. Metab Brain Dis 2009; 24:55–68. View Full Text | PubMed | CrossRef

Nakai N, Katoh N, Germeraad WTV, Kishida T, et al. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. J Dermatol Sci 2009; 53:40–47. PubMed

Pectasides D, Dafni U, Bafaloukos D, Skarlos D, et al. Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma. J Clin Oncol 2009; 27:939–944. PubMed | CrossRef

Perales MA, Yuan JDF, Powel S, Gallardo HF, et al. Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma. Mol Ther 2008; 16:2022–2029, 2008 Dec.

Quezada SA, Peggs KS, Simpson TR, Shen YL, et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205:2125–2138. PubMed | CrossRef

Ridolfi L, Fiorentini G, Guida M, Michiara M, et al. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Melanoma Res 2009; 19:100–105. View Full Text | PubMed | CrossRef

Rocca A, Minucci S, Tosti G, Croci D, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009; 100:28–36.

Saenger YM, Li YY, Chiou KC, Chan B, et al. Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma. Cancer Res 2008; 68:9884–9891. PubMed | CrossRef

Sato T, Eschelman DJ, Gonsalves CF, Terai M, et al. Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol 2008; 26:5436–5442. PubMed | CrossRef

Schwinn N, Vokhminova D, Sucker A, Textor S, et al. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 2009; 124:1594–1604.

Shurin MR, Potapovich AI, Tyurina YY, Tourkova IL, et al. Recognition of Live Phosphatidylserine-Labeled Tumor Cells by Dendritic Cells: A Novel Approach to Immunotherapy of Skin Cancer. Cancer Res 2009; 69:2487–2496. PubMed | CrossRef

Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, et al. IFN-alpha Enhances Peptide Vaccine-Induced CD8(+) T Cell Numbers, Effector Function, and Antitumor Activity. J Immunol 2009; 182:7398–7407. PubMed | CrossRef

Singh V, Ji QY, Feigenbaum L, Leighty RM, et al. Melanoma Progression Despite Infiltration by In Vivo-primed TRP-2-specific T Cells. J Immunother 2009; 32:129–139. View Full Text | PubMed | CrossRef

Slingluff CL, Petroni GR, Olson W, Czarkowski A, et al. Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens. J Clin Oncol 2008; 26:4973–4980. PubMed | CrossRef

Stoeter D, Carino ND, Marshall E, Poston GJ, et al. Extensive necrosis of visceral melanoma metastases after immunotherapy - art. no. 30. World J Surg Oncol 2008:30.

Tarhini AA, Kirkwood JM. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther 2008; 8:1583–1593. PubMed | CrossRef

Tarhini AA, Millward M, Mainwaring P, Kefford R, et al. A Phase 2, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma. Cancer 2009; 115:859–868. PubMed | CrossRef

Teitz-Tennenbaum S, Li QA, Davis MA, Chang AE. Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model. Clin Immunol 2008; 129:482–491. PubMed | CrossRef

Valles L, Gonzalez M, Polo I, Enguita AB, et al. Lipoatrophy Associated With Interferon Alfa Adjuvant Therapy for Melanoma. Arch Dermatol 2009; 145:98–99. View Full Text | PubMed | CrossRef

Wagner S, Krepler C, Allwardt D, Latzka J, et al. Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine. Clin Cancer Res 2008; 14:8178–8183. PubMed

Walker EB, Miller W, Haley D, Floyd K, et al. Characterization of the Class I-Restricted gp100 Melanoma Peptide-stimulated Primary Immune Response in Tumor-Free Vaccine-draining Lymph Nodes and Peripheral Blood. Clin Cancer Res 2009; 15:2541–2551.

Wang W, Edington HD, Rao UNM, Jukic DM, et al. Effects of High-Dose IFN alpha 2b on Regional Lymph Node Metastases of Human Melanoma: Modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 2008; 14:8314–8320.

Zheng MZ, Bocangel D, Ramesh R, Ekmekcioglu S, et al. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O-6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther 2008; 7:3842–3851. PubMed | CrossRef

Back to Top | Article Outline
Imaging modalities in melanoma and other skin neoplasms

Calzavara-Pinton P, Longo C, Venturini M, Sala R, et al. Reflectance Confocal Microscopy for In Vivo Skin Imaging. Photochem Photobiol 2008; 84:1421–1430. PubMed | CrossRef

Chernyavskiy O, Vannucci L, Bianchini P, Difato F, et al. Imaging of Mouse Experimental Melanoma In Vivo and Ex Vivo by Combination of Confocal and Nonlinear Microscopy. Microsc Res Tech 2009; 72:411–423. PubMed | CrossRef

De Giorgi V, Massi D, Sestini S, Cicchi R, et al. Combined non-linear laser imaging (two-photon excitation fluorescence microscopy, fluorescence lifetime imaging microscopy, multispectral multiphoton microscopy) in cutaneous tumours: first experiences. J Eur Acad Dermatol Venereol 2009; 23:314–316. View Full Text | PubMed | CrossRef

Garg S, Kothari K, Thopate SR, Doke AK, et al. Design, Synthesis, and Preliminary in Vitro and in Vivo Evaluation of N-(2-diethylaminoethyl)-4-[F-18]fluorobenzamide ([F-18]-DAFBA): A Novel Potential PET Probe to Image Melanoma Tumors. Bioconjug Chem 2009; 20:583–590.

Guitera P, Pellacani G, Longo C, Seidenari S, et al. In Vivo Reflectance Confocal Microscopy Enhances Secondary Evaluation of Melanocytic Lesions. J Invest Dermatol 2009; 129:131–138. PubMed | CrossRef

Kim JH, Kim JY, Chun KA, Jee WH, et al. MR imaging manifestations of skin tumors. Eur Radiol 2008; 18:2652–2661. View Full Text | PubMed | CrossRef

Mogensen M, Joergensen TM, Nurnberg BM, Morsy HA, et al. Assessment of Optical Coherence Tomography Imaging in the Diagnosis of Non-Melanoma Skin Cancer and Benign Lesions Versus Normal Skin: Observer-Blinded Evaluation by Dermatologists and Pathologists. Dermatol Surg 2009; 35:965–972. View Full Text | PubMed | CrossRef

Povoski SP, Hall NC, Martin EW, Walker MJ. Multimodality approach of perioperative F-18-FDGPET/CT imaging, intraoperative F-18-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma - art. no. 1. World J Surg Oncol 2008:1.

Stanley RJ, Stoecker WV, Moss RH, Rabinovitz HS, et al. A basis function feature-based approach for skin lesion discrimination in dermatology dermoscopy images. Skin Res Technology 2008; 14:425–435.

Tannous Z, Al-Arashi M, Shah S, Yaroslavsky AN. Delineating Melanoma Using Multimodal Polarized Light Imaging. Laser Surg Med 2009; 41:10–16. PubMed | CrossRef

Back to Top | Article Outline
Tumor suppressor genes in melanoma and other skin neoplasms

Bonazzi VF, Irwin D, Hayward NK. Identification of Candidate Tumor Suppressor Genes Inactivated by Promoter Methylation in Melanoma. Gene Chromosomes Cancer 2009; 48.

Cretnik M, Poje G, Musani V, Kruslin B, et al. Involvement of p16 and PTCH in pathogenesis of melanoma and basal cell carcinoma. Int J Oncol 2009; 34:1045–1050. PubMed

Fung JMW, Smith R, Brown MA, Lau SH, et al. Identification and Characterization of a Novel Melanoma Tumor Suppressor Gene on Human Chromosome 6q21. Clin Cancer Res 2009; 15:797–803. PubMed

Gallagher SJ, Thompson JF, Indsto J, Scurr LL, et al. p16(INK4a) Expression and Absence of Activated B-RAF Are Independent Predictors of Chemosensitivity in Melanoma Tumors. Neoplasia 2008; 10:1231–1239. PubMed

Gleason BC, Calder KB, Cibull TL, Thomas AB, et al. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J Cutan Pathol 2009; 36:543–547. View Full Text | PubMed | CrossRef

Gruber F, Kastelan M, Brajac I, Saftic M, et al. Molecular and Genetic Mechanisms in Melanoma. Collegium Antropol 2008; 32:147–152.

Hata S, Hamada J, Maeda K, Murai T, et al. PAX4 has the potential to function as a tumor suppressor in human melanoma. Int J Oncol 2008; 33:1065–1071. PubMed

Hilliard NJ, Krahl D, Sellheyer K. p16 Expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J Cutan Pathol 2009; 36:753–759. View Full Text | PubMed | CrossRef

Kitago M, Martinez SR, Nakamura T, Sim MS, et al. Regulation of RUNX3 Tumor Suppressor Gene Expression in Cutaneous Melanoma. Clin Cancer Res 2009; 15:2988–2994. PubMed

Richmond-Sinclair NM, Lee E, Cummings MC, Williamson R, et al. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas. Melanoma Res 2008; 18:336–345. View Full Text | PubMed | CrossRef

Scott GA, McClelland LA, Fricke AF, Fender A. Plexin C1, A Receptor for Semaphorin 7A, Inactivates Cofilin and Is a Potential Tumor Suppressor for Melanoma Progression. J Invest Dermatol 2009; 129:954–963. PubMed

Udayakumar D, Tsao H. Melanoma Genetics: An Update on Risk-Associated Genes. Hematol Oncol Clin North Am 2009; 23:415–. PubMed | CrossRef

Zheng B, Jeong JH, Asara JM, Yuan YY, et al. Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation. Molecular Cell 2009; 33:237–247. PubMed | CrossRef

Back to Top | Article Outline
Epidemiology and risk factors associated with melanoma and other skin neoplasms

Buljan M, Rajacic N, Zivkovic MV, Blajic I, et al. Epidemiological Data on Melanoma from the Referral Centre in Croatia (2002-2007). Collegium Antropol 2008; 32:47–51.

Nicholls S, Hankins M, Hooley C, Smith H. A survey of the quality and accuracy of information leaflets about skin cancer and sun-protective behaviour available from UK general practices and community pharmacies. J Eur Acad Dermatol Venereol 2009; 23:566–569. View Full Text | PubMed | CrossRef

Roberts DJ, Hornung CA, Polk HC. Another Duel in the Sun: Weighing the Balances Between Sun Protection, Tanning Beds, and Malignant Melanoma. Clin Pediatr (Phila) 2009; 48:614–622.

Situm M, Buljan M, Bulat V, Mihic LL, et al. The Role of UV Radiation in the Development of Basal Cell Carcinoma. Collegium Antropol 2008; 32:167–170.

Steinberg ML, Hubbard K, Utti C, Clas B, et al. Patterns of Persistent DNA Damage Associated with Sun Exposure and the Glutathione S-transferase M1 Genotype in Melanoma Patients. Photochem Photobiol 2009; 85:379–386. PubMed | CrossRef

Vabres P. Genetic susceptibility to skin cancers [French]. Presse Med 2008; 37:1480–1483. PubMed | CrossRef

Young C. Solar ultraviolet radiation and skin cancer [Review]. Occup Med-Oxf 2009:82–88.

Back to Top | Article Outline

Head and neck

Recent advances in surgery for head and neck cancer

Review: (pp. 186–193)

•• Alkureishi LW, Burak Z, Alvarez JA, et al. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Ann Surg Oncol 2009; 16:3190–3210. View Full Text | PubMed | CrossRef [07]

Bomeli SR, Desai SC, Johnson JT, Walvekar RR. Management of salivary flow in head and neck cancer patients - A systematic review [Review]. Eur J Cancer 2009; 44(11):1000-1008, 2008 No.

• Boudreaux BA, Rosenthal EL, Magnuson JS, et al. Robot-assisted surgery for upper aerodigestive tract neoplasms. Arch Otolaryngol Head Neck Surg 2009; 135:397–401. PubMed | CrossRef [35]

Bower WF, Vlantis AC, Chung TML, Cheung SKC, et al. Quality of life in head and neck cancer patients after surgical resection: translation into Cantonese and validation of the EORTC QLQ-H&N35. Acta Otolaryngol (Stockh) 2009; 129:779–785.

Bremke M, Barth PJ, Sesterhenn AM, Budach V, et al. Prospective Study on Neck Dissection after Primary Chemoradiation Therapy in Stage IV Pharyngeal Cancer. Anticancer Res 2009; 29:2645–2653.

Cameron M, Corner A, Diba A, Hankins M. Development of a tracheostomy scoring system to guide airway management after major head and neck surgery. Int J Oral Maxillofac Surg 2009; 38:846–849. PubMed | CrossRef

• Chepeha DB, Sacco AG, Erickson VR, et al. Oropharyngoplasty with template-based reconstruction of oropharynx defects. Arch Otolaryngol Head Neck Surg 2009; 135:887–894. View Full Text | PubMed | CrossRef [20]

Cheung EJ, Wagner H, Botti JJ, Fedok F, et al. Advanced Oral Tongue Cancer in a 22-Year-Old Pregnant Woman. Ann Otol Rhinol Laryngol 2009; 118.

Cheung MC, Koniaris LG, Perez EA, Molina MA, et al. Impact of Hospital Volume on Surgical Outcome for Head and Neck Cancer. Ann Surg Oncol 2009; 16:1001–1009. View Full Text | PubMed | CrossRef

Cooper JS, Porter K, Mallin K, Hoffman HT, et al. National cancer database report on cancer of the head and neck: 10-year update. Head and Neck 2009; 31:748–758.

Dansin E, Lefebvre JL. Information on head, neck and lung cancers [Review] [French]. Bull Cancer (Paris) 2009; 96:S5–S11.

Daramola OO, Flanagan CE, Maisel RH, Odland RM. Diagnosis and treatment of deep neck space abscesses. Otolaryngol Head Neck Surg 2009; 141:123–130. View Full Text | PubMed | CrossRef

de Carvalho TP, Araujo NSS, Curcio D, Goncalves MIR. Tracheostomized patients care: efficacy of a brief theoretical education program for nursing personnel. Support Care Cancer 2009; 17:749–751. PubMed | CrossRef

de Jong FICRS, Kruizenga HM. The influence of dysphagia on nutritional status. B-ENT 2008; 4:3–6.

De Luis DA, Aller R, Izaola O, Cuellar L, et al. Arginine enhanced enteral nutrition, effect on blood inflammatory markers in head and neck cancer patients [Spanish]. Med Clin (Barc) 2009; 132:49–52.

de Luis DA, Izaola O, Cuellar L, Terroba MC, et al. High dose of arginine enhanced enteral nutrition in postsurgical head and neck cancer patients. A randomized clinical trial. Eur Rev Med Pharmacol Sci 2009; 13:279–283. PubMed

Dietz A, de Jong FICRS. Changes in swallowing after partial resection of larynx and hypopharynx. B-ENT 2008; 4:47–52.

Ducic Y, Marra DE, Kennard C. Initial Mohs Surgery Followed by Planned Surgical Resection of Massive Cutaneous Carcinomas of the Head and Neck. Laryngoscope 2009; 119:774–777. PubMed | CrossRef

Eley KA, Watt-Smith SR. Myocardial infarction diagnosed by troponin concentration in postoperative patients with head and neck cancer admitted on the day of operation. Br J Oral Maxillofac Surg 2009; 47:245–246. PubMed | CrossRef

Ethunandan M, Davies B, Pratt CA, Puxeddu R, et al. Primary epithelial submandibular salivary gland tumours - Review of management in a district general hospital setting. Eur J Cancer 2009; 45(2):173-176, 2009 Feb.

Fayda M, Aksu G, Agaoglu FY, Karadeniz A, et al. The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: Review of 30 cases. J Cranio-MaxilloFac Surg 2009; 37:42–48.

Fenner M, Vairaktaris E, Nkenke E, Weisbach V, et al. Prognostic Impact of Blood Transfusion in Patients Undergoing Primary Surgery and Free-flap Reconstruction for Oral Squamous Cell Carcinoma. Cancer 2009; 115:1481–1488. PubMed | CrossRef

Genden EM, Desai S, Sung CK. Transoral robotic surgery for the management of head and neck cancer: a preliminary experience. Head and Neck 2009; 31:283–289.

Gil Z, Fliss DM. Contemporary Management of Head and Neck Cancers [Review]. Isr Med Assoc J 2009; 11:296–300, 2009 May.

• Gonçalves AJ, de Souza Jr JA, Menezes MB, et al. Pharyngocutaneous fistulae following total laryngectomy comparison between manual and mechanical sutures. Eur Arch Otorhinolaryngol 2009; 266:1793–1798. PubMed | CrossRef [54]

Goy J, Hall SF, Feldman-Stewart D, Groome PA. Diagnostic Delay and Disease Stage in Head Neck Cancer: A Systematic Review. Laryngoscope 2009; 119:889–898. PubMed | CrossRef

Guillemaud JP, Seikaly H, Cote DWJ, Barber BR, et al. Double Free-Flap Reconstruction Indications, Challenges, and Prospective Functional Outcomes. Arch Otolaryngol Head Neck Surg 2009; 135:406–410. PubMed | CrossRef

Halle M, Bodin I, Tornvall P, Wickman M, et al. Timing of radiotherapy in head and neck free flap reconstruction - a study of postoperative complications. J Plast Reconstr Aesthet Surg 2009; 62.

Hanasono MM, Weinstock YE, Yu PR. Reconstruction of Extensive Head and Neck Defects with Multiple Simultaneous Free Flaps. Plast Reconstr Surg 2008; 122:1739–1746. View Full Text | PubMed | CrossRef

Hatoum GF, Patron B, Takita C, Abdel-Wahab M, et al. Small cell carcinoma of the head and neck: the university of miami experience. Int J Radiat Oncol Biol Phys 2009; 74.

Huslee R, Schlittler FL, Kreutziger F, Streit M, et al. Staged surgical therapy of basal cell carcinoma of the head and neck region: an evaluation of 500 procedures. Swiss Med Wkly 2008; 138:746–751. PubMed

Janot F, de Raucourt D, Benhamou E, Ferron C, et al. Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma. J Clin Oncol 2008; 26:5518–5523. PubMed | CrossRef

Kim PD, Fleck T, Heffelfinger R, Blackwell KE. Avoiding Secondary Skin Graft Donor Site Morbidity in the Fibula Free Flap Harvest. Arch Otolaryngol Head Neck Surg 2008; 134:1324–1327. View Full Text | PubMed | CrossRef

King B, Corry J. Pathology reporting in head and neck cancer-snapshot of current status. Head and Neck 2009; 31:227–231.

Kuriakose MA, Trivedi NP. Sentinel node biopsy in head and neck squamous cell carcinoma [Review]. Curr Opin Otolaryngol Head Neck Surg 2009; 17:100–110. View Full Text | PubMed | CrossRef

Lalami Y, de Castro G, Bernard-Marty C, Awada A. Management of Head and Neck Cancer in Elderly Patients [Review]. Drugs Aging 2009; 26:571–583. View Full Text | PubMed | CrossRef

Lango MN. Multimodal Treatment for Head and Neck Cancer. Surg Clin North Am 2009; 89:43. PubMed | CrossRef

Le Tourneau C, Jung GM, Borel C, Bronner G, et al. Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. Acta Otolaryngol (Stockh) 2008; 128:706–712.

Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Head and Neck 2009; 31:429–441.

Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 2009; 73.

Liebig C, Ayala G, Wilks JA, Berger DH, et al. Perineural Invasion in Cancer A Review of the Literature [Review]. Cancer 2009; 115:3379–3391. PubMed

• Lorenz KJ, Maier H. Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients. Eur Arch Otorhinolaryngol 2009; 266:1937–1944. PubMed | CrossRef [48]

Ludwig E. Dental Care in Case of Head and Neck Cancer - Part II: Resection [German]. Laryngo-Rhino-Otol 2009; 88:121–136. PubMed | CrossRef

Mao JC, Kayali FM, Dworkin JP, Stachler RJ, et al. Conservative management of iatrogenic esophageal perforation in head and neck cancer patients with esophageal stricture. Otolaryngol Head Neck Surg 2009; 140:505–511. View Full Text | PubMed | CrossRef

Marsh M, Elliott S, Anand R, Brennan PA. Early postoperative care for free flap head & neck reconstructive surgery - a national survey of practice. Br J Oral Maxillofac Surg 2009; 47:182–185. PubMed | CrossRef

Mello GFDE, Lukashok HP, Meine GC, Small IA, et al. Outpatient percutaneous endoscopic gastrostomy in selected head and neck cancer patients. Surg Endosc 2009; 23:1487–1493.

Mlynarek AM, Rieger JM, Harris JR, O'Connell DA, et al. Methods of Functional Outcomes Assessment following Treatment of Oral and Oropharyngeal Cancer: Review of the Literature [Review]. J Otolaryngol-Head Neck Surg 2008; 37:2–10.

Mochizuki Y, Matsushima E, Omura K. Perioperative assessment of psychological state and quality of life of head and neck cancer patients undergoing surgery. Int J Oral Maxillofac Surg 2009; 38:151–159.

• Moreno MA, Skoracki RJ, Hanna EY, Hanasono MM. Microvascular free flap reconstruction versus palatal obturation for maxillectomy defects. Head Neck 2009. [Epub ahead of print][22]

Mundin EO, De La Vega FA. Enteral nutrition support of head and neck cancer patients [Spanish]. Med Clin (Barc) 2009; 132:59–61.

• Nicolai P, Battaglia P, Bignami M, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol 2008; 22:308–316. PubMed | CrossRef [28]

Nuara MJ, Sauder CL, Alam DS. Prospective Analysis of Outcomes and Complications of 300 Consecutive Microvascular Reconstructions. Arch Facial Plast Surg 2009; 11:235–239. View Full Text | PubMed | CrossRef

O'Neill JP, Hughes JP, Manning KP, Fenton JE. Controversies in the management of tongue base cancer [Review]. Ir J Med Sci 2009; 178:1–5. View Full Text | PubMed | CrossRef

Oddone N, Morgan GJ, Palme CE, Perera L, et al. Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck The Immunosuppression, Treatment, Extranodal Spread, and Margin Status (ITEM) Prognostic Score to Predict Outcome and the Need to Improve Survival. Cancer 2009; 115:1883–1891. PubMed

Ogihara H, Takeuchi K, Majima Y. Risk factors of postoperative infection in head and neck surgery. Auris Nasus Larynx 2009; 36.

Pauloski BR. Rehabilitation of Dysphagia Following Head and Neck Cancer [Review]. Phys Med Rehabil Clin N Am 2008; 19:889–. PubMed | CrossRef

Pehlivan B, Zouhair A, Luthi F, Bron L, et al. Decrease in Hemoglobin Levels Following Surgery Influences the Outcome in Head and Neck Cancer Patients Treated with Accelerated Postoperative Radiotherapy. Ann Surg Oncol 2009; 16:1331–1336. View Full Text | PubMed | CrossRef

Rampazzo A, Salgado CJ, Gharb BB, Mardini S, et al. Donor-Site Morbidity after Free Ileocolon Flap Transfer for Esophageal and Voice Reconstruction. Plast Reconstr Surg 2008; 122:186E–194E. View Full Text | PubMed | CrossRef

Robotic surgery now used to treat head and neck cancer. Future Oncol 2008; 4:320.

Rogers SN, Brown JS, Woolgar JA, Lowe D, et al. Survival following primary surgery for oral cancer. Eur J Cancer 2009; 45(3):201-211, 2009 Mar.

Sanguineti G, Califano J, Stafford E, Fox J, et al. Defining the risk of involvement for each neck nodal level in patients with early t-stage node-positive oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2009; 74.

Schache AG, Lieger O, Rogers P, Kelly A, et al. Predictors of swallowing outcome in patients treated with surgery and radiotherapy for advanced oral and oropharyngeal cancer. Eur J Cancer 2009; 45(9):803-808, 2009 Sep.

Schelthauer MO, Riechelmann H. Role of Surgery in Multimodal Treatment of Oral and Oropharyngeal Cancer [German]. Laryngo-Rhino-Otol 2009; 88:101–105. PubMed

Sepehr A, Santos BJG, Chou C, Karimi K, et al. Antibiotics in Head and Neck Surgery in the Setting of Malnutrition, Tracheotomy, and Diabetes. Laryngoscope 2009; 119:549–553. PubMed | CrossRef

Shah JP, Gil Z. Current concepts in management of oral cancer - Surgery [Review]. Eur J Cancer 2009; 45(4-5):394-401, 2009 Apr.

Sharan R, Sharma M, Vijayaraghavan S, Sasidharan PR, et al. HOW I DO IT A Simplified Technique of Free Flap Pedicle Transfer for Reconstruction of Defects Following Head and Neck Cancer Ablation. J Surg Oncol 2009; 99:80–81.

Shimizu F, Lin MP, Ellabban M, Evans GRD, et al. Superficial Temporal Vessels as a Reserve Recipient Site for Microvascular Head and Neck Reconstruction in Vessel-Depleted Neck. Ann Plast Surg 2009; 62:134–138. View Full Text | PubMed | CrossRef

Singer S, Wollbruck D, Wulke C, Dietz A, et al. Validation of the eortc qlq-c30 and eortc qlq-h&n35 in patients with laryngeal cancer after surgery. Head and Neck 2009; 31:64–76.

Smith JE, Suh JD, Erman A, Nabili V, et al. Risk Factors Predicting Aspiration After Free Flap Reconstruction of Oral Cavity and Oropharyngeal Defects. Arch Otolaryngol Head Neck Surg 2008; 134:1205–1208. View Full Text | PubMed | CrossRef

•• Snyderman CH, Carrau RL, Kassam AB, et al. Endoscopic skull base surgery: principles of endonasal oncological surgery. J Surg Oncol 2008; 97:658–666. PubMed | CrossRef [24]

Sorensen LTCD, McCarthy M, Baumgartner MAJB, Demars CPTS. Perioperative Immunonutrition in Head and Neck Cancer. Laryngoscope 2009; 119:1358–1364. PubMed | CrossRef

Stableforth WD, Thomas S, Lewis SJ. A systematic review of the role of immunonutrition in patients undergoing surgery for head and neck cancer [Review]. Int J Oral Maxillofac Surg 2009; 38:103–110. PubMed | CrossRef

• Stoeckli SJ, Alkureishi LW, Ross GL. Sentinel node biopsy for early oral and oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 2009; 266:787–793. PubMed | CrossRef [06]

Stoeckli SJ, Alkureishi LWT, Ross GL. Sentinel node biopsy for early oral and oropharyngeal squamous cell carcinoma [Review]. Eur Arch Otorhinolaryngol 2009; 266:787–793. PubMed | CrossRef

Suh JD, Kim BP, Abemayor E, Sercarz JA, et al. Reirradiation after salvage surgery and microvascular free flap reconstruction for recurrent head and neck carcinoma. Otolaryngol Head Neck Surg 2008; 139:781–786. View Full Text | PubMed | CrossRef

Sumer BD, Gastman BR, Nussenbaum B, Gao F, et al. Microvascular Flap Reconstruction of Major Pharyngeal Resections With the Intent of Laryngeal Preservation. Arch Otolaryngol Head Neck Surg 2009; 135:801–806. View Full Text | PubMed | CrossRef

Sumer BD, Myers LL, Leach J, Truelson JM. Correlation Between Intraoperative Hypothermia and Perioperative Morbidity in Patients With Head and Neck Cancer. Arch Otolaryngol Head Neck Surg 2009; 135:682–686. View Full Text | PubMed | CrossRef

Supriya M, Shakeel M, Santangeli L, Ah-See KW. Controlling MRSA in head and neck cancer patients: What works? Otolaryngol Head Neck Surg 2009; 140:224–227.

Syrigos KN, Karachalios D, Karapanagiotou EM, Nutting CM, et al. Head and neck cancer in the elderly: An overview on the treatment modalities [Review]. Cancer Treat Rev 2009; 35:237–245. PubMed | CrossRef

van der Eerden PA, Lohuis PJFM, Hart AAM, Mulder WC, et al. Secondary Intention Healing after Excision of Nonmelanoma Skin Cancer of the Head and Neck: Statistical Evaluation of Prognostic Values of Wound Characteristics and Final Cosmetic Results. Plast Reconstr Surg 2008; 122:1747–1755. View Full Text | PubMed | CrossRef

Vartanian JG, Kowalski LP. Acceptance of Major Surgical Procedures and Quality of Life Among Long-term Survivors of Advanced Head and Neck Cancer. Arch Otolaryngol Head Neck Surg 2009; 135:376–379. PubMed | CrossRef

Vaughan ED. Functional outcomes of free tissue transfer in head and neck cancer reconstruction [Review]. Eur J Cancer 2009; 45(4-5):421-430, 2009 Apr.

Waltonen JD, Ozer E, Schuller DE, Agrawal A. Tonsillectomy vs. Deep Tonsil Biopsies in Detecting Occult Tonsil Tumors. Laryngoscope 2009; 119:102–106. PubMed | CrossRef

• Weinstein GS, O'Malley Jr BW, Desai SC, Quon H. Transoral robotic surgery: does the ends justify the means? Curr Opin Otolaryngol Head Neck Surg 2009; 17:126–131.[37]

Yu PR, Chang DW, Miller MJ, Reece G, et al. Analysis of 49 cases of flap compromise in 1310 free flaps for head and neck reconstruction. Head and Neck 2009; 31:45–51.

Back to Top | Article Outline
Advances in radiotherapy of head and neck cancers

Review: (pp. 194–199)

Agada FO, Alhamarneh O, Stafford ND, Greenman J. Immunotherapy in head and neck cancer: current practice and future possibilities [Review]. J Laryngol Otol 2009; 123:19–28. PubMed

Ash L, Teknos TN, Gandhi D, Patel S, et al. Head and Neck Squamous Cell Carcinoma: CT Perfusion Can Help Noninvasively Predict Intratumoral Microvessel Density. Radiology 2009; 251:422–428. PubMed | CrossRef

Baek CH, Chung MK, Jeong HS, Son YI, et al. The Clinical Usefulness of F-18-FDG PET/CT for the Evaluation of Lymph Node Metastasis in Periorbital Malignancies. Korean J Radiol 2009; 10:1–7. PubMed | CrossRef

Berson AM, Stein NF, Riegel AC, Destian S, et al. Variability of gross tumor volume delineation in head-and-neck cancer using pet/ct fusion, part ii: the impact of a contouring protocol. Med Dosim 2009; 34:30–35. PubMed | CrossRef

Bomeli SR, Desai SC, Johnson JT, Walvekar RR. Management of salivary flow in head and neck cancer patients - A systematic review [Review]. Eur J Cancer 2009; 44(11):1000-1008, 2008 No.

• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21–28. PubMed | CrossRef [09]

Brennan PA, Oeppen RS, Bater MC, Khosla N, et al. CT and duplex scanning: A comparison of imaging techniques for evaluation of the carotid tree in head and neck cancer patients. Eur J Cancer 2009; 44(11):1009-1013, 2008 No

Cao Y, Popovtzer A, Li D, Chepeha DB, et al. Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int J Radiat Oncol Biol Phys 2009; 72.

Chen AY, Pavluck A, Halpern M, Ward E. Impact of treating facilities' volume on survival for early-stage laryngeal cancer. Head and Neck 2009; 31:1137–1143.

Cheung EJ, Wagner H, Botti JJ, Fedok F, et al. Advanced Oral Tongue Cancer in a 22-Year-Old Pregnant Woman. Ann Otol Rhinol Laryngol 2009; 118.

Christian N, Lee JA, Bol A, De Bast M, et al. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol 2009; 91:101–106. PubMed | CrossRef

Cooper JS, Porter K, Mallin K, Hoffman HT, et al. National cancer database report on cancer of the head and neck: 10-year update. Head and Neck 2009; 31:748–758.

Cozens NJA. A systematic review that evaluates one-stop neck lump clinics [Review]. Clin Otolaryngol 2009; 34:6–11. View Full Text | PubMed | CrossRef

Dawson P, Punwani S. The thyroid dose burden in medical imaging A re-examination. Eur J Radiol 2009; 69:74–79. PubMed | CrossRef

de Bondt BJ, Stokroos R, Casselman JW, van Engelshoven JMA, et al. Clinical impact of short tau inversion recovery mri on staging and management in patients with cervical lymph node metastases of head and neck squamous cell carcinomas. Head and Neck 2009; 31:928–937.

de Bree R, van der Putten L, Brouwer J, Castelijns JA, et al. Detection of locoregional recurrent head and neck cancer after (chemo) radiotherapy using modern imaging [Review]. Eur J Cancer 2009; 45(4-5):386-393, 2009 Apr.

De Luis DA, Aller R, Izaola O, Cuellar L, et al. Arginine enhanced enteral nutrition, effect on blood inflammatory markers in head and neck cancer patients [Spanish]. Med Clin (Barc) 2009; 132:49–52.

De Schutter H, Geeraerts H, Verbeken E, Nuyts S. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. Oncol Rep 2009; 21:507–513. PubMed

Deng G, Hou BL, Holodny AI, Cassileth BR. Functionalmagneticresonanceimaging(fMRI) changesandsaliva production associated with acupuncture at LI-2 acupuncture point: a randomized controlled study - art. no. 137. BMC Complement Altern Med 2008:137.

Ding GX, Coffey CW. Radiation dose from kilovoltage cone beam computed tomography in an image-guided radiotherapy procedure. Int J Radiat Oncol Biol Phys 2009; 73.

Dumur CI, Ladd AC, Wright HV, Penberthy LT, et al. Genes Involved in Radiation Therapy Response in Head and Neck Cancers. Laryngoscope 2009; 119:91–101. PubMed | CrossRef

Emonts P, Bourgeois P, Lemort M, Flamen P. Functional imaging of head and neck cancers [Review]. Curr Opin Oncol 2009; 21:212–217. View Full Text | PubMed | CrossRef

Ethunandan M, Davies B, Pratt CA, Puxeddu R, et al. Primary epithelial submandibular salivary gland tumours - Review of management in a district general hospital setting. Eur J Cancer 2009; 45(2):173-176, 2009 Feb.

Fayda M, Aksu G, Agaoglu FY, Karadeniz A, et al. The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: Review of 30 cases. J Cranio-MaxilloFac Surg 2009; 37:42–48.

Fischer M, Strauss G, Gahr S, Richter I, et al. Three-dimensional Visualization for Preoperative Planning and Evaluation in Head and Neck Surgery [Review] [German]. Laryngo-Rhino-Otol 2009; 88:229–233. PubMed | CrossRef

Flynn RT, Hartmann J, Bani-Hashemi A, Nixon E, et al. Dosimetric characterization and application of an imaging beam line with a carbon electron target for megavoltage cone beam computed tomography. Med Phys 2009; 36:2181–2192. PubMed | CrossRef

Gagnon PJ, Galderisi C, Page BR, Holland JM. Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx. Head and Neck 2009; 31:829–832.

Gardner M, Halimi P, Valinta D, Plantet MM, et al. Use of single mri and 18f-fdg pet-ct scans in both diagnosis and radiotherapy treatment planning in patients with head and neck cancer: advantage on target volume and critical organ delineation. Head and Neck 2009; 31:461–467.

Gerard K, Grandhaye JP, Marchesi V, Kafrouni H, et al. A comprehensive analysis of the IMRT dose delivery process using statistical process control (SPC). Med Phys 2009; 36:1275–1285. PubMed | CrossRef

Gil Z, Fliss DM. Contemporary Management of Head and Neck Cancers [Review]. Isr Med Assoc J 2009; 11:296–300, 2009 May.

Gourin CG, Watts T, Williams HT, Patel VS, et al. Identification of Distant Metastases With PET-CT in Patients With Suspected Recurrent Head and Neck Cancer. Laryngoscope 2009; 119:703–706. PubMed | CrossRef

Goy J, Hall SF, Feldman-Stewart D, Groome PA. Diagnostic Delay and Disease Stage in Head Neck Cancer: A Systematic Review. Laryngoscope 2009; 119:889–898. PubMed | CrossRef

Graveland AP, de Maaker M, Braakhuis BJM, de Bree R, et al. Molecular detection of minimal residual cancer in surgical margins of head and neck cancer patients. Cellular Oncology 2009; 31:317–328.

Guido A, Barbieri E, Fuccio L, Eusebi LH, et al. “Combined f-18-fdg-pet/ct imaging in radiotherapy target delineation for head-and-neck cancer”: in regard to guido et al. (int j radiat oncol biol phys 2009;73:759-763) response. Int J Radiat Oncol Biol Phys 2009; 74.

Guido A, Fuccio L, Rombi B, Castellucci P, et al. Combined f-18-fdg-pet/ct imaging in radiotherapy target delineation for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 73.

Hall WH, Guiou M, Lee NY, Dublin A, et al. Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with imrt for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 72.

Halle M, Bodin I, Tornvall P, Wickman M, et al. Timing of radiotherapy in head and neck free flap reconstruction - a study of postoperative complications. J Plast Reconstr Aesthet Surg 2009; 62.

Hanvey S, Glegg M, Foster J. Magnetic resonance imaging for radiotherapy planning of brain cancer patients using immobilization and surface coils. Phys Med Biol 2009; 54:5381–5394. PubMed | CrossRef

Hatoum GF, Patron B, Takita C, Abdel-Wahab M, et al. Small cell carcinoma of the head and neck: the university of miami experience. Int J Radiat Oncol Biol Phys 2009; 74.

Ho K, Fowler J, Sykes A, Yap B, et al. IMRT dose fractionation for head and neck cancer: Variation in current approaches will make standardisation difficult. Acta Oncol 2009; 48:431–439. PubMed | CrossRef

Hundt W, Yuh EL, Steinbach S, Bednarski MD. Effect of Continuous High Intensity Focused Ultrasound in a Squamous Cell Carcinoma Tumor Model Compared to Muscle Tissue Evaluated by MRI, Histology, and Gene Expression. Technol Cancer Res Treatment 2009; 8:85–97.

Iseli TA, Kulbersh BD, Iseli CE, Carroll WR, et al. Functional outcomes after transoral robotic surgery for head and neck cancer. Otolaryngol Head Neck Surg 2009; 141:166–171. View Full Text | PubMed | CrossRef

• Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26:5518–5523. PubMed | CrossRef [27]

Janot F, de Raucourt D, Benhamou E, Ferron C, et al. Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma. J Clin Oncol 2008; 26:5518–5523. PubMed | CrossRef

Kim S, Loevner L, Quon H, Sherman E, et al. Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck. Clin Cancer Res 2009; 15:986–994. PubMed

Kim TB, Klein HZ, Glastonbury CM, Eisele DW. Primary squamous cell carcinoma of stensen's duct in a patient with hiv: the role of magnetic resonance imaging and fine-needle aspiration. Head and Neck 2009; 31:278–282.

Kizaka-Kondoh S, Konse-Nagasawa H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia [Review]. Cancer Science 2009; 100:1366–1373. PubMed | CrossRef

Kodaira T, Tomita N, Tachibana H, Nakamura T, et al. Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical tomotherapy. Int J Radiat Oncol Biol Phys 2009; 73.

Kruser TJ, Bradley KA, Bentzen SM, Anderson BM, et al. The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. Technol Cancer Res Treatment 2009; 8:149–158.

Lalami Y, de Castro G, Bernard-Marty C, Awada A. Management of Head and Neck Cancer in Elderly Patients [Review]. Drugs Aging 2009; 26:571–583. View Full Text | PubMed | CrossRef

Lango MN. Multimodal Treatment for Head and Neck Cancer. Surg Clin North Am 2009; 89:43. PubMed | CrossRef

Laramore GE. Role of particle radiotherapy in the management of head and neck cancer [Review]. Curr Opin Oncol 2009; 21:224–231. View Full Text | PubMed | CrossRef

Laytragoon-Lewin N, Ustun H, Castro J, Friesland S, et al. In vitro effect of radiation, antibody to epidermal growth factor receptor and Docetaxel in human head and neck squamous carcinoma cells with mutant P53 and over-expressed EGFR. J Cancer Res Clin Oncol 2009; 135:203–209. PubMed | CrossRef

Le Tourneau C, Jung GM, Borel C, Bronner G, et al. Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. Acta Otolaryngol (Stockh) 2008; 128:706–712.

Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 2009; 73.

Li LF, Zhou SH, Zhao K, Wang SQ, et al. Clinical Significance of FDG Single-Photon Emission Computed Tomography: Computed Tomography in the Diagnosis of Head and Neck Cancers and Study of Its Mechanism. Cancer Biother Radiopharm 2008; 23:701–714. PubMed | CrossRef

Lin MH, Chao TC, Lee CC, Tung CJ, et al. Measurement-based Monte Carlo dose calculation system for IMRT pretreatment and on-line transit dose verifications. Med Phys 2009; 36:1167–1175. PubMed | CrossRef

Liu LZ, Liang SB, Li L, Mao YP, et al. Prognostic Impact of Magnetic Resonance Imaging-detected Cranial Nerve Involvement in Nasopharyngeal Carcinoma. Cancer 2009; 115:1995–2003.

Ludwig E. Dental Care in Case of Head and Neck Cancer - Part I: Radiotherapy [German]. Laryngo-Rhino-Otol 2008; 87:885–899. PubMed | CrossRef

MacManus M, Nestle U, Rosenzweig KE, Carrio I, et al. Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006-2007 [Review]. Radiother Oncol 2009; 91:85–94. PubMed | CrossRef

Martin RCW, Fulham M, Shannon KF, Hughes C, et al. Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head and Neck 2009; 31:244–250.

Mauri D, Polyzos NP, Salanti G, Pavlidis N, et al. Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer [Review]. J Natl Cancer Inst 2008; 100:1780–1791. View Full Text | PubMed | CrossRef

Mazeron JJ, Ardiet JM, Haie-Meder C, Kovacs G, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009; 91:150–156. PubMed | CrossRef

Mazeron R, Tao YG, Lusinchi A, Bourhis J. Current concepts of management in radiotherapy for head and neck squamous-cell cancer [Review]. Eur J Cancer 2009; 45(4-5):402-408, 2009 Apr.

Mechalakos J, Lee N, Hunt M, Ling CC, et al. The effect of significant tumor reduction on the dose distribution in intensity modulated radiation therapy for head-and-neck cancer: a case study. Med Dosim 2009; 34:250–255. PubMed | CrossRef

Miller MC, Agrawal A. Hypothyroidism in postradiation head and neck cancer patients: incidence, complications, and management. Curr Opin Otolaryngol Head Neck Surg 2009; 17:111–115. View Full Text | PubMed | CrossRef

Mlynarek AM, Rieger JM, Harris JR, O'Connell DA, et al. Methods of Functional Outcomes Assessment following Treatment of Oral and Oropharyngeal Cancer: Review of the Literature [Review]. J Otolaryngol-Head Neck Surg 2008; 37:2–10.

Moeller BJ, Rana V, Cannon BA, Williams MD, et al. Prospective Risk-Adjusted [F-18]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. J Clin Oncol 2009; 27:2509–2515.

Mundin EO, De La Vega FA. Enteral nutrition support of head and neck cancer patients [Spanish]. Med Clin (Barc) 2009; 132:59–61.

Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography [Review]. Phys Med Biol 2009; 54:R1–R25. PubMed | CrossRef

Newbold K, Castellano I, Charles-Edwards E, Mears D, et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74.

Nguyen NP, Frank C, Moltz CC, Millar C, et al. Aspiration Risk and Postoperative Radiation for Head and Neck Cancer. Cancer Invest 2009; 27:47–51. PubMed | CrossRef

Nitin N, Rosbach KJ, El-Naggar A, Williams M, et al. Optical Molecular Imaging of Epidermal Growth Factor Receptor Expression to Improve Detection of Oral Neoplasia. Neoplasia 2009; 11:542–551. PubMed

Niyazi M, Marini P, Daniel PT, Humphreys R, et al. Efficacy of a Triple Treatment with Irradiation, Agonistic TRAIL Receptor Antibodies and EGFR Blockade. Strahlenther Onkol 2009; 185:8–18. PubMed | CrossRef

• Nutting C, A'Hern R, Rogers MS, et al. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J Clin Oncol (Meeting Abstracts) 2009; 27:LBA6006.[44]

Nyst HJ, Tan IB, Stewart FA, Balm AJM. Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer? [Review]. Photodiagnosis and Photodynamic Therapy 2009; 6:3–11.

Patel UA, Patadia MO, Holloway N, Rosen F. Poor Radiotherapy Compliance Predicts Persistent Regional Disease in Advanced Head/Neck Cancer. Laryngoscope 2009; 119:528–533. PubMed | CrossRef

Pauloski BR. Rehabilitation of Dysphagia Following Head and Neck Cancer [Review]. Phys Med Rehabil Clin N Am 2008; 19:889. PubMed | CrossRef

Pehlivan B, Pichenot C, Castaing M, Auperin A, et al. Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients. Acta Oncol 2009; 48:440–445. PubMed | CrossRef

Pehlivan B, Zouhair A, Luthi F, Bron L, et al. Decrease in Hemoglobin Levels Following Surgery Influences the Outcome in Head and Neck Cancer Patients Treated with Accelerated Postoperative Radiotherapy. Ann Surg Oncol 2009; 16:1331–1336. View Full Text | PubMed | CrossRef

•• Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4–14.[03]

Poeppel TD, Krause BJ, Heusner TA, Boy C, et al. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009; 70:382–392. PubMed | CrossRef

• Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101:498–506. View Full Text | PubMed | CrossRef [19]

Popovtzer A, Gluck I, Chepeha DB, Teknos TN, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 2009; 74.

Porceddu SV, Burmeister BH, Hicks RJ. Role of Functional Imaging in Head and Neck Squamous Cell Carcinoma: Fluorodeoxyglucose Positron Emission Tomography and Beyond. Hematol Oncol Clin North Am 2008; 22:1221. PubMed | CrossRef

Rigual NR, Thankappan K, Cooper M, Sullivan MA, et al. Photodynamic Therapy for Head and Neck Dysplasia and Cancer. Arch Otolaryngol Head Neck Surg 2009; 135:784–788. View Full Text | PubMed | CrossRef

Rosenthal DI, Mendoza TR, Chambers MS, Burkerr VS, et al. The m. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys 2009; 72.

Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V15-32, INTEREST and IPASS trials [Review]. Nat Rev Clin Oncol 2009; 6:287–294.

Sanguineti G, Forastiere AA. Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer. Nat Clin Pract Oncol 2008; 5:694–695. View Full Text | PubMed | CrossRef

Schache AG, Lieger O, Rogers P, Kelly A, et al. Predictors of swallowing outcome in patients treated with surgery and radiotherapy for advanced oral and oropharyngeal cancer. Eur J Cancer 2009; 45(9):803-808, 2009 Sep.

Schinagl DAX, Hoffmann AL, Vogel WV, van Dalen JA, et al. Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer? Radiother Oncol 2009; 91:95–100.

Schinagl DAX, Troost EGC, Kaanders JHAM. “Combined f-18-fdg-pet/ct imaging in radiotherapy target delineation for head-and-neck cancer”: in regard to guido et al. (int j radiat oncol biol phys 2009;73:759-763). Int J Radiat Oncol Biol Phys 2009; 74.

Sennhenn-Kirchner S, Freund F, Grundmann S, Martin A, et al. Dental therapy before and after radiotherapy-an evaluation on patients with head and neck malignancies. Clin Oral Investig 2009; 13:157–164. PubMed | CrossRef

Shah JP, Gil Z. Current concepts in management of oral cancer - Surgery [Review]. Eur J Cancer 2009; 45(4-5):394-401, 2009 Apr.

Siddiqui F, Patel M, Khan M, McLean S, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009; 74.

Silva P, Slevin NJ, Sloan P, Valentine H, et al. Prognostic significance of tumor hypoxia inducible factor-1 alpha expression for outcome after radiotherapy in oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2009; 72.

Singh S, Rosenthal DI, Ginsberg LE. Enlargement and Transformation of Thyroglossal Duct Cysts in Response to Radiotherapy: Imaging Findings. AJNR Am J Neuroradiol 2009; 30:800–802. PubMed | CrossRef

Smith GL, Smith BD, Garden AS, Rosenthal DI, et al. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head and Neck 2009; 31:1031–1038.

Sovik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review [Review]. Int J Radiat Oncol Biol Phys 2009; 73.

Suh JD, Kim BP, Abemayor E, Sercarz JA, et al. Reirradiation after salvage surgery and microvascular free flap reconstruction for recurrent head and neck carcinoma. Otolaryngol Head Neck Surg 2008; 139:781–786. View Full Text | PubMed | CrossRef

Sulman EP, Schwartz DL, Le TT, Ang KK, et al. Imrt reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009; 73.

Supriya M, Shakeel M, Santangeli L, Ah-See KW. Controlling MRSA in head and neck cancer patients: What works? Otolaryngol Head Neck Surg 2009; 140:224–227.

Syrigos KN, Karachalios D, Karapanagiotou EM, Nutting CM, et al. Head and neck cancer in the elderly: An overview on the treatment modalities [Review]. Cancer Treat Rev 2009; 35:237–245. PubMed | CrossRef

Tiziani S, Lopes V, Gunther UL. Early Stage Diagnosis of Oral Cancer Using H-1 NMR-Based Metabolomics. Neoplasia 2009; 11:269–NIL_69. PubMed

van Elmpt W, Nusten S, Petit S, Munheer B, et al. 3d in vivo dosimetry using megavoltage cone-beam ct and epid dosimetry. Int J Radiat Oncol Biol Phys 2009; 73.

Vavassis P, Gelinas M, Tr JC, Nguyen-Tan PF. Phase 2 Study of Silver Leaf Dressing for Treatment of Radiation-Induced Dermatitis in Patients Receiving Radiotherapy to the Head and Neck. J Otolaryngol-Head Neck Surg 2008; 37:124–129.

Verduijn GM, Bartels LW, Raaijmakers CPJ, Terhaard CHJ, et al. Magnetic resonance imaging protocol optimization for delineation of gross tumor volume in hypopharyngeal and laryngeal tumors. Int J Radiat Oncol Biol Phys 2009; 74.

Vlad RM, Brand S, Giles A, Kolios MC, et al. Quantitative Ultrasound Characterization of Responses to Radiotherapy in Cancer Mouse Models. Clin Cancer Res 2009; 15:2067–2075. PubMed

Wang WL, Georgi JC, Nehmeh SA, Narayanan M, et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol 2009; 54:3083–3099.

Wang YJ, Wells W, Waldron J. Indications and Outcomes of Radiation Therapy for Skin Cancer of the Head and Neck. Clin Plast Surg 2009; 36:335–. PubMed | CrossRef

Watkins JM, Shirai KS, Wahiquist AE, Stuart RK, et al. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head and Neck 2009; 31:493–502.

Watson JM, Logan HL, Tomar SL, Sandow P. Factors associated with early-stage diagnosis of oral and pharyngeal cancer. Community Dent Oral Epidemiol 2009; 37:333–341. View Full Text | PubMed | CrossRef

Webster GJ, Kilgallon JE, Ho KF, Rowbottom CG, et al. A novel imaging technique for fusion of high-quality immobilised MR images of the head and neck with CT scans for radiotherapy target delineation. Br J Radiol 2009; 82:497–503. PubMed | CrossRef

Wendling M, McDermott LN, Mans A, Sonke JJ, et al. A simple backprojection algorithm for 3D in vivo EPID dosimetry of IMRT treatments. Med Phys 2009; 36:3310–3321. PubMed | CrossRef

Wildeman MAM, Gibcus JH, Hauptmann M, Begg AC, et al. Radiotherapy in Laryngeal Carcinoma: Can a Panel of 13 Markers Predict Response? Laryngoscope 2009; 119:316–322.

Wong CYO, Noujaim D, Fu HF, Huang WS, et al. Time Sensitivity: A Parameter Reflecting Tumor Metabolic Kinetics by Variable Dual-Time F-18 FDG PET Imaging. Mol Imaging Biol 2009; 11:283–290. PubMed | CrossRef

Yao M, Smith RB, Hoffman HT, Funk GF, et al. Clinical significance of postradiotherapy [f-18]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 2009; 74.

Back to Top | Article Outline
Role of biomarkers in the management of head and neck cancers

Agarwal JP, Jain S, Gupta T, Tiwari M, et al. Intraoral adenoid cystic carcinoma: Prognostic factors and outcome. Eur J Cancer 2009; 44(10):986-993, 2008 Oct.

Ahmad SM, Esmaeli B, Williams M, Nguyen J, et al. American Joint Committee on Cancer Classification Predicts Outcome of Patients with Lacrimal Gland Adenoid Cystic Carcinoma. Ophthalmology 2009; 116:1210–1215. PubMed | CrossRef

Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA Expression Ratio Is Predictive of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2009; 15:2850–2855. PubMed

Bauvet F, Awada A, Gil T, Hendlisz A. Therapeutic consequences of molecular biology advances in oncology [Review] [French]. Bull Cancer (Paris) 2009; 96:59–71.

Bergmann C, Wimmer E. Role of tyrosine kinases in tumor progression of the head and neck [German]. HNO 2009; 57:123–132. PubMed | CrossRef

Bian YS, Terse A, Du J, Hall B, et al. Progressive Tumor Formation in Mice with Conditional Deletion of TGF-beta Signaling in Head and Neck Epithelia Is Associated with Activation of the PI3K/Akt Pathway. Cancer Res 2009; 69:5918–5926. PubMed | CrossRef

Bijian K, Mlynarek AM, Balys RL, Jie S, et al. Serum Proteomic Approach for the Identification of Serum Biomarkers Contributed by Oral Squamous Cell Carcinoma and Host Tissue Microenvironment. J Proteome Res 2009; 8:2173–2185. PubMed | CrossRef

Bilde A, von Buchwald C, Dabelsteen E, Therkildsen MH, et al. Molecular markers in the surgical margin of oral carcinomas. J Oral Pathol Med 2009; 38:72–78. PubMed

Cao J, Zhou J, Gao Y, Gu LK, et al. Methylation of p16 CpG Island Associated with Malignant Progression of Oral Epithelial Dysplasia: A Prospective Cohort Study. Clin Cancer Res 2009; 15:5178–5183. PubMed

Chen CB, Su YC, Huang TT, Ho HC, et al. Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer. Clin Chim Acta 2008; 398:48–52. PubMed | CrossRef

Chi LM, Lee CW, Chang KP, Hao SP, et al. Enhanced Interferon Signaling Pathway in Oral Cancer Revealed by Quantitative Proteome Analysis of Microdissected Specimens Using O-16/O-18 Labeling and Integrated Two-dimensional LC-ESI-MALDI Tandem MS [Review]. Mol Cell Proteomics 2009; 8:1453–1474. PubMed | CrossRef

Childs G, Fazzari M, Kung G, Kawachi N, et al. Low-Level Expression of MicroRNAs let-7d and miR-205 Are Prognostic Markers of Head and Neck Squamous Cell Carcinoma. Am J Pathol 2009; 174:736–745. PubMed | CrossRef

Chung YL, Lee MY, Horng CF, Jian JJM, et al. Use of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiotherapy alone. Head and Neck 2009; 31:9–20.

Cohen AN, Veena MS, Srivatsan ES, Wang MB. Suppression of Interleukin 6 and 8 Production in Head and Neck Cancer Cells With Curcumin via Inhibition of I kappa beta Kinase. Arch Otolaryngol Head Neck Surg 2009; 135:190–197. View Full Text | PubMed | CrossRef

Cojocariu OM, Huguet F, Lefevre M, Perie S. Prognosis and predictive factors in head-and-neck cancers [French]. Bull Cancer (Paris) 2009; 96:369–378.

Colombo J, Fachel AA, Calmon MD, Cury PM, et al. Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma. Oncol Rep 2009; 21:649–663. PubMed

Czeminski R, Amornphimoltham P, Patel V, Molinolo AA, et al. Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model. Cancer Prev Res 2009; 2:27–36.

De Schutter H, Geeraerts H, Verbeken E, Nuyts S. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. Oncol Rep 2009; 21:507–513. PubMed

Dumur CI, Ladd AC, Wright HV, Penberthy LT, et al. Genes Involved in Radiation Therapy Response in Head and Neck Cancers. Laryngoscope 2009; 119:91–101. PubMed | CrossRef

Escher A, Piotet E, Waridel F, Iggo R, et al. p53 mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients. Eur Arch Otorhinolaryngol 2009; 266:547–551. PubMed | CrossRef

Ferguson PJ, Brisson AR, Koropatnick J, Vincent MD. Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. Cancer Lett 2009; 274:279–289. PubMed | CrossRef

Fetz V, Bier C, Habtemichael N, Schuon R, et al. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer 2009; 124:2033–2041. PubMed | CrossRef

Freed GL, Cazares LH, Fichandler CE, Fuller TW, et al. Differential Capture of Serum Proteins for Expression Profiling and Biomarker Discovery in Pre- and Posttreatment Head and Neck Cancer Samples. Laryngoscope 2008; 118:61–68. View Full Text | PubMed | CrossRef

Fulda S. Tumor resistance to apoptosis [Review]. Int J Cancer 2009; 124:511–515. PubMed | CrossRef

Gallagher TQ, Derkay CS. Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg 2008; 16:536–542. View Full Text | PubMed | CrossRef

Glazer CA, Chang SS, Ha PK, Califano JA. Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice [Review]. Eur J Cancer 2009; 45(4-5):440-446, 2009 Apr.

Gold KA, Kim ES. Role of molecular markers and gene profiling in head and neck cancers [Review]. Curr Opin Oncol 2009; 21:206–211. View Full Text | PubMed | CrossRef

Gourin CG, Zhi WB, Adam BL. Proteomic Identification of Serum Biomarkers for Head and Neck Cancer Surveillance. Laryngoscope 2009; 119:1291–1302. PubMed | CrossRef

Gunduz E, Gunduz M, Beder L, Nagatsuka H, et al. Downregulation of TESTIN and Its Association With Cancer History and a Tendency Toward Poor Survival in Head and Neck Squamous Cell Carcinoma. Arch Otolaryngol Head Neck Surg 2009; 135:254–260. PubMed | CrossRef

Hall SF, Groorne PA, Irish J, O'Sullivan B. Towards Further Understanding of Prognostic Factors for Head and Neck Cancer Patients: The Example of Hypopharyngeal Cancer. Laryngoscope 2009; 119:696–702. PubMed | CrossRef

Hashibe M, Brennan P, Chuang SC, Boccia S, et al. Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18.

Hoffmann TK, Sonkoly E, Hauser U, Liero A, et al. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Eur J Cancer 2009; 44(12):1100-1109, 2008 De.

Hsiao JR, Leu SF, Huang BM. Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines. J Oral Pathol Med 2009; 38:188–197. View Full Text | PubMed | CrossRef

Jumah MD, Fleiner F, Wendt S, Pavel M, et al. Poorly differentiated neuroendocrine carcinoma of the larynx Diagnostic features, treatment strategy, and prognosis [German]. HNO 2009; 57:135–141. PubMed | CrossRef

Katase N, Gunduz M, Beder L, Gunduz E, et al. Deletion at Dickkopf (Dkk)-3 Locus (11p15.2) Is Related With Lower Lymph Node Metastasis and Better Prognosis in Head and Neck Squamous Cell Carcinomas. Oncol Res 2008; 17:273–282. PubMed | CrossRef

Kesting MR, Loeffelbein DJ, Hasler RJ, Wolff KD, et al. Expression Profile of Human Beta-Defensin 3 in Oral Squamous Cell Carcinoma. Cancer Invest 2009; 27:575–581.

Klussmann JP, Preuss SF, Speel EJ. Human papillomavirus and cancer of the oropharynx Molecular interaction and clinical implications [German]. HNO 2009; 57:113–122. PubMed | CrossRef

Kong CS, Narasimhan B, Cao HB, Kwok S, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74.

La TH, Filion EJ, Turnbull BB, Chu JN, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74.

Lee JI, Jin BH, Kim MA, Yoon HJ, et al. Prognostic significance of CXCR-4 expression in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107:678–684. View Full Text | PubMed | CrossRef

Llorente J, Perez-Escuredo J, Alvarez-Marcos C, Suarez C, et al. Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review [Review]. Eur Arch Otorhinolaryngol 2009; 266:1–7.

Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009; 58:1855–1864. PubMed

Ma XJ, Pan XL, Lv ZH, Xu FL, et al. Therapeutic influence on circulating and monocyte-derived dendritic cells in laryngeal squamous cell carcinoma patients. Acta Otolaryngol (Stockh) 2009; 129:84–91.

Marcos CA, Martinez DAK, de los Toyos JR, Iglesias FD, et al. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 140:375–380.

Marijon H, Bouyon A, Vignot S, Besse B. Pronostic and predictive factors in lung cancer [French]. Bull Cancer (Paris) 2009; 96:391–404.

Markowski J, Oczko-Wojciechowska M, Gierek T, Jarzab M, et al. Gene expression profile analysis in laryngeal cancer by high-density oligonucleotide microarrays. J Physiol Pharmacol 2009; 60:57–63. PubMed

Markowski J, Tyszkiewicz T, Jarzab M, Oczko-Wojciechowska M, et al. Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma [Review]. Eur Arch Otorhinolaryngol 2009; 266:1501–1507.

Matta A, Tripathi SC, De Souza LV, Grigull J, et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 2009; 125:1398–1406. PubMed | CrossRef

Meissner M, Whiteside T, Kaufmann R, Seliger B. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells. Arch Dermatol Res 2009; 301:189–193. View Full Text | PubMed | CrossRef

Melle C, Ernst G, Winkler R, Schimmel B, et al. Proteomic analysis of human papillomavirus-related oral squamous cell carcinoma: Identification of thioredoxin and epidermal-fatty acid binding protein as upregulated protein markers in microdissected tumor tissue. Proteomics 2009; 9:2193–2201. PubMed | CrossRef

Michaud WA, Nichols AC, Mroz EA, Faquin WC, et al. Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma. Clin Cancer Res 2009; 15:1645–1654.

Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, et al. Dysregulated molecular networks in head and neck carcinogenesis [Review]. Eur J Cancer 2009; 45(4-5):324-334, 2009 Apr.

Moral M, Segrelles C, Lara MF, Martinez-Cruz AB, et al. Akt Activation Synergizes with Trp53 Loss in Oral Epithelium to Produce a Novel Mouse Model for Head and Neck Squamous Cell Carcinoma. Cancer Res 2009; 69:1099–1108. PubMed | CrossRef

Negishi A, Masuda M, Ono M, Honda K, et al. Quantitative proteomics using formalin-fixed paraffin-embedded tissues of oral squamous cell carcinoma. Cancer Science 2009; 100:1605–1611. View Full Text | PubMed | CrossRef

Neumann HPH, Erlic Z, Boedeker CC, Rybicki LA, et al. Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Res 2009; 69:3650–3656. PubMed | CrossRef

Newman JR, Helman EE, Safavy S, Zhang WY, et al. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Lett 2009; 274:313–318. PubMed | CrossRef

Ozturk B, Coskun U, Sancak B, Yaman E, et al. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol 2009; 9:645–648. View Full Text | PubMed | CrossRef

Pedruzzi PAG, Kowalski LP, Nishimoto IN, Oliveira BV, et al. Analysis of Prognostic Factors in Patients With Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy Alone or in Combination With Systemic Chemotherapy. Arch Otolaryngol Head Neck Surg 2008; 134:1196–1204. View Full Text | PubMed | CrossRef

Pernas FG, Allen CT, Winters ME, Yan B, et al. Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer. Clin Cancer Res 2009; 15:2361–2372. PubMed

Raimondi AR, Molinolo A, Gutkind JS. Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K-ras and p53 Two-Hit Carcinogenesis Model. Cancer Res 2009; 69:4159–4166. PubMed | CrossRef

Ralhan R, De Souza LV, Matta A, Tripathi SC, et al. iTRAQ-Multidimensional Liquid Chromatography and Tandem Mass Spectrometry-Based Identification of Potential Biomarkers of Oral Epithelial Dysplasia and Novel Networks between Inflammation and Premalignancy. J Proteome Res 2009; 8:300–309. PubMed | CrossRef

Rodrigo JP, Garcia-Carracedo D, Garcia LA, Menendez ST, et al. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol 2009; 217:516–523. View Full Text | PubMed | CrossRef

Roh JL, Cho KJ, Kwon GY, Ryu CH, et al. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Eur J Cancer 2009; 45(1):63-68, 2009 Jan.

Saito K, Khan K, Yu SZ, Ronson S, et al. The Predictive and Therapeutic Value of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Capecitabine (Xeloda)-Based Chemotherapy for Head and Neck Cancer. Laryngoscope 2009; 119:82–88. PubMed | CrossRef

Schaaij-Visser TBM, Brakenhoff RH, Jansen JWA, O'Flaherty MC, et al. Comparative proteome analysis to explore p53 pathway disruption in head and neck carcinogenesis. J Proteomics 2009; 72:803–814. PubMed

Sen B, Saigal B, Parikh N, Gallick G, et al. Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding. Cancer Res 2009; 69:1958–1965.

Shang ZJ, Liu K, Shao Z. Expression of chemokine receptor CCR7 is associated with cervical lymph node metastasis of oral squamous cell carcinoma. Eur J Cancer 2009; 45(6):480-485, 2009 Jun.

Shillitoe EJ. The role of viruses in squamous cell carcinoma of the oropharyngeal mucosa [Review]. Eur J Cancer 2009; 45(4-5):351-355, 2009 Apr.

Silva P, Slevin NJ, Sloan P, Valentine H, et al. Prognostic significance of tumor hypoxia inducible factor-1 alpha expression for outcome after radiotherapy in oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2009; 72.

Snitcovsky I, Leitao GM, Pasini FS, Brunialti KCS, et al. Plasma Osteopontin Levels in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2009; 135:807–811. View Full Text | PubMed | CrossRef

Tanvetyanon T, Padhya T, McCaffrey J, Zhu WW, et al. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol 2009; 27:1983–1991. PubMed | CrossRef

Tiziani S, Lopes V, Gunther UL. Early Stage Diagnosis of Oral Cancer Using H-1 NMR-Based Metabolomics. Neoplasia 2009; 11:269–NIL_69. PubMed

van den Broek GB, Wildeman M, Rasch CRN, Armstrong N, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 2009; 124:2643–2650.

Wang SJ, Wong G, de Heer AM, Xia WL, et al. CD44 Variant Isoforms in Head and Neck Squamous Cell Carcinoma Progression. Laryngoscope 2009; 119:1518–1530. PubMed | CrossRef

Weinberger PM, Merkley M, Lee JR, Adam BL, et al. Use of Combination Proteomic Analysis to Demonstrate Molecular Similarity of Head and Neck Squamous Cell Carcinoma Arising From Different Subsites. Arch Otolaryngol Head Neck Surg 2009; 135:694–703. View Full Text | PubMed | CrossRef

Yamada Y, Itoh Y, Aoki S, Nakamura K, et al. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium. Cancer Chemother Pharmacol 2009; 64:1079–1083. PubMed | CrossRef

Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, et al. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Lett 2009; 276:95–101. PubMed | CrossRef

Zhang MB, Zhang P, Zhang CP, Sun J, et al. Prognostic significance of Bcl-2 and Bax protein expression in the patients with oral squamous cell carcinoma. J Oral Pathol Med 2009; 38:307–313. View Full Text | PubMed

Back to Top | Article Outline
Advances in the systemic treatment of head and neck cancers

Review: (pp. 200–205)

Abuzeid WM, Jiang XL, Shi GL, Wang H, et al. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest 2009; 119:1974–1985. View Full Text | PubMed | CrossRef

•• Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 2009; 27:15s. (suppl; 303s: abstr 6011)[29]

Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, et al. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009; 100:1379–1384. PubMed | CrossRef

Ekshyyan O, Rong YH, Rong XH, Pattani KM, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009; 8:2255–2265.

Erlich RB, Rickwood D, Coman WB, Saunders NA, et al. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2009; 63:381–389. PubMed | CrossRef

Guntinas-Lichius O, Ruhlow S, Veelken F, Klussmann JP. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 2009; 135:901–908. View Full Text | PubMed | CrossRef

Haouala A, Zanolari B, Rochat B, Montemurro M, et al. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B 2009; 877:1982–1996, 2009 Jul 15.

Lee JJ, Hah JH, Im SA, Kim SY, et al. Neoadjuvant Chemotherapy Followed by Limited Surgery in a Mouse Model of Head and Neck Cancer. Anticancer Res 2009; 29:255–259. PubMed

Li CY, Zang Y, Sen M, Leeman-Neill RJ, et al. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther 2009; 8:2211–2220.

Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009; 58:1855–1864. PubMed

Mucke T, Holzle F, Kesting MR, Loeffelbein DJ, et al. Tumor Size and Depth in Primary Malignant Melanoma in the Oral Cavity Influences Survival. J Oral Maxillofac Surg 2009; 67:1409–1415. PubMed | CrossRef

Neves S, Faneca H, Bertin S, Konopka K, et al. Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response. Cancer Gene Ther 2009; 16:91–101. View Full Text | PubMed | CrossRef

Ng W, Jacob S, De laney G, Barton M. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: Setting an evidence-based benchmark for the best-quality cancer care. Eur J Cancer 2009; 45:2150–2159. PubMed | CrossRef

Psyrri A, Gouveris P, Vermorken JB. Human papillomavirus-related head and neck tumors: clinical and research implication [Review]. Curr Opin Oncol 2009; 21:201–205. View Full Text | PubMed | CrossRef

Scarpace SL, Brodzik FA, Mehdi S, Belgam R. Treatment of Head and Neck Cancers: Issues for Clinical Pharmacists. Pharmacotherapy 2009; 29:578–592. View Full Text | PubMed | CrossRef

Shakeel M, Newton JR, Bruce J, Ah-See KW. Use of complementary and alternative medicine by patients attending a head and neck oncology clinic. J Laryngol Otol 2008; 122:1360–1364. PubMed | CrossRef

Snitcovsky I, Leitao GM, Pasini FS, Brunialti KCS, et al. Plasma Osteopontin Levels in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2009; 135:807–811. View Full Text | PubMed | CrossRef

Soundararajan A, Bao A, Phillips WT, Perez R, et al. [Re-186]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Int J Rad Appl Instrum B 2009; 36:515–524. PubMed | CrossRef

•• Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864–1871. PubMed | CrossRef [27]

Stewart JSW, Cohen EEW, Licitra L, Van Herpen CML, et al. Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. J Clin Oncol 2009; 27:1864–1871. PubMed | CrossRef

•• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116–1127.[03]

Wang SX, Bao A, Phillips WT, Goins B, et al. Intraoperative therapy with liposomal drug delivery: Retention and distribution in human head and neck squamous cell carcinoma xenograft model. Int J Pharm 2009; 373:156–164. View Full Text | PubMed | CrossRef

Xu F, Li S, Li XL, Guo Y, et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009; 16:723–730. View Full Text | PubMed | CrossRef

Yang ES, Murphy BM, Chung CH, Netterville JL, et al. Evolution of clinical trials in head and neck cancer [Review]. Crit Rev Oncol/Hematol 2009; 71:29–42. PubMed | CrossRef

Back to Top | Article Outline
Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer

Review: (pp. 206–211)

•• Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. Head Neck 2009; 31:1393–1422. PubMed | CrossRef [15]

•• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21–28. PubMed | CrossRef [06]

• Bozec A, Sudaka A, Fischel JL, et al. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008; 99:93–99. PubMed | CrossRef [25]

• Bozec A, Sudaka A, Toussan N, et al. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol 2009; 20:1703–1707. View Full Text | PubMed | CrossRef [26]

Bremke M, Barth PJ, Sesterhenn AM, Budach V, et al. Prospective Study on Neck Dissection after Primary Chemoradiation Therapy in Stage IV Pharyngeal Cancer. Anticancer Res 2009; 29:2645–2653.

Burri RJ, Lee NY. Concurrent chemotherapy and radiotherapy for head and neck cancer [Review]. Expert Rev Anticancer Ther 2009; 9:293–302. View Full Text | PubMed | CrossRef

Chandana SR, Conley BA. Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects [Review]. Curr Opin Oncol 2009; 21:218–223. View Full Text | PubMed | CrossRef

•• Egloff AM, Grandis JR. Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol 2009; 2009:896407. PubMed[02]

•• Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261–269.[17]

Fetz V, Bier C, Habtemichael N, Schuon R, et al. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer 2009; 124:2033–2041. PubMed | CrossRef

Finnegan V, Parsons JT, Greene BD, Sharma V. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (t3-t4) oropharyngeal squamous cell carcinoma. Head and Neck 2009; 31:167–174.

Fountzilas G, Bamias A, Kalogera-Fountzila A, Karayannopoulou G, et al. Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck. Anticancer Res 2009; 29:529–538. PubMed

Franchin G, Minatel E, Politi D, Gobitti C, et al. Postoperative Reduced Dose of Cisplatin Concomitant With Radiation Therapy in High-Risk Head and Neck Squamous Cell Carcinoma. Cancer 2009; 115:2464–2471. PubMed | CrossRef

Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, et al. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer. Cancer Gene Ther 2009; 16:383–392. View Full Text | PubMed | CrossRef

Geurts TW, Balm AJM, van Velthuysen MLF, van Tinteren H, et al. Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head and Neck 2009; 31:220–226.

Gil Z, Fliss DM. Contemporary Management of Head and Neck Cancers [Review]. Isr Med Assoc J 2009; 11:296–300, 2009 May.

Glazer CA, Chang SS, Ha PK, Califano JA. Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice [Review]. Eur J Cancer 2009; 45(4-5):440-446, 2009 Apr.

•• Harrington KJ, El-Hariry IA, Holford CS, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1100–1107. PubMed | CrossRef [28]

He PJ, Ahn JC, Shin JI, Hwang HJ, et al. Enhanced apoptotic effect of combined modality of 9-hydroxypheophorbide alpha-mediated photodynamic therapy and carboplatin on AMC-HN-3 human head and neck cancer cells. Oncol Rep 2009; 21:329–334.

Hoffmann TK, Sonkoly E, Hauser U, Liero A, et al. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Eur J Cancer 2009; 44(12):1100-1109, 2008 De.

Kim S, Loevner L, Quon H, Sherman E, et al. Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck. Clin Cancer Res 2009; 15:986–994. PubMed

Kiyota N, Tahara M, Kadowaki S, Fuse N, et al. Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan. Jpn J Clin Oncol 2009; 39:225–230. View Full Text | PubMed | CrossRef

• Klein JD, Grandis JR. The molecular pathogenesis of head and neck cancer. Cancer Biol Ther 2010. [Epub ahead of print][19]

• Kruser TJ, Armstrong EA, Ghia AJ, et al. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008; 72:534–542. PubMed | CrossRef [12]

•• Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26:3128–3137. PubMed | CrossRef [18]

• Langer CJ, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; 30 May to 3 June 2008. p. 317s.[09]

Lango MN. Multimodal Treatment for Head and Neck Cancer. Surg Clin North Am 2009; 89:43. PubMed | CrossRef

• Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1992–1998.[16]

Lee JJ, Hah JH, Im SA, Kim SY, et al. Neoadjuvant Chemotherapy Followed by Limited Surgery in a Mouse Model of Head and Neck Cancer. Anticancer Res 2009; 29:255–259. PubMed

• Licitra L, Locati LD, Bossi P. Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. Ann Oncol 19(Suppl 7)2008:vii200–vii203.[07]

Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction Chemotherapy in Locally Advanced Head and Neck Cancer: A New Standard of Care? Hematol Oncol Clin North Am 2008; 22:1155–.

•• Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83:489–501. View Full Text | PubMed | CrossRef [03]

Matzinger O, Zouhair A, Mirimanoff RO, Ozsahin M. Radiochemotherapy in Locally Advanced Squamous Cell Carcinomas of the Head and Neck. Clin Oncol 2009:525–531.

Michaud WA, Nichols AC, Mroz EA, Faquin WC, et al. Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma. Clin Cancer Res 2009; 15:1645–1654.

• Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 2009; 315:572–582. View Full Text | PubMed | CrossRef [27]

Ng W, Jacob S, De laney G, Barton M. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: Setting an evidence-based benchmark for the best-quality cancer care. Eur J Cancer 2009; 45:2150–2159. PubMed | CrossRef

Niyazi M, Marini P, Daniel PT, Humphreys R, et al. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin. Oncol Rep 2009; 21:1455–1460. PubMed

O'Neill JP, Hughes JP, Manning KP, Fenton JE. Controversies in the management of tongue base cancer [Review]. Ir J Med Sci 2009; 178:1–5. View Full Text | PubMed | CrossRef

Pedruzzi PAG, Kowalski LP, Nishimoto IN, Oliveira BV, et al. Analysis of Prognostic Factors in Patients With Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy Alone or in Combination With Systemic Chemotherapy. Arch Otolaryngol Head Neck Surg 2008; 134:1196–1204. View Full Text | PubMed | CrossRef

•• Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17 346 patients. Radiother Oncol 2009; 92:4–14.[04]

• Rischin D. Oropharyngeal cancer, human papilloma virus, and clinical trials. J Clin Oncol 2010; 28:1–3.[01]

Saito K, Khan K, Yu SZ, Ronson S, et al. The Predictive and Therapeutic Value of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Capecitabine (Xeloda)-Based Chemotherapy for Head and Neck Cancer. Laryngoscope 2009; 119:82–88. PubMed | CrossRef

Scarpace SL, Brodzik FA, Mehdi S, Belgam R. Treatment of Head and Neck Cancers: Issues for Clinical Pharmacists. Pharmacotherapy 2009; 29:578–592. View Full Text | PubMed | CrossRef

•• Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010; 21:342–347.[13]

Wolff HA, Overbeck T, Roedel RM, Hermann RM, et al. Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. J Cancer Res Clin Oncol 2009; 135:961–967. View Full Text | PubMed | CrossRef

Yang ES, Murphy BM, Chung CH, Netterville JL, et al. Evolution of clinical trials in head and neck cancer [Review]. Crit Rev Oncol/Hematol 2009; 71:29–42. PubMed | CrossRef

•• Zhang N, Erjala K, Kulmala J, et al. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 2009; 92:388–392. PubMed | CrossRef [08]

Back to Top | Article Outline
Molecular targeted therapies in all histologies of head and neck cancers: an update

Review: (pp. 212–220)

Ashimori N, Zeitlin BD, Zhang ZC, Warner K, et al. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther 2009; 8:893–903. PubMed | CrossRef

Bao LW, Gorin MA, Zhang MC, Ventura AC, et al. Preclinical Development of a Bifunctional Cancer Cell Homing, PKC epsilon Inhibitory Peptide for the Treatment of Head and Neck Cancer. Cancer Res 2009; 69:5829–5834. PubMed | CrossRef

Benavente S, Huang SM, Armstrong EA, Chi A, et al. Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells. Clin Cancer Res 2009; 15:1585–1592. PubMed

Bergmann C, Wimmer E. Role of tyrosine kinases in tumor progression of the head and neck [German]. HNO 2009; 57:123–132. PubMed | CrossRef

Bernier J. Incorporation of Molecularly Targeted Agents in the Primary Treatment of Squamous Cell Carcinomas of the Head and Neck. Hematol Oncol Clin North Am 2008; 22:1193–. PubMed | CrossRef

Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology [Review]. Nat Rev Clin Oncol 2009; 6:266–277.

•• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2009; 11:21–28.[29]

Bozec A, Peyrade F, Fischel JL, Milano G. Emerging molecular targeted therapies in the treatment of head and neck cancer [Review]. Expert Opin Emerg Drugs 2009; 14:299–310. PubMed | CrossRef

Brizel DM. Targeting the future in head and neck cancer. Lancet Oncol 2009; 10:204–205. PubMed | CrossRef

Capdevila J, Elez E, Macarulla T, Ramos FJ, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment [Review]. Cancer Treat Rev 2009; 35:354–363. PubMed | CrossRef

Czeminski R, Amornphimoltham P, Patel V, Molinolo AA, et al. Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model. Cancer Prev Res 2009; 2:27–36.

Dahse R, Driemel O, Schwarz S, Kromeyer-Hauschild K, et al. KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Eur J Cancer 2009; 45(9):826-829, 2009 Sep.

Dean NR, Newman JR, Helman EE, Zhang WY, et al. Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck Cancer. Clin Cancer Res 2009; 15:4058–4065. PubMed

Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, et al. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009; 100:1379–1384. PubMed | CrossRef

Ekshyyan O, Rong YH, Rong XH, Pattani KM, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009; 8:2255–2265.

Fujiwara T. Telomerase-specific virotherapy for human squamous cell carcinoma [Review]. Expert Opin Biol Ther 2009; 9:321–329. PubMed | CrossRef

Haouala A, Zanolari B, Rochat B, Montemurro M, et al. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B 2009; 877:1982–1996, 2009 Jul 15.

Hegymegi-Barakonyi B, Eros D, Szantai-Kis C, Breza N, et al. Tyrosine kinase inhibitors - Small molecular weight compounds inhibiting EGFR [Review]. Curr Opin Mol Ther 2009; 11:308–321. PubMed

Laytragoon-Lewin N, Ustun H, Castro J, Friesland S, et al. In vitro effect of radiation, antibody to epidermal growth factor receptor and Docetaxel in human head and neck squamous carcinoma cells with mutant P53 and over-expressed EGFR. J Cancer Res Clin Oncol 2009; 135:203–209. PubMed | CrossRef

Le Tourneau C, Chen EX. Molecularly Targeted Agents in the Treatment of Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck. Hematol Oncol Clin North Am 2008; 22:1209. PubMed | CrossRef

Li CY, Zang Y, Sen M, Leeman-Neill RJ, et al. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther 2009; 8:2211–2220.

Lorch JH, Posner MR, Wirth LJ, Haddad RI. Seeking alternative biological therapies: The future of targeted molecular treatment [Review]. Eur J Cancer 2009; 45(4-5):447-453, 2009 Apr.

Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract [Review]. Exp Cell Res 2009; 315:572–582. View Full Text | PubMed | CrossRef

Newman JR, Helman EE, Safavy S, Zhang WY, et al. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Lett 2009; 274:313–318. PubMed | CrossRef

Niyazi M, Marini P, Daniel PT, Humphreys R, et al. Efficacy of a Triple Treatment with Irradiation, Agonistic TRAIL Receptor Antibodies and EGFR Blockade. Strahlenther Onkol 2009; 185:8–18. PubMed | CrossRef

Niyazi M, Marini P, Daniel PT, Humphreys R, et al. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin. Oncol Rep 2009; 21:1455–1460. PubMed

Pernas FG, Allen CT, Winters ME, Yan B, et al. Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer. Clin Cancer Res 2009; 15:2361–2372. PubMed

•• Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009; 106:18740–18744. PubMed | CrossRef [77]

Raimondi AR, Molinolo A, Gutkind JS. Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K-ras and p53 Two-Hit Carcinogenesis Model. Cancer Res 2009; 69:4159–4166. PubMed | CrossRef

Rogers SJ, Box C, Chambers P, Barbachano Y, et al. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol 2009; 218:122–130. PubMed | CrossRef

Saba NF, Khuri FR. Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents [Review]. Curr Opin Oncol 2009; 21:232–237. View Full Text | PubMed | CrossRef

Su X, Lacouture ME, Jia YX, Wu SH. Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab - an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis [Review]. Oncology (Williston Park) 2009:124–133.

• Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563–572. View Full Text | PubMed | CrossRef [41]

Tsujino K, Kawaguchi T, Kubo A, Aono N, et al. Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib. J Thorac Oncol 2009; 4:994–1001. View Full Text | PubMed

•• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116–1127.[14]

Wagenblast J, Baghi M, Mortel S, Hirth D, et al. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck? Oncol Rep 2009; 22:171–176.

Wang SX, Bao A, Phillips WT, Goins B, et al. Intraoperative therapy with liposomal drug delivery: Retention and distribution in human head and neck squamous cell carcinoma xenograft model. Int J Pharm 2009; 373:156–164. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
Supportive care in head and neck oncology

Review: (pp. 221–225)

Ahlner-Elmqvist M, Bjordal K, Jordhoy MS, Kaasa S, et al. Characteristics and implications of attrition in health-related quality of life studies in palliative care. Palliative Med 2009; 23:432–440. View Full Text | PubMed | CrossRef

• Baum BJ, Zheng C, Alevizos I, et al. Development of a gene transfer-based treatment for radiation-induced salivary hypofunction. Oral Oncol 2010; 46:4–8.[30]

•• Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19:142–149. View Full Text | PubMed | CrossRef [38]

Bower WF, Vlantis AC, Chung TML, Cheung SKC, et al. Quality of life in head and neck cancer patients after surgical resection: translation into Cantonese and validation of the EORTC QLQ-H&N35. Acta Otolaryngol (Stockh) 2009; 129:779–785.

Brintzenhofe-Szoc KM, Levin TT, Li YL, Kissane DW, et al. Mixed Anxiety/Depression Symptoms in a Large Cancer Cohort: Prevalence by Cancer Type. Psychosomatics 2009; 50:383–391.

Chaukar DA, Walvekar RR, Das AK, Deshpande MS, et al. Quality of life in head and neck cancer survivors: a cross-sectional survey. Am J Otolaryngol 2009; 30:176–180.

Chen SC, Liao CT, Lin CC, Chang JTC, et al. Distress and care needs in newly diagnosed oral cavity cancer patients receiving surgery. Eur J Cancer 2009; 45(9):815-820, 2009 Sep.

Coyne JC. Misleading Report on the Prevention of Major Depression Among Patients With Head and Neck Cancer. Arch Otolaryngol Head Neck Surg 2008; 134:1345. View Full Text | PubMed | CrossRef

de Carvalho TP, Araujo NSS, Curcio D, Goncalves MIR. Tracheostomized patients care: efficacy of a brief theoretical education program for nursing personnel. Support Care Cancer 2009; 17:749–751. PubMed | CrossRef

Demez PH, Moreau PR. Perception of head and neck cancer quality of life within the medical world: a multicultural study. Head and Neck 2009; 31:1056–1067.

El-Deiry MW, Futran ND, McDowell JA, Weymuller EA, et al. Influences and Predictors of Long-term Quality of Life in Head and Neck Cancer Survivors. Arch Otolaryngol Head Neck Surg 2009; 135:380–384.

Elackattu A, Jalisi S. Living with Head and Neck Cancer and Coping with Dying when Treatments Fail. Otolaryngol Clin North Am 2009; 42:171. PubMed | CrossRef

• Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation and impact on quality of life. Cancer 2008; 113:2704–2713. PubMed | CrossRef [08]

Guntinas-Lichius O, Ruhlow S, Veelken F, Klussmann JP. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 2009; 135:901–908. View Full Text | PubMed | CrossRef

Head BA, Studts JL, Bumpous JM, Gregg JL, et al. Development of a Telehealth Intervention for Head and Neck Cancer Patients. Telemed J e-Health 2009; 15:44–52.

•• Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127–145. PubMed | CrossRef [21]

Hopkins C. Patient reported outcome measures in rhinology [Review]. Rhinology 2009; 47:10–17.

• Hoskin PJ, Robinson M, Slevin N, et al. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 2009; 27:5751–5756. PubMed | CrossRef [44]

Kagan SH. The influence of nursing in head and neck cancer management [Review]. Curr Opin Oncol 2009; 21:248–253. View Full Text | PubMed | CrossRef

Kanatas AN, Mehanna HM, Lowe D, Rogers SN. A second national survey of health-related quality of life questionnaires in head and neck oncology. Ann R Coll Surg Engl 2009; 91:420–425. View Full Text | PubMed | CrossRef

Kubicek GJ, Wang F, Reddy E, Shnayder Y, et al. Importance of treatment institution in head and neck cancer radiotherapy. Otolaryngol Head Neck Surg 2009; 141:172–176. View Full Text | PubMed | CrossRef

Mlynarek AM, Rieger JM, Harris JR, O'Connell DA, et al. Methods of Functional Outcomes Assessment following Treatment of Oral and Oropharyngeal Cancer: Review of the Literature [Review]. J Otolaryngol-Head Neck Surg 2008; 37:2–10.

Mochizuki Y, Matsushima E, Omura K. Perioperative assessment of psychological state and quality of life of head and neck cancer patients undergoing surgery. Int J Oral Maxillofac Surg 2009; 38:151–159.

Moyer JS, Li J, Wei S, Teitz-Tennenbaum S, et al. Intratumoral Dendritic Cells and Chemoradiation for the Treatment of Murine Squamous Cell Carcinoma. J Immunother 2008; 31:885–895. View Full Text | PubMed | CrossRef

Murphy BA. Advances in quality of life and symptom management for head and neck cancer patients [Review]. Curr Opin Oncol 2009; 21:242–247. View Full Text | PubMed | CrossRef

Nonzee NJ, Dandade NA, Markossian T, Agulnik M, et al. Evaluating the Supportive Care Costs of Severe Radiochemotherapy-Induced Mucositis and Pharyngitis: Results From a Northwestern University Costs of Cancer Program Pilot Study With Head and Neck and Nonsmall Cell Lung Cancer Patients Who Received Care at a County Hospital, a Veterans Administration Hospital, or a Comprehensive Cancer Care Center (vol 113, pg 1446, 2008). Cancer 2009; 115:2805. PubMed

Ouwens MMMTJ, Hermens RRPMG, Hulscher MMEJL, Merkx MAW, et al. Impact of an integrated care program for patients with head and neck cancer on the quality of care. Head and Neck 2009; 31:902–910.

•• Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4–14.[06]

Price KAR, Moore EJ, Moynihan T, Price DL. Symptoms and Terminal Course of Patients Who Died of Head and Neck Cancer. J Palliat Med 2009; 12:117–118. PubMed | CrossRef

Rogers SN. Quality of life for head and neck cancer patients - has treatment planning altered? [Review]. Eur J Cancer 2009; 45(4-5):435-439, 2009 Apr.

Rogers SN, El-Sheikha J, Lowe D. The development of a Patients Concerns Inventory (PCI) to help reveal patients concerns in the head and neck clinic. Eur J Cancer 2009; 45(7):555-561, 2009 Jul.

• Salas S, Baumstarck-Barrau K, Alfonsi M, et al. Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: prospective randomized trial. Radiother Oncol 2009; 93:503–509.[16]

Sayed SI, Elmiyeh B, Rhys-Evans P, Syrigos KN, et al. Quality of life and outcomes research in head and neck cancer: A review of the state of the discipline and likely future directions [Review]. Cancer Treat Rev 2009; 35:397–402. PubMed | CrossRef

Schache AG, Lieger O, Rogers P, Kelly A, et al. Predictors of swallowing outcome in patients treated with surgery and radiotherapy for advanced oral and oropharyngeal cancer. Eur J Cancer 2009; 45(9):803-808, 2009 Sep.

Scharpf J, Karnell LH, Christensen AJ, Funk GF. The Role of Pain in Head and Neck Cancer Recurrence and Survivorship. Arch Otolaryngol Head Neck Surg 2009; 135:789–794. View Full Text | PubMed | CrossRef

Sciubba JJ. End of life considerations in the head and neck cancer patient [Review]. Eur J Cancer 2009; 45(4-5):431-434, 2009 Apr.

Semple CJ, Dunwoody L, Kernohan WG, McCaughan E. Development and evaluation of a problem-focused psychosocial intervention for patients with head and neck cancer. Support Care Cancer 2009; 17:379–388.

Sikora AG, Morris LG, Sturgis EM. Bidirectional Association of Anogenital and Oral Cavity/Pharyngeal Carcinomas in Men. Arch Otolaryngol Head Neck Surg 2009; 135:402–405.

Simo R, Morgan P, Jeannon JP, Odell E, et al. Integrated media presentation in multidisciplinary head and neck oncology meetings. Eur Arch Otorhinolaryngol 2009; 266:261–265. PubMed | CrossRef

Singer S, Wollbruck D, Wulke C, Dietz A, et al. Validation of the eortc qlq-c30 and eortc qlq-h&n35 in patients with laryngeal cancer after surgery. Head and Neck 2009; 31:64–76.

Slovacek L, Slovackova B, Slanska I, Priester P, et al. Cancer and depression: a prospective study. Neoplasma 2009; 56:187–193. PubMed | CrossRef

Teppo H, Alho OP. Comorbidity and diagnostic delay in cancer of the larynx, tongue and pharynx. Eur J Cancer 2009; 45(8):692-695, 2009 Aug.

Tschiesner U, Linseisen E, Baumann S, Siedek V, et al. Assessment of Functioning in Patients with Head and Neck Cancer According to the International Classification of Functioning, Disability, and Health (ICF): A Multicenter Study. Laryngoscope 2009; 119:915–923. PubMed | CrossRef

Tschiesner U, Linseisen E, Coenen M, Rogers S, et al. Evaluating sequelae after head and neck cancer from the patient perspective with the help of the International Classification of Functioning, Disability and Health. Eur Arch Otorhinolaryngol 2009; 266:425–436. PubMed | CrossRef

Turpin M, Dallos R, Owen R, Thomas M. The Meaning and Impact of Head and Neck Cancer: An Interpretative Phenomenological and Repertory Grid Analysis. J Construct Psychol 2009; 22:24–54.

Vartanian JG, Kowalski LP. Acceptance of Major Surgical Procedures and Quality of Life Among Long-term Survivors of Advanced Head and Neck Cancer. Arch Otolaryngol Head Neck Surg 2009; 135:376–379. PubMed | CrossRef

Back to Top | Article Outline

Genitourinary system

Advances in penile cancer management

Review: (pp. 226–235)

Angerer-Shpilenya M, Jakse G. The significance of lymphadenectomy in the management of penile cancer [German]. Urologe 2009:54–58.

Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer [Review]. Cancer Causes Control 2009; 20:449–457. View Full Text | PubMed | CrossRef

Bleeker MCG, Heideman DAM, Snijders PJF, Horenblas S, et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009; 27:141–150.

Brame RS, Zaider M, Zakian KL, Koutcher JA, et al. Regarding the focal treatment of prostate cancer: inference of the gleason grade from magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2009; 74.

Chaux A, Caballero C, Soares F, Guimaraes GC, et al. The Prognostic Index A Useful Pathologic Guide for Prediction of Nodal Metastases and Survival in Penile Squamous Cell Carcinoma. Am J Surg Pathol 2009; 33:1049–1057. View Full Text | PubMed

Chaux A, Reuter V, Lezcano C, Velazquez EF, et al. Comparison of Morphologic Features and Outcome of Resected Recurrent and Nonrecurrent Squamous Cell Carcinoma of the Penis A Study of 81 Cases. Am J Surg Pathol 2009; 33:1299–1306. View Full Text | PubMed | CrossRef

Chaux A, Torres J, Pfannl R, Barreto J, et al. Histologic Grade in Penile Squamous Cell Carcinoma Visual Estimation Versus Digital Measurement of Proportions of Grades, Adverse Prognosis With any Proportion of Grade 3 and Correlation of a Gleason-like System With Nodal Metastasis. Am J Surg Pathol 2009; 33:1042–1048.

Colecchia M, Nicolai N, Secchi P, Bandieramonte G, et al. pT1 Penile Squamous Cell Carcinoma A Clinicopathologic Study of 56 Cases Treated by CO2 Laser Therapy. Anal Quant Cytol Histol 2009; 31:153–160. PubMed

Crawshaw JW, Hadway P, Hoffland D, Bassingham S, et al. Sentinel lymph node biopsy using dynamic lymphoscintigraphy combined with ultrasound-guided fine needle aspiration in penile carcinoma. Br J Radiol 2009; 82:41–48. PubMed | CrossRef

• Crook J, Fleshner N, Jewett M, et al. Squamous cell carcinoma of the penis: results of brachytherapy as primary management for 74 patients over an 18-year period. In 2009 Genitourinary cancers symposium proceedings book. Alexandria: American Society of Clinical Oncology; 2009. pp. 192.[51]

Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol 2009; 27:189–196. PubMed | CrossRef

Cubilla AL. The role of pathologic prognostic factors in squamous cell carcinoma of the penis. World J Urol 2009; 27:169–177. PubMed | CrossRef

Cunha IW, Guimaraes GC, Soares F, Velazquez E, et al. Pseudoglandular (Adenoid, Acantholytic) Penile Squamous Cell Carcinoma A Clinicopothologic and Outcome Study of 7 Patients. Am J Surg Pathol 2009; 33:551–555.

Di Lorenzo G, Carteni G, Autorino R, Gonnella A, et al. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. Anticancer Drug 2009; 20:277–280.

Favorito LA, Nardi AC, Ronalsa M, Zequi SC, et al. Epidemiologic Study on Penile Cancer in Brazil Editorial Comment. J Urol 2009; 181:2117. PubMed

Garaffa G, Raheem AA, Christopher NA, Ralph DJ. Total phallic reconstruction after penile amputation for carcinoma. BJU Int 2009; 104:852–856. PubMed | CrossRef

Graafland NM, Leijte JAP, Olmos RAV, Hoefnagel CA, et al. Scanning with 18F-FDG-PET/CT for Detection of Pelvic Nodal Involvement in Inguinal Node-Positive Penile Carcinoma. Eur Urol 2009; 56:339–345. PubMed | CrossRef

Hage JJ. Simple, Safe, and Satisfactory Secondary Penile Enhancement After Near-Total Oncologic Amputation. Ann Plast Surg 2009; 62:685–689. View Full Text | PubMed | CrossRef

• Haie-Meder C, Bossi A, Dumas I, et al. Brachytherapy results in patients with penile glans squamous cell carcinoma. In 2009 Genitourinary cancers symposium proceedings book. Alexandria: American Society of Clinical Oncology; 2009. pp. 192.[52]

Hakenberg OW. A New Neoadjuvant Chemotherapy Regimen for Penile Cancer with Nodal Metastases: A Step Forward. Eur Urol 2009; 55:552–555. PubMed | CrossRef

Hegarty PK, Shabbir M, Hughes B, Minhas S, et al. Penile preserving surgery and surgical strategies to maximize penile form and function in penile cancer: recommendations from the United Kingdom experience. World J Urol 2009; 27:179–187. PubMed | CrossRef

Hughes B, Leijte J, Shabbir M, Watkin N, et al. Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer. World J Urol 2009; 27:197–203. PubMed | CrossRef

•• Jensen JB, Jensen KM, Ulhoi BP, et al. Sentinel lymph-node biopsy in patients with squamous cell carcinoma of the penis. BJU Int 2009; 103:1199–1203.[45]

Katz A. Penile Rehabilitation. Am J Nurs 2009; 109.

• Kroon BK, Leijte JA, van Boven H, et al. Microarray gene-expression profiling to predict lymph node metastasis in penile carcinoma. BJU Int 2008; 102:510–515.[09]

Krustrup D, Jensen HL, van den Brule AJC, Frisch M. Histological characteristics of human papilloma-virus-positive and -negative invasive and in situ squamous cell tumours of the penis. Int J Exp Pathol 2009; 90:182–189.

•• Leijte JA, Gallee M, Antonini N, Horenblas S. Evaluation of current TNM classification of penile carcinoma. J Urol 2008; 180:933–938. View Full Text | PubMed | CrossRef [08]

•• Leijte JA, Hughes B, Graafland NM, et al. Two-center evaluation of dynamic sentinel node biopsy for squamous cell carcinoma of the penis. J Clin Oncol 2009; 27:3325–3329. PubMed | CrossRef [42]

•• Leijte JA, Kirrander P, Antonini N, et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54:161–168. PubMed | CrossRef [70]

Leijte JAP, Graafland NM, Olmos RAV, van Boven HH, et al. Prospective evaluation of hybrid F-18-fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma. BJU Int 2009; 104:640–644.

Leijte JAP, Horenblas S. Shortcomings of the current TNM classification for penile carcinoma: time for a change? World J Urol 2009; 27:151–154.

Leijte JAP, Hughes B, Graafland NM, Kroon BK, et al. Two-Center Evaluation of Dynamic Sentinel Node Biopsy for Squamous Cell Carcinoma of the Penis. J Clin Oncol 2009; 27:3325–3329. PubMed | CrossRef

Leijte JAP, van der Ploeg IMC, Olmos RAV, Nieweg OE, et al. Visualization of Tumor Blockage and Rerouting of Lymphatic Drainage in the Penile Cancer Patients by Use of SPECT/CT. J Nucl Med 2009; 50:364–367. PubMed | CrossRef

•• Maddineni SB, Lau MW, Sangar VK. Identifying the needs of penile cancer sufferers: a systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer. BMC Urol 2009; 9:8. PubMed | CrossRef [71]

Morichetti D, Mazzucchelli R, Lopez-Beltran A, Cheng L, et al. Secondary neoplasms of the urinary system and male genital organs. BJU Int 2009; 104:770–776. PubMed | CrossRef

Muneer A, Kayes O, Ahmed HU, Arya M, et al. Molecular prognostic factors in penile cancer. World J Urol 2009; 27:161–167. PubMed | CrossRef

Naumann CM, Al-Najar A, Alkatout I, Hegele A, et al. Lymphatic spread in squamous cell carcinoma of the penis is independent of elevated lymph vessel density. BJU Int 2009; 103:1655–1659. View Full Text | PubMed | CrossRef

Naumann CM, Alkatout I, Hamann MF, Al-Najar A, et al. Interobserver variation in grading and staging of squamous cell carcinoma of the penis in relation to the clinical outcome. BJU Int 2009; 103:1660–1665. View Full Text | PubMed | CrossRef

Oliver RTD. Circumcision and/or vaccination against human papillomavirus in the male to prevent infection with human immunodeficiency virus: an early surrogate endpoint for the later prevention of penile, prostate, anal and oral cancer? BJU Int 2009; 104:753–755.

Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol 2009; 27:221–225.

• Petralia G, Villa G, Scardino E, et al. Local staging of penile cancer using magnetic resonance imaging with pharmacologically induced penile erection. Radiol Med 2008; 113:517–528. PubMed | CrossRef [06]

Pettaway CA, Horenblas S. Penile cancer: incremental insights into etiology, diagnosis, staging, and management. World J Urol 2009; 27:139–140. PubMed | CrossRef

Phe V, Roupret M, Mottet N. What's new in 2008 in the field of basic and clinical research in testis and penile cancer? [French]. Prog Urol 2009; 19:S51–S55. PubMed | CrossRef

•• Pizzocaro G, Algaba F, Horenblas S, et al. EAU Guidelines on penile cancer. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Penile_Cancer.pdf; 2009.[01]

• Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009; 55:546–551. PubMed | CrossRef [57]

Pizzocaro G, Nicolai N, Milani A. Taxanes in Combination with Cisplatin and Fluorouracil for Advanced Penile Cancer: Preliminary Results. Eur Urol 2009; 55:546–551. PubMed | CrossRef

Podlasek CA. Sonic Hedgehog, Apoptosis, and the Penis. J Sex Med 2009; 6:334–339. View Full Text | PubMed

Power DG, Galvin DJ, Cuffe S, McVey GP, et al. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol 2009; 27:187–190. PubMed | CrossRef

Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, et al. Lymphadenectomy in the Surgical Management of Penile Cancer [Review]. Eur Urol 2009; 55:1075–1088. PubMed | CrossRef

Protzel C, Hakenberg OW. Chemotherapy in Patients with Penile Carcinoma [Review]. Urol Int 2009; 82:1–7. PubMed | CrossRef

Ramkumar A, Seshadri RA, Narayanaswamy K, Balasubramanian S. Risk factors for lymph node metastasis in clinically node-negative penile cancer patients. Int J Urol 2009; 16:383–386. View Full Text | PubMed | CrossRef

Rigaud J, Durand X. Cancer of the penis and testicle [French]. Prog Urol 2009; 19:F76–F78. PubMed | CrossRef

Senba M, Buziba N, Mori N, Wada A, et al. Detection of human papillomavirus and cellular regulators p16(ink4a), p53, and nf-kappa b in penile cancer cases in kenya. Acta Virol (Praha) 2009; 53:43–48.

Sotelo R, Sanchez-Salas R, Clavijo R. Endoscopic inguinal lymph node dissection for penile carcinoma: the developing of a novel technique. World J Urol 2009; 27:213–219. PubMed | CrossRef

Sternberg CN. A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. Urol Oncol 2009; 27:122–125. PubMed | CrossRef

Suzuki S. Risk factors for lymph node metastasis in clinically node-negative penile cancer patients Comment. Int J Urol 2009; 16:386–387. View Full Text | PubMed | CrossRef

•• Theodore C, Skoneczna I, Bodrogi I, et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 2008; 19:1304–1307. View Full Text | PubMed | CrossRef [58]

• Tobias-Machado M, Starling E, Pompeu A, Wroclawski E. Video endoscopic inguinal lymphadenectomy (VEIL): a critical analysis after a 5-year experience. In 2009 Genitourinary cancers symposium proceedings book. Alexandria: American Society of Clinical Oncology; 2009. pp. 193.[47]

Tobias-MacHado M, Tavares A, Silva MN, Molina WR, et al. Can Video Endoscopic Inguinal Lymphadenectomy Achieve a Lower Morbidity Than Open Lymph Node Dissection in Penile Cancer Patients? Editorial Comment. J Urol 2009; 181:2118–2119. PubMed

van der Merwe A, Zarrabi A, Basson J, Stander J, et al. Distant cutaneous metastases secondary to squamous carcinoma of the penis. Can J Urol 2009; 16:4498–4501. PubMed

Yuan JH, Westney OL, Ruan KH, Wang R. A New Strategy, SuperEnzyme Gene Therapy in Penile Rehabilitation. J Sex Med 2009; 6:328–333. View Full Text | PubMed

Zhu Y, Zhang SL, Ye DW, Yao XD, et al. Prospectively Packaged Ilioinguinal Lymphadenectomy for Penile Cancer: The Disseminative Pattern of Lymph Node Metastasis. J Urol 2009; 181:2103–2108. View Full Text | PubMed | CrossRef

Zini L, Cloutier V, Isbarn H, Perrotte P, et al. A Simple and Accurate Model for Prediction of Cancer-Specific Mortality in Patients Treated with Surgery for Primary Penile Squamous Cell Carcinoma. Clin Cancer Res 2009; 15:1013–1018.

Back to Top | Article Outline
Update on castrate-resistant prostate cancer: 2010

Review: (pp. 263–267)

Ang J, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer [Review]. Br J Cancer 2009; 100:671–675.

Antonarakis ES, Eisenberger MA. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nat Clin Pract Oncol 2009; 6:12–13.

Armstrong AJ, Halabi S, de Wit R, Tannocks IF, et al. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis 2009; 12:88–93. View Full Text | PubMed | CrossRef

Attar RM, Takimoto CH, Gottardis MM. Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes. Clin Cancer Res 2009; 15:3251–3255.

• Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP 17 with abiraterone acetate is highly active in the treatment of castrate-resistant prostate cancer. J Clin Oncol 2009; 27:3742–3748.[10]

Attard G, Reid AH, Yap TA, Raynaud F, et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. J Urol 2009; 181:1124. PubMed

Attard G, Reid AHM, A'Hern R, Parker C, et al. Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. J Clin Oncol 2009; 27:3742–3748.

Attard G, Reid AHM, Olmos D, de Bono JS. Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven [Review]. Cancer Res 2009; 69:4937–4940.

Attard G, Swermenhuis JF, Olmos D, Reid AHM, et al. Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer. Cancer Res 2009; 69:2912–2918. PubMed | CrossRef

Cai CM, Wang HY, Xu YY, Chen SY, et al. Reactivation of Androgen Receptor-Regulated TMPRSS2:ERG Gfene Expression in Castration-Resistant Prostate Cancer. Cancer Res 2009; 69:6027–6032. PubMed | CrossRef

Curigliano G, Spitaleri G, De Cobelli O, Scardino E, et al. Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib. Urol Int 2009; 82:196–202. PubMed | CrossRef

• De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302–6309.[21]

de Bono JS, Parker C, Scher HI, Montgomery RB, et al. Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration - Resistant Prostate Cancer: Missing Parts in a Superb Study Response. Clin Cancer Res 2009; 15:1504–1505. PubMed

de Bono JS, Scher HI, Montgomery RB. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer (vol 14, pg 6302, 2008). Clin Cancer Res 2009; 15:1506. PubMed

de Bono JS, Scher HI, Montgomery RB, Parker C, et al. Circulating Tumor Cells Predict Survival Benefit From Treatment in Metastatic Castration-Resistant Prostate Cancer Editorial Comment. J Urol 2009; 181:2535–2536. PubMed

Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008; 295:115–120. PubMed | CrossRef

Eisenberger MA. Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Eur Urol 2009; 55:248. PubMed | CrossRef

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, et al. Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer. J Clin Oncol 2009; 27:2429–2435. PubMed | CrossRef

Glinsky GV. Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration - Resistant Prostate Cancer: Missing Parts in a Superb Study. Clin Cancer Res 2009; 15:1504. PubMed

Goodman OB, Fink LM, Symanowski JT, Wong B, et al. Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors. Cancer Epidemiol Biomarkers Prev 2009; 18.

Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion [Review]. Nat Clin Pract Urol 2009; 6:76–85. PubMed

Hussain A, Di Paola RS, Baron AD, Higano CS, et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20:492–497. View Full Text | PubMed | CrossRef

Italiano A, Ortholan C, Oudard S, Pouessel D, et al. Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer. Eur Urol 2009; 55:1368–1376. PubMed | CrossRef

• James N, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic: a double-blind, placebo-controlled, randomized, phase 2 trial. Eur Urology 2008; 55:1112–1123.[33]

James ND, Caty A, Borre M, Zonnenberg BA, et al. Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial. Eur Urol 2009; 55:1112–1123. PubMed | CrossRef

Lara PN, Longmate J, Evans CP, Quinn DI, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drug 2009; 20:179–184.

Locke JA, Fazli L, Adomat H, Smyl J, et al. A Novel Communication Role for CYP17A1 in the Progression of Castration-Resistant Prostate Cancer. Prostate 2009; 69:928–937.

Locke JA, Nelson CC, Adomat HH, Hendy SC, et al. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol 2009; 115:126–136.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009; 20:703–708. View Full Text | PubMed | CrossRef

Michaelson MD, Regan MM, Oh WK, Kaufman DS, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20:913–920. View Full Text | PubMed | CrossRef

Mitsogiannis IC, Skolarikos A, Deliveliotis C. Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC) [Review]. Expert Opin Pharmacother 2009; 10:493–501. PubMed | CrossRef

Morris MJ, Huang D, Kelly WK, Slovin SF, et al. Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer. Eur Urol 2009; 56:237–244. PubMed | CrossRef

Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, et al. Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol 2009; 27:2436–2442. PubMed | CrossRef

Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009; 27:251–257. PubMed | CrossRef

Nelson JB. Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer. European Urology Supplements 2009; 8:20–28. PubMed | CrossRef

• No Authors Given. ??? http://www.dendreon.com/pipeline/sipuleucel_t/[13]

Olmos D, Arkenau HT, Ang JE, Ledaki I, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009; 20:27–33. View Full Text | PubMed | CrossRef

Paris PL, Kobayashi Y, Zhao Q, Zeng W, et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett 2009; 277:164–173. PubMed | CrossRef

Pezaro C, Rosenthal MA, Gurney H, Davis ID, et al. An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. Am J Clin Oncol-Cancer Clin Trials 2009; 32:338–341, 2009 Aug.

Rosenberg JE, Oh WK. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nat Clin Pract Urol 2008; 5:650–651.

Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, et al. Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. J Clin Oncol 2009; 27:2772–2778. PubMed | CrossRef

Schalken JA. Re: Phase I Clinical Trial of a Selective inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Eur Urol 2008; 54:1438–1439. PubMed | CrossRef

Scher HI, Jia XY, de Bono JS, Fleisher M, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10:233–239.

Schroder FH, Bangma CH, Wolff JM, Alcaraz A, et al. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study. BJU Int 2009; 103:590–596. View Full Text | PubMed | CrossRef

Sella A, Yarom N, Zisman A, Kovel S. Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer. Oncology (Williston Park) 2009:442–446.

Serrate C, Loriot Y, Rouge TD, Gross-Goupil M, et al. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 2009; 20:965. View Full Text | PubMed | CrossRef

Shen HC, Balk SP. Development of Androgen Receptor Antagonists with Promising Activity in Castration-Resistant Prostate Cancer. Cancer Cell 2009; 15:461–463. PubMed | CrossRef

Simmons MN, Klein EA. Combined Androgen Blockade Revisited: Emerging Options for the Treatment of Castration-Resistant Prostate Cancer [Review]. Urology 2009; 73:697–705.

Singer EA, Golijanin DJ, Messing EM. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? Can J Urol 2008; 15:4381–4387.

• Slovin SF, Beer TM, Higano CS, et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) abstr 5138. J Clin Oncol 2009; 27:15s.[17]

• Small E, Demkow T, Gerritsen WR, et al. A phase III study of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium. ASCO 2009 [Abstract 7].[16]

Snoek R, Cheng H, Margiotti K, Wafa LA, et al. In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clin Cancer Res 2009; 15:39–47. PubMed

Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20:1264–1269.

Sung T, Wang QB, Balk S, Brown M, et al. The Role of microRNA-221 and microRNA-222 in Androgen-Independent Prostate Cancer Cell Lines. Cancer Res 2009; 69:3356–3363.

Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, et al. A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer. Eur Urol 2009; 56:97–103.

Tamura K, Furihata M, Chung SY, Uemura M, et al. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Science 2009; 100:914–919. View Full Text | PubMed | CrossRef

Tran C, Ouk S, Clegg NJ, Chen Y, et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science 2009; 324:787–790. View Full Text | PubMed | CrossRef

Tu SM, Mathew P, Wong FC, Jones D, et al. Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol 2009; 27:3319–3324. PubMed | CrossRef

Turner J, Chaudhary U. Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer. Anticancer Drug 2009; 20:215–216.

van der Poel HG. Editorial Comment on: A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer. Eur Urol 2009; 56:103–104. PubMed | CrossRef

Verhagen P. Predicting the future in castration-resistant prostate cancer. Lancet Oncol 2009; 10:201–202. PubMed | CrossRef

Walsh PC. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Comment. J Urol 2009; 181:1124. PubMed

Welsbie DS, Xu J, Chen Y, Borsu L, et al. Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer. Cancer Res 2009; 69:958–966.

Wilson C, Scullin P, Worthington J, Seaton A, et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br J Cancer 2008; 99:2054–2064. PubMed | CrossRef

Winquist E, Julian JA, Moore MJ, Nabid A, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa in Men With Castration-Resistant Prostate Cancer and Anemia. J Clin Oncol 2009; 27:644–646. PubMed | CrossRef

Yang JC, Ok JH, Busby JE, Borowsky AD, et al. Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer. Cancer Res 2009; 69:151–160. PubMed | CrossRef

Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27:36–41. PubMed | CrossRef

Back to Top | Article Outline
Update on radiation-based therapies for prostate cancer

Review: (pp. 257–262)

Al-Mamgani A, Heemsbergen WD, Peeters STH, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73.

•• Al-Mamgani A, van Putten W, Heemsbergen W, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72:980–988. PubMed | CrossRef [08]

Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103:1636–1640. PubMed | CrossRef

Arcangeli S, Strigari L, Soete G, De Meerleer G, et al. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Int J Radiat Oncol Biol Phys 2009; 73.

Bolla M, Fourneret P, Descotes JL. Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer [Review] [French]. Bull Cancer (Paris) 2008; 95:1213–1218.

Bria E, Cuppone F, Giannarelli D, Milella M, et al. Does Hormone Treatment Added to Radiotherapy Improve Outcome in Locally Advanced Prostate Cancer? Meta-Analysis of Randomized Trials. Cancer 2009; 115:3446–3456. PubMed

Coen JJ, Zietman AL. Proton radiation for localized prostate cancer [Review]. Nat Rev Urol 2009; 6:324–330.

Crook J, Ludgate C, Malone S, Perry G, et al. Final report of multicenter canadian phase iii randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73.

Cunha JAM, Hsu IC, Pouliot J. Dosimetric equivalence of nonstandard HDR brachytherapy catheter patterns. Med Phys 2009; 36:233–239. PubMed | CrossRef

D'Ambrosio DJ, Li T, Horwitz EM, Chen DYT, et al. Does treatment duration affect outcome after radiotherapy for prostate cancer? Int J Radiat Oncol Biol Phys 2009; 72.

D'Amico AV, Moran BJ, Braccioforte MH, Dosoretz D, et al. Risk of Death From Prostate Cancer After Brachytherapy Alone or With Radiation, Androgen Suppression Therapy, or Both in Men With High-Risk Disease. J Clin Oncol 2009; 27:3923–3928. PubMed | CrossRef

Dawson NA, Collins SP. Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy [Review]. Expert Rev Anticancer Ther 2009; 9:953–962. View Full Text | PubMed | CrossRef

de Crevoisier R, Slimane K, Sanfilippo N, Bossi A, et al. Long-term results of brachytherapy for carcinoma of the penis confined to the glans (n- or nx). Int J Radiat Oncol Biol Phys 2009; 74.

Denham JW, Kumar M, Gleeson PS, Lamb DS, et al. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74.

Di Muzio N, Fiorino C, Cozzarini C, Alongi F, et al. Phase i-ii study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74.

Efstathiou JA, Trofimov AV, Zietman AL. Life, Liberty, and the Pursuit of Protons: An Evidence-Based Review of the Role of Particle Therapy in the Treatment of Prostate Cancer [Review]. Cancer J 2009; 15:312–318.

Fletcher BAS, Schumacher KL, Dodd M, Paul SM, et al. Trajectories of Fatigue in Family Caregivers of Patients Undergoing Radiation Therapy for Prostate Cancer. Res Nurs Health 2009; 32:125–139. PubMed | CrossRef

Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74.

•• Fransson P, Lund JA, Damber JE, et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: four-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009; 10:370–380. PubMed | CrossRef [28]

Ghadjar P, Keller T, Rentsch CA, Isaak B, et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009; 8:45–51. PubMed | CrossRef

Ghadjar P, Matzinger O, Isaak B, Behrensmeier F, et al. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiother Oncol 2009; 91:237–242. PubMed | CrossRef

Godley A, Ahunbay E, Peng C, Li XA. Automated registration of large deformations for adaptive radiation therapy of prostate cancer. Med Phys 2009; 36:1433–1441. PubMed | CrossRef

Hepel JT, MacAusland SG, Long JP, Wazer DE, et al. Intensity-Modulated Radiotherapy of the Prostate After Cryotherapy: Initial Experience. Urology 2008; 72:1310–1314. PubMed | CrossRef

Ho AY, Burri RJ, Cesaretti JA, Stone NN, et al. intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75.

Hormone therapy before radiation seed implants for prostate cancer may shorten life for older patients. Oncology (Williston Park) 2008:1306–1307.

Hou AH, Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: a review [Review]. Curr Opin Urology 2009; 19:283–289.

Huo DZ, Hetzel JT, Roy H, Rubin DT. Association of Colorectal Cancer and Prostate Cancer and Impact of Radiation Therapy. Cancer Epidemiol Biomarkers Prev 2009; 18.

Ishiyama H, Kitano M, Satoh T, Kotani S, et al. Radiation dose predicts for biochemical control in genitourinary toxicity after high-dose-rate (hdr) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in hdr brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys 2009; 75.

Karlsdottir A, Muren LP, Wentzel-Larsen T, Johannessen DC, et al. Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy. Acta Oncol 2009; 48:874–881. PubMed | CrossRef

• King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II trial. Int J Radiat Oncol Biol Phys 2009; 73:1043–1048. PubMed | CrossRef [18]

Klein EA, Ciezki J, Kupelian PA, Mahadevan A. Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol 2009; 27:67–71.

Koontz BF, Chino J, Lee WR, Hahn CA, et al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Brachytherapy 2009; 8:191–196. PubMed | CrossRef

Lawton CAF, Michalski J, El-Naqa I, Buyyounouski MK, et al. Rtog gu radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74.

Lawton CAF, Michalski J, El-Naqa I, Kuban D, et al. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74.

•• Lee WR. The ethics of hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73:969–970. PubMed | CrossRef [20]

Leonardo C, Simone G, Papalia R, Franco G, et al. Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. Int J Urol 2009; 16:584–586. View Full Text | PubMed | CrossRef

Liauw SL, Fricano J, Correa D, Weichselbaum RR, et al. Dose-Escalated Radiation Therapy for Intermediate-Risk Prostate Cancer. Cancer 2009; 115:1784–1790. PubMed | CrossRef

Liauw SL, Weichselbaum RR, Rash C, Correa D, et al. Biochemical Control and Toxicity after Intensity-Modulated Radiation Therapy for Prostate Cancer. Technol Cancer Res Treatment 2009; 8:201–206.

Linden RA, Weiner PR, Gomella LG, Dicker AP, et al. Technique of Outpatient Placement of Intraprostatic Fiducial Markers Before External Beam Radiotherapy. Urology 2009; 73:881–886. PubMed | CrossRef

Michalski JM, Roach M, Merrick G, Anscher MS, et al. Appropriateness criteria (r) on external beam radiation therapy treatment planning for clinically localized prostate cancer Expert Panel on Radiation Oncology-Prostate [Review]. Int J Radiat Oncol Biol Phys 2009; 74.

•• Moinpour CM, Hayden KA, Unger JM, et al. Health-related quality-of-life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008; 26:112–120. PubMed | CrossRef [22]

Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009; 74.

• Norkus D, Miller A, Kurtinaitis J, et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlenther Onkol 2009; 185:715–721. Epub 2009 Nov 10[15]

Olapade-Olaopa EO, Yisa GT, Obamuyide HA. Management of advanced prostate cancer in Africa. Can J Urol 2008; 15:3890–3898. PubMed

Pai HHH, Eldridge B, Bishop D, Alexander A, et al. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? Can J Urol 2009; 16:4541–4552.

Papatheofanis FJ, Smith C, Najib M. Improvement in Sensory Pain Rating After Palliative Systemic Radionuclide Therapy in Patients With Advanced Prostate Cancer. Am J Therapeut 2009; 16:127–132.

Prada PJ, Gonzalez H, Menendez C, Llaneza A, et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009; 8:210–217. PubMed | CrossRef

Radiation added to hormone therapy increases survival for men with prostate cancer. Oncology (Williston Park) 2008:1278.

Roach M. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer COMMENT. Urology 2008; 72:1302–1303. PubMed | CrossRef

•• Robinson JW, Donnelly BJ, Siever JE, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009; 115:4695–4704. PubMed | CrossRef [29]

Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, et al. Phase iii multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of rtog 99-02. Int J Radiat Oncol Biol Phys 2009; 73.

Salvador-Morales C, Gao WW, Ghatalia P, Murshed F, et al. Multifunctional nanoparticles for prostate cancer therapy [Review]. Expert Rev Anticancer Ther 2009; 9:211–221. View Full Text | PubMed | CrossRef

Schelin S, Madsen M, Palmqvist E, Makela E, et al. Long-term follow-up after triple treatment of prostate cancer stage pT3. Scand J Urol Nephrol 2009; 43:186–191. PubMed | CrossRef

Schnarr K, Boreham D, Sathya J, Julian J, et al. Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients. Int J Radiat Oncol Biol Phys 2009; 74.

Serefoglu EC, Balbay MD. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases. Med Hypotheses 2009; 73:387–388. PubMed | CrossRef

Smith WP, Doctor J, Meyer J, Kalet IJ, et al. A decision aid for intensity-modulated radiation-therapy plan selection in prostate cancer based on a prognostic Bayesian network and a Markov model. Artif Intell Med 2009; 46:119–130. PubMed | CrossRef

Solan AN, Cesaretti JA, Stone NN, Stock RG. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 73.

Soto DE, Andridge RR, Pan CC, Williams SG, et al. Determining if pretreatment PSA doubling time predicts PSA trajectories after radiation therapy for localized prostate cancer. Radiother Oncol 2009; 90:389–394. PubMed | CrossRef

Souhami L, Bae K, Pilepich M, Sandler H. Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31. J Clin Oncol 2009; 27:2137–2143. PubMed | CrossRef

Stock RG, Klein TJ, Cesaretti JA, Stone NN. Prognostic significance of 5-year psa value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74.

Takizawa I, Hara N, Nishiyama T, Kaneko M, et al. Oncological results, functional outcomes and health-related quality-of-life in men who received a radical prostatectomy or external beam radiation therapy for localized prostate cancer: a study on long-term patient outcome with risk stratification. Asian J Androl 2009; 11:283–290. PubMed | CrossRef

Tang CI, Loblaw DA, Cheung P, Holden L, et al. Phase I/II Study of a Five-fraction Hypofractionated Accelerated Radiotherapy Treatment for Low-risk Localised Prostate Cancer: Early Results of pHART3. Clin Oncol 2008:729–737.

Taussky D, Liu A, Abraharnowicz M, Leger-Belanger E, et al. Factors influencing treatment decisions in patients with low risk prostate cancer referred to a brachytherapy clinic [Review]. Can J Urol 2008; 15:4415–4420. PubMed

Teloken PE, Parker M, Mohideen N, Mulhall JP. Predictors of Response to Sildenafil Citrate Following Radiation Therapy for Prostate Cancer. J Sex Med 2009; 6:1135–1140. PubMed

Thompson IM. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer EDITORIAL COMMENT. Urology 2008; 72:1303–1304. PubMed | CrossRef

•• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 2009; 181:956–962. View Full Text | PubMed | CrossRef [21]

Trabulsi EJ, Valicenti RK. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer REPLY. Urology 2008; 72:1303. PubMed | CrossRef

Trabulsi EJ, Valicenti RK. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer REPLY. Urology 2008; 72:1304. PubMed | CrossRef

Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, et al. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology 2008; 72:1298–1302.

Valdagni R, Rancati T, Fiorino C. Predictive Models of Toxicity With External Radiotherapy for Prostate Cancer Clinical Issues. Cancer 2009; 115:3141–3149.

van Haaren PMA, Bel A, Hofman P, van Vulpen M, et al. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiother Oncol 2009; 90:291–298. PubMed | CrossRef

Vargas C, Falchook A, Indelicato D, Yeung A, et al. Proton Therapy for Prostate Cancer Treatment Employing Online Image Guidance and an Action Level Threshold. Am J Clin Oncol-Cancer Clin Trials 2009; 32:180–186, 2009 Apr.

Viani GA, Pellizzon AC, Guimaraes FS, Jacinto AA, et al. High Dose Rate and External Beam Radiotherapy in Locally Advanced Prostate Cancer. Am J Clin Oncol-Cancer Clin Trials 2009; 32:187–190, 2009 Apr.

•• Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 2009; 373:301–308.[27]

•• Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27:2924–2930. Epub 2009 May 11[24]

Yamazaki H, Nishiyama K, Tanaka E, Maeda O, et al. Reduction of Irradiation Volume and Toxicities with 3-D Radiotherapy Planning over Conventional Radiotherapy for Prostate Cancer Treated with Long-term Hormonal Therapy. Anticancer Res 2008; 28:3913–3920. PubMed

Back to Top | Article Outline
Recent updates in renal cell carcinoma

Review: (pp. 250–256)

Allen NE, Roddam AW, Sieri S, Boeing H, et al. A prospective analysis of the association between macronutrient intake and renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2009; 125:982–987. PubMed | CrossRef

Amato RJ, Jac J, Giessinger S, Saxena S, et al. A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer. Cancer 2009; 115:2438–2446. PubMed | CrossRef

Amato RJ, Shingler W, Goonewardena M, de Belin J, et al. Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-alpha (IFN-alpha) A Phase 2 Trial. J Immunother 2009; 32:765–772. View Full Text | PubMed | CrossRef

Arikan-Sengul C, Pehlivan Y, Sevinc A, Karakok M, et al. A Case of Metachronous Triple Primary Urogenital Cancer: Urinary Bladder, Prostate, and Renal Cancer. Onkologie 2009; 32:122–124. View Full Text | PubMed | CrossRef

Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma - art. no. 20 [Review]. Mol Cancer 2009:20.

Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, et al. Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference. Cancer 2009; 115:2247–2251. PubMed | CrossRef

Bastien L, Culine S, Paule B, Ledbai S, et al. Targeted therapies in metastatic renal cancer in 2009 [Review]. BJU Int 2009; 103:1334–1342. View Full Text | PubMed | CrossRef

Bellmunt J, Calvo E, Castellano D, Climent MA, et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol 2009; 63:S1–S13. PubMed

Bellmunt J, Negrier S, Escudier B, Awada A, et al. The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce [Review]. Crit Rev Oncol/Hematol 2009; 69:64–72. PubMed | CrossRef

Bex A, van der Veldt AAM, Blank C, van den Eertwegh AJM, et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009; 27:533–539. PubMed | CrossRef

Blom JHM, van Poppel H, Marechal JM, Jacqmin D, et al. Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881. Eur Urol 2009; 55:28–34. PubMed | CrossRef

Bolenz C, Shariat SF, Fernandez MI, Margulis V, et al. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int 2009; 103:302–306.

Boorjian SA, Blute ML. Surgery for vena caval tumor extension in renal cancer [Review]. Curr Opin Urology 2009; 19:473–477.

Bregni M, Bernardi M, Servida P, Pescarollo A, et al. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant 2009; 44:237–242.

Bukowski RM. Optimizing Utilization of Targeted Therapies in Genitourinary Cancers. Clin Genitourin Cancer 2008; 6:S6. View Full Text | PubMed | CrossRef

Capitanio U, Shariat SF, Isbarn H, Weizer A, et al. Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. Eur Urol 2009; 56:1–9. PubMed | CrossRef

Cha TL, Chuang MJ, Wu ST, Sun GH, et al. Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G(2)-M Arrest and Apoptosis of Renal Cancer Cells. Clin Cancer Res 2009; 15:840–850.

Chowdhury S, Choueiri TK. Recent advances in the systemic treatment of metastatic papillary renal cancer [Review]. Expert Rev Anticancer Ther 2009; 9:373–379. View Full Text | PubMed | CrossRef

Chung SD, Chu SH, Tsai CC. Re: Capitanio et al. Cytoreductive Partial Nephrectomy Does Not Undermine Cancer Control in Metastatic Renal Cell Carcinoma: A Population-based Study. (Urology 2008;72:1090-1095). Urology 2009; 73:682–683. PubMed | CrossRef

Chung SD, Wang SM, Lai MK, Huang CY, et al. Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. BJU Int 2009; 103:1047–1051. PubMed | CrossRef

Clague J, Shao L, Lin J, Chang S, et al. Sensitivity to NNKOAc is associated with renal cancer risk. Carcinogenesis 2009; 30:706–710. View Full Text | PubMed | CrossRef

Coleman JA. Familial and Hereditary Renal Cancer Syndromes. Urol Clin North Am 2008; 35:563–572. PubMed | CrossRef

Corbin M, de Reynies A, Rickman DS, Berrebi D, et al. WNT/beta-Catenin Pathway Activation in Wilms Tumors: A Unifying Mechanism with Multiple Entries? Gene Chromosomes Cancer 2009; 48.

• Cowey CL, Fielding JR, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology 2009 [Epub ahead of print].[11]

Dasanu CA, Clark BA, Alexandrescu DT. mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option [Review]. Expert Opin Investig Drugs 2009; 18:175–187.

Datta D, Contreras AG, Grimm M, Waaga-Gasser AM, et al. Calcineurin Inhibitors Modulate CXCR3 Splice Variant Expression and Mediate Renal Cancer Progression. J Am Soc Nephrol 2008; 19:2437–2446. PubMed | CrossRef

de Fatima A, Zambuzzi WF, Modolo LV, Tarsitano CAB, et al. Cytotoxicity of goniothalamin enantiomers in renal cancer cells: Involvement of nitric oxide, apoptosis and autophagy. Chem Biol Interact 2008; 176:143–150. PubMed | CrossRef

de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, et al. EORTC-GU group expert opinion on metastatic renal cell cancer [Review]. Eur J Cancer 2009; 45:765–773. PubMed | CrossRef

Diaconu I, Denby L, Pesonen S, Cerullo V, et al. Serotype Chimeric and Fiber-Mutated Adenovirus Ad5/19p-HIT for Targeting Renal Cancer and Untargeting the Liver. Hum Gene Ther 2009; 20:611–620. PubMed | CrossRef

Escudier B, Eisen T, Stadler WM, Szczylik C, et al. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol 2009; 27:3312–3318. PubMed | CrossRef

Eskens FALM, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit? Eur J Cancer 2008; 44:2350–2356.

Feldstein MS, Rhodes DJ, Parker AS, Orford RR, et al. The haphazard approach to the early detection of asymptomatic renal cancer: results from a contemporary executive health programme. BJU Int 2009; 104:53–56. View Full Text | PubMed | CrossRef

Fritzsche FR, Weichert W, Roske A, Gekeler V, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer - art. no. 381. BMC Cancer 2008:381.

Garg S, Carroll RP, Walker RG, Ramsay HM, et al. Skin cancer surveillance in renal transplant recipients: re-evaluation of UK practice and comparison with Australian experience. Br J Dermatol 2009; 160:177–179. View Full Text | PubMed | CrossRef

Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer [Review]. Expert Rev Anticancer Ther 2009; 9:785–793.

Gonzalez E, Andres A, Polanco N, Hernandez A, et al. Everolimus Represents an Advance in Immunosuppression for Patients Who Have Developed Cancer After Renal Transplantation. Transplant Proc 2009; 41:2332–2336.

• Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435–446. [02]

Grabowski J, Silberstein J, Saltzstein SL, Saenz N. Renal tumors in the second decade of life: results from the California Cancer Registry. J Pediatr Surg 2009; 44:1148–1151.

Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 2009; 45:478–489.

Haendl T, Strobel D, Legal W, Frieser M, et al. Renal Cell Cancer Does Not Show a Typical Perfusion Pattern in Contrast-Enhanced Ultrasound [German]. Ultraschall Med 2009; 30:58–63.

Hawkins RE, Macdermott C, Shablak A, Hamer C, et al. Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-alpha. J Immunother 2009; 32:424–429.

Heng DYC, Chi KN, Murray N, Jin T, et al. A Population based Study Evaluating the Impact of Sunitinb on Overall Survival in the Treatment of Patients With Metastatic Renal Cell Cancer. Cancer 2009; 115:776–783.

Hirata H, Hinoda Y, Nakajima K, Kikuno N, et al. The bcl2-938CC Genotype Has Poor Prognosis and Lower Survival in Renal Cancer. J Urol 2009; 182:721–727.

Holweger K, Lipp HP, Dietz K, Hartmann JT, et al. Novel Algorithm for More Accurate Calculation of Renal Function in Adults with Cancer. Ann Pharmacother 2008; 42:1749–1757.

Hutchison N, Hendry BM, Sharpe CC. Rho isoforms have distinct and specific functions in the process of epithelial to mesenchymal transition in renal proximal tubular cells. Cell Signal 2009; 21:1522–1531.

Inman BA, Tran VT, Fradet Y, Lacombe L. Carcinoma of the Upper Urinary Tract. Cancer 2009; 115:2853–2862.

Inozume T, Hanada KI, Wang QJ, Yang JC. IL-17 Secreted by Tumor Reactive T Cells Induces IL-8 Release by Human Renal Cancer Cells. J Immunother 2009; 32:109–117.

Jeong IG, Kim SH, Jeon HG, Kim BH, et al. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol 2009; 40:668–677.

Jost G, Zimmerer S, Frank S, Cordier D, et al. Intradural spinal metastasis of renal cell cancer. Report of a case and review of 26 published cases [Review]. Acta Neurochir (Wien) 2009; 151:815–821.

Kamihira O, Hattori R, Yamaguchi A, Kawa G, et al. Laparoscopic Radical Nephroureterectomy: A Multicenter Analysis in Japan. Eur Urol 2009; 55:1397–1409.

Kempkensteffen C, Fritzsche FR, Johannsen M, Weikert S, et al. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer - art. no. 276. BMC Cancer 2009:276.

Khawam K, Giron-Michel J, Gu YH, Perier A, et al. Human Renal Cancer Cells Express a Novel Membrane-Bound Interleukin-15 that Induces, in Response to the Soluble Interleukin-15 Receptor alpha Chain, Epithelial-to-Mesenchymal Transition. Cancer Res 2009; 69:1561–1569.

•• Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27:746–753. [04]

Kluijt I, de Jong D, Teertstra HJ, Axwijk PH, et al. Early onset of renal cancer in a family with Birt-Hogg-DubE syndrome. Clin Genet 2009; 75:537–543.

Koski TA, Lehtonen HJ, Jee KJ, Ninomiya S, et al. Array Comparative Genomic Hybridization Identifies a Distinct DNA Copy Number Profile in Renal Cell Cancer Associated with Hereditary Leiomyomatosis and Renal Cell Cancer. Gene Chromosomes Cancer 2009; 48.

Kuroda K, Horiguchi A, Sumitomo M, Asano T, et al. Activated Akt Prevents Antitumor Activity of Gefitinib in Renal Cancer Cells. Urology 2009; 74:209–215.

Laber DA, Mushtaq M. Compassionate Use of Sorafenib in Patients with Advanced Renal Cell Cancer. Clin Genitourin Cancer 2009; 7:34–38.

Lee JE, Hankinson SE, Cho E. Reproductive Factors and Risk of Renal Cell Cancer. Am J Epidemiol 2009; 169:1243–1250.

Lee JE, Mannisto S, Spiegelman D, Hunter DJ, et al. Intakes of Fruit, Vegetables, and Carotenoids and Renal Cell Cancer Risk: A Pooled Analysis of 13 Prospective Studies. Cancer Epidemiol Biomarkers Prev 2009; 18.

Lee JE, Spiegelman D, Hunter DJ, Albanes D, et al. Fat, Protein, and Meat Consumption and Renal Cell Cancer Risk: A Pooled Analysis of 13 Prospective Studies. J Natl Cancer Inst 2008; 100:1695–1706.

Lemoine FM, Cherai M, Giverne C, Dimitri D, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 2009; 35:569–581.

Lund L, Jacobsen J, Norgaard M, McLaughlin JK, et al. The Prognostic Impact of Comorbidities on Renal Cancer, 1995 to 2006: A Danish Population Based Study. J Urol 2009; 182:35–40.

Majid S, Dar AA, Ahmad AE, Hirata H, et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 2009; 30:662–670.

Margulis V, Shariat SF, Matin SF, Kamat AM, et al. Outcomes of Radical Nephroureterectomy: A Series From the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115:1224–1233.

May M, Brookman-Amissah S, Kendel F, Knoll N, et al. Validation of a postoperative prognostic model consisting of tumor microvascular invasion, size, and grade to predict disease-free and cancer-specific survival of patients with surgically resected renal cell carcinoma. Int J Urol 2009; 16:616–621.

Mills EJ, Rachlis B, O'Regan C, Thabane L, et al. Metastatic renal cell cancer treatments: An indirect comparison meta-analysis - art. no. 34. BMC Cancer 2009:34.

Mohammed A, Shergill I, Little B. Management of metastatic renal cell carcinoma: current trends [Review]. Expert Rev Mol Diagn 2009; 9:75–83.

•• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449–456.[33]

• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584–3590. [29]

Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 2008; 216:418–427.

Nguyen MM, Gill IS. Effect of Renal Cancer Size on the Prevalence of Metastasis at Diagnosis and Mortality. J Urol 2009; 181:1020–1027.

Porta C, Imarisio I, Paglino C, Ferraris E, et al. Prognostic factors in advanced renal cell cancer. EJC Suppl 2008; 6:35–37.

Prager GW, Poettler M, Schmidinger M, Mazal PR, et al. CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest 2009; 39:304–310.

Prenen H, Gil T, Awada A. New therapeutic developments in renal cell cancer [Review]. Crit Rev Oncol/Hematol 2009; 69:56–63.

Rao D, Butt Z, Rosenbloom S, Robinson D, et al. A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Pain Symptom Manage 2009; 38:291–298.

Remzi M, Haitel A, Margulis V, Karakiewizc P, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 2009; 103:307–311.

Roos FC, Hampel C, Thuroff JW. Renal cancer surgery in the elderly [Review]. Curr Opin Urology 2009; 19:459–464.

Russo P, O'Brien MF. Surgical intervention in Patients with Metastatic Renal Cancer: Metastasectomy and Cytoreductive Nephrectomy. Urol Clin North Am 2008; 35:679–686.

Sanz L, Cuesta AM, Salas C, Corbacho C, et al. Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Lab Invest 2009; 89:91–97.

Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, et al. Does Arterial Spin-labeling MR Imaging-measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model? Radiology 2009; 251:731–742.

Setiawan VW, Kolonel LN, Henderson BE. Menstrual and Reproductive Factors and Risk of Renal Cell Cancer in the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 2009; 18.

Silberstein J, Grabowski J, Saltzstein SL, Kane CJ. Renal Cell Carcinoma in the Pediatric Population: Results From the California Cancer Registry. Pediatric Blood Cancer 2009; 52:237–241.

Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, et al. Glutathione S-transferases in kidney and urinary bladder tumors [Review]. Nat Rev Urol 2009; 6:281–289.

Simone G, Papalia R, Guaglianone S, Ferriero M, et al. Laparoscopic versus Open Nephroureterectomy: Perioperative and Oncologic Outcomes from a Randomised Prospective Study. Eur Urol 2009; 56:520–526.

Siu KWM, De Souza LV, Scorilas A, Romaschin AD, et al. Differential Protein Expressions in Renal Cell Carcinoma: New Biomarker Discovery by Mass Spectrometry. J Proteome Res 2009; 8:3797–3807.

Sohaib SA, Cook G, Allen SD, Hughes M, et al. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br J Radiol 2009; 82:632–639.

Sternberg CN. A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. Urol Oncol 2009; 27:122–125.

Sudarshan S, Sourbier C, Kong HS, Block K, et al. Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1 alpha Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species. Mol Cell Biol 2009; 29:4080–4090.

Theis RP, Grieb SMD, Burr D, Siddiqui T, et al. Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study - art. no. 387. BMC Cancer 2008:387.

• Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181:518–523. discussion 523[22]

Tolle A, Jung M, Lein M, Johannsen M, et al. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? - art. no. 248. BMC Cancer 2009:248.

Vaezzadeh AR, Steen H, Freeman MR, Lee RS. Proteomics and Opportunities for Clinical Translation in Urological Disease [Review]. J Urol 2009; 182:835–843.

Van Poppel H. Treatment of Advanced and Metastatic Renal Cancer: A Revolution? European Urology Supplements 2009; 8:483–488.

Varlet F, Stephan JL, Guye E, Allary R, et al. Laparoscopic Radical Nephrectomy for Unilateral Renal Cancer in Children. Surg Laparosc Endosc Pct Tech 2009; 19.

Vasudev NS, Ferguson RE, Cairns DA, Stanley AJ, et al. Serum biomarker discovery in renal cancer using 2-DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same? Proteomics 2008; 8:5074–5085.

Vaziri SAJ, Grabowski DR, Hill J, Rybicki LR, et al. Inhibition of Proteasome Activity by Bortezomib in Renal Cancer Cells Is p53 Dependent and VHL Independent. Anticancer Res 2009; 29:2961–2969.

Vroling L, van der Veldt AAM, de Haas RR, Haanen JBAG, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009; 12:69–79.

Vuononvirta R, Sebire NJ, Messahel B, Perusinghe N, et al. Expression of Hepatocyte Growth Factor and Its Receptor Met in Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development. Clin Cancer Res 2009; 15:2723–2730.

Weber A, Kristiansen I, Johannsen M, Oelrich B, et al. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer - art. no. 369. BMC Cancer 2008:369.

Westermann J, Hecker AC, Florcken A, Dorken B, et al. Granulocyte Macrophage-Colony Stimulating Factor Plus Interleukin-2 Plus alpha-interferon Plus 5-Fluorouracil in the Treatment of Metastatic Renal Cell Cancer Induction of CD80/86(+) T Cells Indicates Adverse Outcome. J Immunother 2009; 32:667–675.

Wiklund F, Tretli S, Choueiri TK, Signoretti S, et al. Risk of Bilateral Renal Cell Cancer. J Clin Oncol 2009; 27:3737–3741.

Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target [Review]. Expert Rev Mol Diagn 2009; 9:231–241.

Xie H, Valera VA, Merino MJ, Amato AM, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009; 8:626–635.

Yang HY, Wang JD, Lo TC, Chen PC. Increased Mortality Risk for Cancers of the Kidney and Other Urinary Organs among Chinese Herbalists. J Epidemiol 2009; 19:17–23.

Yuen JSP, Akkaya E, Wang Y, Takiguchi M, et al. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 2009; 8:1448–1459.

Zastrow S, Froehner M, Platzek I, Novotny V, et al. Treatment of Metastatic Renal Cell Cancer With Sunitinib During Chronic Hemodialysis. Urology 2009; 73:868–870.

Zheng JN, Pei DS, Mao LJ, Liu XY, et al. Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther 2009; 16:20–32.

Zini L, Patard JJ, Capitanio U, Crepel M, et al. Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma. BJU Int 2009; 103:894–898.

Back to Top | Article Outline
Update on testicular germ cell tumors

Review: (pp. 236–241)

Ahmed FE. The role of capillary electrophoresis-mass spectrometry to proteome analysis and biomarker discovery [Review]. J Chromatogr B 2009; 877:1963–1981, 2009 Jul 15.

Akre O, Pettersson A, Richiardi L. Risk of contralateral testicular cancer among men with unilaterally undescended testis: A meta analysis. Int J Cancer 2009; 124:687–689.

Boyer A, Paquet M, Lague MN, Hermo L, et al. Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis. Carcinogenesis 2009; 30:869–878.

Canda AE, Atmaca AF, Ozdemir AT, Akbulut Z, et al. Testis sparing surgery for sequential bilateral testicular tumors. Can J Urol 2009; 16:4677–4681.

Classen J, Schmidberger H, Souchon R, Weissbach L, et al. What Is the Value of Routine Follow-Up in Stage I Seminoma after Paraaortic Radiotherapy? An Analysis of the German Testicular Cancer Study Group (GTCSG) in 675 Prospectively Followed Patients. Strahlenther Onkol 2009; 185:349–354.

Dahm P, Rosser CJ, McKiernan JM. Quality of care for testis cancer. Urol Oncol 2009; 27:448–453.

de Bruin D, de Jong IJ, Arts EGJM, Nuver J, et al. Semen quality in men with disseminated testicular cancer: relation with human chorionic gonadotropin beta-subunit and pituitary gonadal hormones. Fertil Steril 2009; 91:2481–2486.

Delbes G, Chan D, Pakarinen P, Trasler JM, et al. Impact of the Chemotherapy Cocktail Used to Treat Testicular Cancer on the Gene Expression Profile of Germ Cells from Male Brown-Norway Rats. Biol Reprod 2009; 80:320–327.

Durand X, Desfemmes FR, Bauduceau O. Place of scrotal radiotherapy after conservative surgery for germ cell tumours of the testis [French]. Prog Urol 2008; 18:F11–F14.

Eberhard J, Stahl O, Cohn-Cedermark G, Cavallin-Stahl E, et al. Sexual Function in Men Treated for Testicular Cancer. J Sex Med 2009; 6:1979–1989.

Ellinger J, Wittkarnp V, Albers P, Perabo FGE, et al. Cell-Free Circulating DNA: Diagnostic Value in Patients With Testicular Germ Cell Cancer. J Urol 2009; 181:363–371.

• Ferlin A, Ganz F, Pengo M, et al. Association of testicular germ cell tumour with polymorphisms in estrogen receptor and steroid metabolism genes. Endocrine Relat Cancer 2010; 17:17–25.[11]

Gilbert DC, Chandler I, McIntyre A, Goddard NC, et al. Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J Pathol 2009; 217:94–102.

Godmann M, Lambrot R, Kimmins S. The Dynamic Epigenetic Program in Male Germ Cells: Its Role in Spermatogenesis, Testis Cancer, and Its Response to the Environment [Review]. Microsc Res Tech 2009; 72:603–619.

Guney S, Guney N, Sonmez NC, Ergenekon E. Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis. Med Oncol 2009; 26:136–142.

Hartmann M, Siener R, Krege S, Schmelz H, et al. Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I [German]. Urologe 2009:523–528.

Heidenreich A, Pfister D, Witthuhn R, Thuer D, et al. Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Testicular Cancer: Radical or Modified Template Resection. Eur Urol 2009; 55:217–226.

Holl K, Lundin E, Surcel HM, Grankvist K, et al. Endogenous steroid hormone levels in early pregnancy and risk of testicular cancer in the offspring: A nested case-referent study. Int J Cancer 2009; 124:2923–2928.

• Honecker F, Wermann H, Mayer F, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009; 27:2129–2136. [07]

Houlgatte A. Diagnosis and principles of treatment of cancer of the testicle [French]. Prog Urol 2009; 19:241–243.

Kenney PA, Tuerk IA. Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol 2008; 26:561–569.

Kleinschmidt K, Dieckmann KP, Georgiew A, Loy V, et al. Chemotherapy Is of Limited Efficacy in the Control of Contralateral Testicular Intraepithelial Neoplasia in Patients with Testicular Germ Cell Cancer. Oncology (Williston Park) 2009:33–39.

Krege S. Value of retroperitoneal lymphadenectomy for germ cell cancer [German]. Urologe 2009:32.

Kumaraswamy P, Cox R, O'Rourke JS, Willis RG. Audit of two-week rule referrals for suspected testicular cancer in Cornwall, 2003-2005. Ann R Coll Surg Engl 2009; 91:239–244.

Labarthe P, Khedis M, Chevreau C, Mazerolles C, et al. Management of pure teratoma of the testis in adult, results of a multicenter study over 15 years [French]. Prog Urol 2008; 18:1075–1081.

Laiyemo AO, Jack M, Dawkins FW, Smoot DT. Upper Gastrointestinal Bleeding From Metastatic Testicular Cancer. J Natl Med Assoc 2009; 101:808–809.

Lee EK, Holzbeierlein JM. Management of the contralateral testicle in patients with unilateral testicular cancer [Review]. World J Urol 2009; 27:421–426.

Liu XC, Zhu P, Sham KWY, Yuen JML, et al. Identification of a Membrane Estrogen Receptor in Zebrafish with Homology to Mammalian GPER and Its High Expression in Early Germ Cells of the Testis. Biol Reprod 2009; 80:1253–1261.

Loriot A, Reister S, Parvizi GK, Lysy PA, et al. DNA Methylation-Associated Repression of Cancer-Germline Genes in Human Embryonic and Adult Stem Cells. Stem Cells 2009; 27:822–824.

Maddineni SB, Clarke NW. Testis cancer: the UK as a model [German]. Urologe 2009:386–.

Morichetti D, Mazzucchelli R, Lopez-Beltran A, Cheng L, et al. Secondary neoplasms of the urinary system and male genital organs. BJU Int 2009; 104:770–776.

Murugaesu N, Powles T, Bestwick J, Oliver RTD, et al. Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis. Osteoporosis Int 2009; 20:1627–1630.

• Nicolai N, Necchi A, Gianni L, et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumors. BJU International 2009; 104:340–346. [19]

Okayama S, Matsui M, Somekawa S, Iwano M, et al. Non-Contrast MRI for the Evaluation of Hydronephrotic and Dysfunctioning Kidney Secondary to Testicular Cancer. Ren Fail 2009; 31:153–158.

Ortiz RJ, Lizama C, Codelia VA, Moreno RD. A molecular evaluation of germ cell death induced by etoposide in pubertal rat testes. Mol Human Reprod 2009; 15:363–371.

Pettus JA, Carver BS, Masterson T, Stasi J, et al. Preservation of Ejaculation in Patients Undergoing Nerve-Sparing Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer. Urology 2009; 73:328–331.

Phe V, Roupret M, Mottet N. What's new in 2008 in the field of basic and clinical research in testis and penile cancer? [French]. Prog Urol 2009; 19:S51–S55.

Rigaud J, Durand X. Cancer of the penis and testicle [French]. Prog Urol 2009; 19:F76–F78.

Spiess PE, Pisters LL, Liu P, Pettaway CA, et al. Malignant transformation of testicular teratoma: A chemoresistant phenotype. Urol Oncol 2008; 26:595–599.

Sternberg CN. A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. Urol Oncol 2009; 27:122–125.

• Svatek RS, Spiess PE, Sundi D, et al. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 2009; 115:1310–1317. [20]

•• Tandstad T, Dahl O, Cohn-Cedarmark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27:2122–2128. [12]

Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, et al. Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program. J Clin Oncol 2009; 27:2122–2128.

Tarin TV, Sonn G, Shinghal R. Estimating the Risk of Cancer Associated With Imaging Related Radiation During Surveillance for Stage I Testicular Cancer Using Computerized Tomography. J Urol 2009; 181:627–632.

• Velasco A, Corvalan A, Wistuba II, et al. Mismatch repair and expression in testicular cancer predicts recurrence and survival. Int J Cancer 2008; 122:1774–1777. [06]

•• Westermann DH, Schefer H, Thalmann GN, et al. Long-term follow up results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage 1 nonseminomatous germ cell tumors of the testis. J Urol 2008; 179:163–166. [13]

Wood HM, Elder JS. Cryptorchidism and Testicular Cancer: Separating Fact From Fiction [Review]. J Urol 2009; 181:452–461.

Xylinas E. Cancer of the bladder and upper urinary system, cancer of the testicle, adrenal, incontinence, BPH, kidney transplant [French]. Prog Urol 2009; 19:F73–F75.

• Yu H, Madison R, Setodji C, et al. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 2009; 27:4327–4332. [14]

Back to Top | Article Outline
Bladder cancer

Review: (pp. 242–249)

Arikan-Sengul C, Pehlivan Y, Sevinc A, Karakok M, et al. A Case of Metachronous Triple Primary Urogenital Cancer: Urinary Bladder, Prostate, and Renal Cancer. Onkologie 2009; 32:122–124.

Armatys SA, Mellon MJ, Beck SDW, Koch MO, et al. Use of Ileum as Ureteral Replacement in Urological Reconstruction. J Urol 2009; 181:177–181.

• Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54:303–314. [23]

Bukowski RM. Optimizing Utilization of Targeted Therapies in Genitourinary Cancers. Clin Genitourin Cancer 2008; 6:S6.

Capitanio U, Shariat SF, Isbarn H, Weizer A, et al. Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. Eur Urol 2009; 56:1–9.

Cho KS, Choi HM, Koo K, Park SJ, et al. Clinical Significance of Lymph Node Dissection in Patients with Muscle- Invasive Upper Urinary Tract Transitional Cell Carcinoma Treated with Nephroureterectomy. J Korean Med Sci 2009; 24:674–678.

Chung SD, Wang SM, Lai MK, Huang CY, et al. Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. BJU Int 2009; 103:1047–1051.

David KA, Mallin K, Milowsky MI, Ritchey J, et al. Surveillance of Urothelial Carcinoma Stage and Grade Migration, 1993-2005 and Survival Trends, 1993-2000. Cancer 2009; 115:1435–1447.

Dragicevic D, Djokic M, Pekmezovic T, Vuksanovic A, et al. Comparison of Open Nephroureterectomy and Open Conservative Management of Upper Urinary Tract Transitional Cell Carcinoma. Urol Int 2009; 82:335–340.

• Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009; 27:4055–4061. [77]

Fernandez MI, Shariat SF, Margulis V, Bolenz C, et al. Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. Urology 2009; 73:142–146.

• Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with nonmuscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009; 55:773–780.[24]

Hattori R, Yoshino Y, Komatsu T, Matsukawa Y, et al. Pure laparoscopic complete excision of distal ureter with a bladder cuff for upper tract urothelial carcinoma. World J Urol 2009; 27:253–258.

Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, et al. Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration. J Urol 2009; 182:900–906.

• Hollenbeck BK, Ye Z, Dunn RL, et al. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 2009; 101:571–580. [21]

Husain E, Khawaja A, Shaikh T, Yaqoob M, et al. Transitional cell carcinoma of the urinary tract in renal transplant recipients. Pathology 2009; 41:406–408.

Inman BA, Tran VT, Fradet Y, Lacombe L. Carcinoma of the Upper Urinary Tract. Cancer 2009; 115:2853–2862.

Jeong IG, Kim SH, Jeon HG, Kim BH, et al. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol 2009; 40:668–677.

Jiang X, Castelao JE, Groshen S, Cortessis VK, et al. Urinary tract infections and reduced risk of bladder cancer in Los Angeles. Br J Cancer 2009; 100:834–839.

Kamihira O, Hattori R, Yamaguchi A, Kawa G, et al. Laparoscopic Radical Nephroureterectomy: A Multicenter Analysis in Japan. Eur Urol 2009; 55:1397–1409.

Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, et al. Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. J Clin Oncol 2009; 27:612–618.

Li WM, Li CC, Ke HL, Wu WJ, et al. The Prognostic Predictors of Primary Ureteral Transitional Cell Carcinoma After Radical Nephroureterectomy. J Urol 2009; 182:451–458.

•• Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for nonmuscle-invasive bladder cancer. Eur Urol 2009; 56:247–256.[36]

Margulis V, Shariat SF, Matin SF, Kamat AM, et al. Outcomes of Radical Nephroureterectomy: A Series From the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115:1224–1233.

Morichetti D, Mazzucchelli R, Lopez-Beltran A, Cheng L, et al. Secondary neoplasms of the urinary system and male genital organs. BJU Int 2009; 104:770–776.

• Ng C, Kauffman E, Lee M, et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 2010; 57:274–282. [61]

Novara G, De Marco V, Dalpiaz O, Galfano A, et al. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: Multi-institutional dataset from three European centers. Int J Urol 2009; 16:187–191.

Ozsahin M, Ugurluer G, Zouhair A. Management of transitional-cell carcinoma of the renal pelvis and ureter [Review]. Swiss Med Wkly 2009; 139:353–356.

Pak RW, Moskowitz EJ, Bagley DH. What Is the Cost of Maintaining a Kidney in Upper-Tract Transitional-Cell Carcinoma? An Objective Analysis of Cost and Survival. J Endourol 2009; 23:341–346.

Park J, Ha SH, Min GE, Song C, et al. The Protective Role of Renal Parenchyma as a Barrier to Local Tumor Spread of Upper Tract Transitional Cell Carcinoma and its Impact on Patient Survival. J Urol 2009; 182:894–899.

Remzi M, Haitel A, Margulis V, Karakiewizc P, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 2009; 103:307–311.

Roscigno M, Shariat SF, Margulis V, Karakiewicz P, et al. Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. J Urol 2009; 181:2482–2489.

Roupret M, Smyth G, Irani J, Guy L, et al. Oncological risk of laparoscopic surgery in urothelial carcinomas [Review]. World J Urol 2009; 27:81–88.

• Schmidbauer J, Remzi M, Klatte T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol 2009; 56:914–919. [05]

• Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55:164–176. [47]

Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, et al. Glutathione S-transferases in kidney and urinary bladder tumors [Review]. Nat Rev Urol 2009; 6:281–289.

Simone G, Papalia R, Guaglianone S, Ferriero M, et al. Laparoscopic versus Open Nephroureterectomy: Perioperative and Oncologic Outcomes from a Randomised Prospective Study. Eur Urol 2009; 56:520–526.

• Solsona E, Climent MA, Iborra I, et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2009; 55:911–919.[74]

• Sonn GA, Jones S-NE, Tarin TV, et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol 2009; 182:1299–1305. [06]

Sternberg CN. A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. Urol Oncol 2009; 27:122–125.

Tai HC, Lai MK, Chung SD, Huang KH, et al. Intermediate-Term Oncological Outcomes of Hand-Assisted Laparoscopic Versus Open Bilateral Nephroureterectomy for Dialysis and Kidney Transplant Patients with Upper Urinary Tract Urothelial Carcinoma. J Endourol 2009; 23:1139–1144.

Tan LB, Chang LL, Cheng KI, Huang CH, et al. Transitional cell carcinomas of the renal pelvis and the ureter: comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population. BJU Int 2009; 103:312–316.

Unoki M, Kelly JD, Neal DE, Ponder BAJ, et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 2009; 101:98–105.

Vaezzadeh AR, Steen H, Freeman MR, Lee RS. Proteomics and Opportunities for Clinical Translation in Urological Disease [Review]. J Urol 2009; 182:835–843.

Vikram R, Sandler CM, Ng CS. Imaging and Staging of Transitional Cell Carcinoma: Part 1, Lower Urinary Tract [Review]. AJR Am J Roentgenol 2009; 192:1481–1487.

Vikram R, Sandler CM, Ng CS. Imaging and Staging of Transitional Cell Carcinoma: Part 2, Upper Urinary Tract [Review]. AJR Am J Roentgenol 2009; 192:1488–1493.

Waldert M, Remzi M, Klingler HC, Mueller L, et al. The oncological results of laparoscopic nephroureterectomy for upper urinary tract transitional cell cancer are equal to those of open nephroureterectomy. BJU Int 2009; 103:66–70.

Wang LJ, Wong YC, Chuang CK, Huang CC, et al. Diagnostic Accuracy of Transitional Cell Carcinoma on Multidetector Computerized Tomography Urography in Patients With Gross Hematuria. J Urol 2009; 181:524–531.

Wood DP. When Does Lymphadenectomy Improve Survival of Patients With Genitourinary Malignancies? J Urol 2009; 181:2412–2413.

Zhang Q, Fu S, Liu TF, Peng LH, et al. Adjuvant intraoperative electron radiotherapy and external beam radiotherapy for locally advanced transitional cell carcinoma of the ureter. Urol Oncol 2009; 27:14–20.

Back to Top | Article Outline
Pediatric genitourinary tumors

Review: (pp. 268–273)

• Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol 2009; 27:5182–5188. [24]

• Carkaci S, Ozkan E, Lane D, Yang WT. Scrotal sonography revisited. J Clin Ultrasound 2010; 38:21–37. [35]

Castellino SM, Martinez-Borges AR, McLean TW. Pediatric genitourinary tumors [Review]. Curr Opin Oncol 2009; 21:278–283.

• Cotton CA, Peterson S, Norkool PA, et al. Early and late mortality after diagnosis of Wilms tumor. J Clin Oncol 2009; 27:1304–1309.[37]

•• Davidoff AM. Wilms' tumor. Curr Opin Pediatr 2009; 21:357–364. [01]

Gilbert DC, Chandler I, McIntyre A, Goddard NC, et al. Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J Pathol 2009; 217:94–102.

• Hayes-Jordan A, Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr 2009; 21:373–378. [22]

•• Jenkins ZA, van Kogelenberg M, Morgan T, et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet 2009; 41:95–100. [16]

•• Rivera MN, Kim WJ, Wells J, et al. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci U S A 2009; 106:8338–8343. [15]

• Rodeberg DA, Stoner JA, Hayes-Jordan A, et al. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2009; 27:3705–3711. [25]

• Ross JH. Prepubertal testicular tumors. Urology 2009; 74:94–99. [34]

• Sausville JE, Hernandez DJ, Argani P, Gearhart JP. Pediatric renal cell carcinoma. J Pediatr Urol 2009; 5:308–314. [21]

•• Sebire NJ, Vujanic GM. Paediatric renal tumours: recent developments, new entities and pathological features. Histopathology 2009; 54:516–528. [19]

Silberstein J, Grabowski J, Saltzstein SL, Kane CJ. Renal Cell Carcinoma in the Pediatric Population: Results From the California Cancer Registry. Pediatric Blood Cancer 2009; 52:237–241.

• Sredni ST, Gadd S, Huang CC, et al. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res 2009; 15:6800–6809. [04]

Stehr M. Pediatric urologic rhabdomyosarcoma [Review]. Curr Opin Urology 2009; 19:402–406.

Sternberg CN. A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. Urol Oncol 2009; 27:122–125.

Varlet F, Stephan JL, Guye E, Allary R, et al. Laparoscopic Radical Nephrectomy for Unilateral Renal Cancer in Children. Surg Laparosc Endosc Pct Tech 2009; 19.

Back to Top | Article Outline
‘Image and treat’: an individualized approach to urological tumors

Review: (pp. 274–280)

Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 2009; 101:19–26.

• Bischoff CJ, Clark PE. Bladder cancer. Curr Opin Oncol 2009; 21:272–277. [05]

• Bouchelouche K, Capala J, Oehr P. Positron emission tomography/computed tomography and radioimmuotherapy of prostate cancer. Curr Opin Oncol 2009; 21:469–474.[40]

Chen CL, Guo HX, Liu P, Huang R, et al. Three-dimensional reconstruction of the uterine vascular supply through vascular casting and thin slice computed tomography scanning. Minim Invasive Ther Allied Technol 2009; 18:98–102, 2009.

•• Choudhary S, Sudarshan S, Choyke PL, Prasad SR. Renal cell carcinoma: recent advances in genetics and imaging. Semin Ultrasound CT MR 2009; 30:315–325. [15]

• Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009; 10:118–125.[41]

• Elsasser-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009; 50:606–611. [51]

• Garcia JA, Cowey CL, Godley PA. Renal cell carcinoma. Curr Opin Oncol 2009; 21:266–271. [14]

Graafland NM, Leijte JAP, Olmos RAV, Hoefnagel CA, et al. Scanning with 18F-FDG-PET/CT for Detection of Pelvic Nodal Involvement in Inguinal Node-Positive Penile Carcinoma. Eur Urol 2009; 56:339–345.

•• Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69:6932–6940. [57]

•• Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239–249. [06]

Kim CK, Park BK, Lee HM. Prediction of Locally Recurrent Prostate Cancer after Radiation Therapy: Incremental Value of 3T Diffusion-Weighted MRI. J Magn Reson Imaging 2009; 29:391–397.

Kitazume Y, Satoh S, Taura S, Kimula Y. Diffusion-Weighted Magnetic Resonance Imaging Detection of Renal Cancer Presenting With Diffuse Peritoneal Metastases in a Patient With Hemodialysis-Associated Acquired Cystic Disease of the Kidney. J Magn Reson Imaging 2009; 29:953–956.

•• Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18F-labeled Affibody molecules. J Nucl Med 2009; 50:1131–1139.[74]

• Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009; 21:260–265. [36]

•• Lawrentschuk N, Lee FT, Jones G, et al. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT. Urol Oncol 2009, June 11 [Epub ahead of print].[30]

Leijte JAP, Graafland NM, Olmos RAV, van Boven HH, et al. Prospective evaluation of hybrid F-18-fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma. BJU Int 2009; 104:640–644.

Leijte JAP, van der Ploeg IMC, Olmos RAV, Nieweg OE, et al. Visualization of Tumor Blockage and Rerouting of Lymphatic Drainage in the Penile Cancer Patients by Use of SPECT/CT. J Nucl Med 2009; 50:364–367.

Leyendecker JR, Gianini JW. Magnetic resonance urography. Abdom Imaging 2009; 34:527–540.

Masterson TA, Touijer K. The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer [Review]. Magn Reson Mat Phys Biol Med 2009; 21.

•• McLarty K, Cornelissen B, Cai Z, et al. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009; 50:1340–1348. [68]

Okayama S, Matsui M, Somekawa S, Iwano M, et al. Non-Contrast MRI for the Evaluation of Hydronephrotic and Dysfunctioning Kidney Secondary to Testicular Cancer. Ren Fail 2009; 31:153–158.

• Orlova A, Tran TA, Ekblad T, et al. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2009 Sep 22. [Epub ahead of print][77]

• Orlova A, Wallberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled Affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50:417–425. [72]

Peng C, Kainz K, Lawton C, Li XA. A Comparison of daily megavoltage CT and ultrasound image guided radiation therapy for prostate cancer. Med Phys 2008; 35:5619–5628.

•• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373:1119–1132. [04]

Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, et al. Does Arterial Spin-labeling MR Imaging-measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model? Radiology 2009; 251:731–742.

Sohaib SA, Cook G, Allen SD, Hughes M, et al. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br J Radiol 2009; 82:632–639.

Stattaus J, Forsting M. Relevance of radiological imaging for lymph node surgery of urological tumors [German]. Urologe 2009:12.

Takeuchi M, Matsuzaki K, Kubo H, Nishitani H. Diffusion-Weighted Magnetic Resonance Imaging of Urinary Epithelial Cancer with Upper Urinary Tract Obstruction: Preliminary Results. Acta Radiol 2008; 49:1195–1199.

Tarin TV, Sonn G, Shinghal R. Estimating the Risk of Cancer Associated With Imaging Related Radiation During Surveillance for Stage I Testicular Cancer Using Computerized Tomography. J Urol 2009; 181:627–632.

•• Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 2009; 192:1471–1480. [37]

Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74.

Vikram R, Sandler CM, Ng CS. Imaging and Staging of Transitional Cell Carcinoma: Part 1, Lower Urinary Tract [Review]. AJR Am J Roentgenol 2009; 192:1481–1487.

Vikram R, Sandler CM, Ng CS. Imaging and Staging of Transitional Cell Carcinoma: Part 2, Upper Urinary Tract [Review]. AJR Am J Roentgenol 2009; 192:1488–1493.

Wang LJ, Wong YC, Chuang CK, Huang CC, et al. Diagnostic Accuracy of Transitional Cell Carcinoma on Multidetector Computerized Tomography Urography in Patients With Gross Hematuria. J Urol 2009; 181:524–531.

White EA, Brock KK, Jaffray DA, Catton CN. Inter-observer Variability of Prostate Delineation on Cone Beam Computerised Tomography Images. Clin Oncol 2009:32–38.

• Wolf P, Freudenberg N, Buhler P, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2009 Nov 24. [Epub ahead of print].[50]

Zapatero A, Minguez R, Nieto S, de Vidales CM, et al. Post-treatment Prostate Biopsies in the Era of Three-Dimensional Conformal Radiotherapy: What Can They Teach Us? Eur Urol 2009; 55:902–910.

•• Zoller F, Eisenhut M, Haberkorn U, Mier W. Endoradiotherapy in cancer treatment: basic concepts and future trends. Eur J Pharmacol 2009; 625:55–62. [13]

© 2010 Lippincott Williams & Wilkins, Inc.

Login